[
  {
    "text": "# IA # Human Papillomavirus (HPV) Vaccine Coverage Monitoring Manual World Health Organization Department of Immunization, Vaccines and Biologicals # Human Papillomavirus (HPV) Vaccine Coverage Monitoring Manual World Health Organization Department of Immunization, Vaccines and Biologicals Human papillomavirus (HPV) vaccine coverage monitoring manua ISBN 978-92-4-000274-6 (electronic version) ISBN 978-92-4-000275-3 (print version) $\\circledcirc$ World Health Organization 2020 Some rights reserved.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "This work is available under the Creative Commons Attribution-NonCommercial-Share­ Alike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services.The use of the WHO logo is not permitted.If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO).WHO is not responsible for the content or accuracy of this translation.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The original English edition shall be the binding and authentic edition”.Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Suggested citation.Human papillomavirus (HPV) vaccine coverage monitoring manual.Geneva: World Health Organization; 2020.Licence: CC BY-NC-SA 3.0 IGO.Cataloguing-in-Publication (CIP) data.CIP data are available at http://apps.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "who.int/iris.Sales, rights and licensing.To purchase WHO publications, see http://apps.who.int/bookorders.To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Third-party materials.If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.General disclaimers.The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.All reasonable precautions have been taken by WHO to verify the information contained in this publication.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "However, the published material is being distributed without warranty of any kind, either expressed or implied.The responsibility for the interpretation and use of the material lies with the reader.In no event shall WHO be liable for damages arising from its use.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Printed in Switzerland # Contents Preface 1 .Introduction 2 1.1 Background on HPV vaccination 3 1.2 Monitoring HPV vaccination coverage: Objectives, data needs and challenges 4 ...Objectives for monitoring HPV vaccination coverage 4 .",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "..Data required to meet these objectives 5 1.3 Considerations for school-based vaccination 6 \u00071.4 \u0007Considerations for continuous (routine) versus periodic (campaign-style) HPV vaccination 8 1.5 Determining denominators for monitoring HPV vaccination 10 # Tools for recording and reporting HPV vaccination 11 2.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "1 Types of data and reporting tools needed 12 ...Required tools 12 ...Data to collect 13 2.2 Tally sheets 14 2.3 Immunization registers 16 2.4 Home-based records 18 2.5 Stock records and wastage monitoring 21 2.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "6 Monthly Summary Reports 22 ...Data to include 22 ...Flow of data up the health system 24 2.7 Tracking doses and defaulters 25 3.Monitoring Coverage 26 3.1 Administrative coverage 27 3.2 Coverage surveys 32 3.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "3 Monitoring drop-out from HPV1 to HPV2 33 4.Final observations 34 Appendix 1.Data collection for HPV vaccination included in the WHO/UNICEF Join Reporting Form (JRF) 37 Appendix 2.Use of a summary indicator of HPV vaccine coverage 38 Appendix 3.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Generating estimates of the target population for HPV vaccination 39 ![](images/19ffe8b43f9afe351ae2a39c19fc9646cf69c9c4035e134b7873b1c01081032e.jpg) # Preface The World Health Organization (WHO) recommends the introduction of the Human Papillomavirus (HPV) vaccine into national immunization schedules as a means to address cervical cancer and other HPV-related diseases.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The current recommendation is for two doses of HPV vaccine, targeted primarily towards girls aged 9 to 14 years in countries where the prevention of cervical cancer is a public health priority, and the introduction of the vaccine is programmatically and economically feasible.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "All countries should make efforts to monitor and evaluate HPV vaccine delivery, as well as the prevalence of cervical cancer; some countries may also be able to monitor type-specific HPV prevalence.Vaccine coverage information is of utmost importance to guide HPV vaccine strategies and to correctly interpret data on vaccine impact measures.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "However, assessing HPV vaccine coverage presents unique challenges given the different age groups being targeted and the variety of vaccine delivery strategies.This manual focuses on the routine monitoring of HPV vaccine coverage, discussing challenges and options for estimating coverage; which can be done effectively with good technical support and a clear understanding of potential caveats.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "HPV coverage monitoring by survey is discussed briefly as more details are covered in another WHO manual1.Similarly, further guidance on HPV vaccination impact monitoring is available in a separate WHO document2.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Note that, due to potential complexity and resource implications, HPV disease monitoring should not be considered a prerequisite or an essential requirement for an HPV vaccination programme.This manual is most useful when planning to introduce HPV vaccination into a country’s immunization schedule and in the event difficulties are experienced during monitoring its use and estimating coverage.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "It provides generic instructions and guidance on how to approach the routine monitoring of HPV vaccine coverage by vaccine dose and by age, from the vaccine delivery site up to the national level.It outlines the processes of data recording, aggregation and reporting and flags key issues to consider and clarify for this reporting.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Three reporting levels are highlighted for demonstration purposes (i.e., service delivery, district and national).The Manual highlights some of the most common challenges and presents possible solutions.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The tally sheets, reporting forms, summary tables and other forms presented in this document are for illustration purposes only and should be adapted to suit local needs.Countries that have monitoring systems in place for HPV vaccination do not need to introduce the reporting instruments found in this document but should ensure that their current systems and tools can generate the data required to effectively monitor HPV vaccine coverage.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Introduction ![](images/074fda16f5c296af467c3207c676bfc0db57ffe167476f802af97641bf87a478.jpg) # Background on HPV vaccination Persistent infection with Human Papillomavirus (HPV) is the main cause of cervical cancer, with HPV types 16 and 18 accounting for $70 \\%$ of all cases worldwide.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The disease burden of cervical cancer is highest among women in low-resource countries.In 2009, the World Health Organization (WHO) recommended that routine HPV vaccination be included in national immunization programmes in countries wherein the prevention of cervical cancer and/or other HPV-related diseases constitutes a public health priority.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Consideration should be given to vaccination cost-effectiveness, programmatic feasibility and sustainable financing.For the prevention of cervical cancer, the primary WHO recommended target group for HPV vaccination is girls aged 9-14 years, prior to becoming sexually active.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Since 2017, WHO also recommends that when HPV vaccine is first introduced, multiple cohorts of girls 9-14 years should be vaccinated.Vaccination of secondary target populations, such as older adolescent females or young women, is recommended only if feasible, affordable, cost-effective, and when resources are not diverted from vaccinating the primary target population or from effective cervical cancer screening programmes.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "HPV vaccination of males is currently not recommended as a priority.3,4 Initially, the recommended schedule included three HPV vaccine doses.This was changed in 2014 to two doses for children who are less than 15 years of age when they receive their first dose.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The recommended minimum interval between the two doses is six months, and ideally no more than 12 to 15 months, though there is no maximum interval between doses for persons aged 9-14 years.The three-dose schedule is still recommended for HIV positive and immunocompromised persons and for those aged 15 years or more.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "This document focuses on HPV vaccination targeting girls 9-14 years using a two-dose schedule; some of the monitoring tools presented here could be adapted for other target groups and schedules.As of 2020, more than 100 countries had introduced HPV vaccine into their national immunization schedules.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The most recent data on HPV vaccine use is available at: http://www.who.int/immunization/monitoring_surveillance/en/.While several examples of monitoring tools for HPV vaccination are presented in this manual, additional examples of monitoring tools from countries that have introduced HPV vaccine are available in the HPV section of the TechNet-21 website.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "# Monitoring HPV vaccination coverage: Objectives, data needs and challenges # Objectives for monitoring HPV vaccination coverage The primary purpose for monitoring HPV vaccination coverage at the country level is to monitor the performance of the vaccine programme, track vaccine uptake, and ensure that coverage is maximized and maintained.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Secondary purposes are to estimate the long-term impact of HPV vaccination on morbidity and mortality, demonstrate the vaccine’s effectiveness in real world settings, and understand epidemiologic changes in disease patterns after the vaccine’s introduction.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "This can include identifying changes in the age distribution of the disease or changes in disease-causing strains, as well as assessing herd immunity and long-term immunity.Coverage data are of paramount importance to correctly interpret measures of the vaccine’s impact, especially given that a reduction in cervical cancer incidence cannot be detected for many years after the vaccine has been introduced in a country.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Monitoring HPV vaccine coverage requires a different approach from the one used to monitor routine infant vaccines that are included in the Expanded Programme on Immunization (EPI) and, as such, it presents unique challenges.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "HPV vaccine can target a wide age range and there are several delivery strategies that can be used including school-, community- and health facility-based delivery.In addition, HPV vaccine doses administered in special settings, such as factories, hospitals and in the private sector, may not be routinely captured in the national immunization coverage data.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The regional and global levels of WHO and other international agencies also need coverage data to assess the performance of country programmes and the impact of the vaccine, as well as to compare and monitor vaccine coverage across geographical areas and trends over time.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Since 2010, the WHO/UNICEF Joint Reporting Form (JRF) on immunization systematically collects information on HPV vaccine doses administered by age and by dose for a given calendar year.5 The JRF spread sheet, which includes female as well as male vaccination (for 2018 data) is shown in Appendix 1.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "# Data required to meet these objectives HPV vaccine coverage monitoring by dose and by age or year of birth is needed for country and international reporting.Date of birth (or an approximation), date of vaccine administration, and dose number should be recorded for every dose administered.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "One rationale for monitoring HPV vaccine by dose and by age or year of birth, as opposed to a broader age group, is that the vaccination targeting or eligibility criteria may change, resulting in challenges to monitor and compare coverage over time.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "This may include situations where catch-up vaccination of older age groups is done in the early years of vaccine introduction.It may also result from revising the eligibility criteria (age or school grade) for vaccination.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "One challenge that may arise in calculating coverage is when eligibility criteria include an age range, for example, when a school grade (class) is being targeted with girls who range in age from 9 to 12 years old.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "This may make it difficult to estimate and interpret coverage levels for the different ages separately.In this case, a school grade may be assigned a single age as a proxy for a single age cohort, though this is not preferred.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "For example, if vaccination is done in $6 ^ { \\mathrm { { t h } } }$ grade, for practical reasons, the data can be attributed to girls aged 11 years, even if in $6 ^ { \\mathrm { { t h } } }$ grade there are also girls who are 10, 12 and above.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "A summary indicator (the proportion of girls vaccinated with the complete series of HPV doses by age 15) to resolve this issue is presented in Appendix 2.As per WHO recommendations, this is the age by which all girls should have received the HPV vaccine.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "This summary indicator – similar to DPT3 coverage for infants – can be used to calculate in-country coverage when eligibility criteria include multiple age cohorts within a school grade-based vaccination approach, or when HPV vaccine introduction targets multiple age cohorts.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Countries may also want to monitor HPV vaccine coverage by delivery strategy in order to guide programme strategies.In this case, data on the delivery strategy (e.g., schoolbased outreach, community-based outreach, periodic campaigns, health facility-based) should also be collected.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Finally, as it will be discussed later in the document, the denominator to calculate coverage should be the total number of girls in a given geographic region by age.For example, a denominator based on the number of girls enrolled in school would not provide coverage data for the entire target population in a given community as it may exclude girls not attending school.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "“Date of birth, date of vaccine administration, and dose number should be recorded for every dose administered.” # Considerations for school-based vaccination There are special considerations and potential challenges for monitoring HPV vaccine coverage when a school-based vaccination strategy is used.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "While school grades are often used as a proxy for age for school-based immunization programmes, it is strongly recommended that vaccination data be recorded by year of birth or age, and dose, even when the vaccine is delivered by school grade.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Compared to age, the year of birth for each girl vaccinated can result in more accurate data, since it accounts for the following: \u0007The range of ages present in a single school grade which could include ages for which the HPV vaccine is not licenced (e.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "g., girls in fourth grade who are less than 9 years old); I\u0007n that girls can begin and complete the vaccination series over an age range, it is easier to follow a given birth cohort over time and estimate its cumulative coverage; \u0007Changes in the recommended school grade to target for HPV vaccination, especially if older girls tend to be in the grade initially targeted; \u0007To produce coverage data for the entire targeted population of girls, the ability to combine the number of girls vaccinated in schools and the number of girls absent from or not enrolled in school vaccinated through other delivery strategies (e.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "g., outreach, health centres).Of note: alternative strategies should be considered in cases wherein accurate dates of birth and age may be difficult to obtain, may not be well documented or culturally unimportant (see Section 2.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "1).“It is strongly recommended that vaccination data be recorded by year of birth or age, and dose, even when the vaccine is delivered by school grade.” Other challenges and special considerations for monitoring school-based vaccination coverage include: School year crosses over the reporting year.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The school year may not align with the calendar reporting year.For example, the school year may start in September while the reporting year for immunization programmes usually begins in January.This can lead to variations in reporting HPV coverage.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Immunization programmes should consider this at the start of HPV vaccination and decide how the data will be collected.However, over time, given the similar size of age cohorts, the estimate of HPV coverage should become an adequate approximation, as for other infant vaccines.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "6 Deciding what to use for the denominators.Even when the main delivery strategy is school-based, monitoring HPV vaccine coverage should include vulnerable populations that may not attend school.The denominator, therefore, should include all girls eligible for HPV vaccination.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "See Section 1.5.![](images/9526e4b7cf361fc5ce8c504a6cc1bad9c53f10eb99e14c8edb4768c904e6b12d.jpg) # Challenges in correctly recording school-based HPV vaccination When vaccination takes place in schools, countries may target girls either by age or by grade.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "A coun­ try may establish a defined age for starting the HPV vaccination series, but the next dose may be given when the girl has already had her next birthday (e.g., HPV1 at 11 years and HPV2 at 12 years).",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Similarly, when the school year stretches over two calendar years, the first dose may be given during one calendar year and the second during the next (e.g., HPV1 in 2014 and HPV2 in 2015).Thus the doses reported for a calendar year may reflect the vaccination of different cohorts of girls.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Without a clear definition or guidance on how to collect and report HPV vaccine data, the resulting “number of doses administered” may be difficult to interpret.These challenges in reporting the numerators (number of doses) are in addition to the challenges discussed in this guide in accurately quantifying the population to be used as denominator for HPV vaccination.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "7 # Considerations for continuous (routine) versus periodic (campaign-style) HPV vaccination Different ways of delivering HPV vaccine may affect the design of the HPV vaccination reporting system.\u0007HPV vaccines delivered on a continuous basis (“routinely”) throughout the year like other childhood vaccines.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Girls who reach the defined eligible age (e.g., 12 years) go to the health facility and receive the first dose (HPV1).This strategy results in HPV vaccine being available and delivered throughout the year.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "In this situation, data on HPV vaccination flow through the country’s reporting system on a continuous basis, making it easier to integrate HPV monitoring with the monitoring of other routine vaccines or other health interventions.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "With contin­ uous vaccination, as for other vaccines, the annual target for HPV can be divided in 12 monthly targets to monitor the cumulative vaccination coverage by dose and by month.\u0007HPV vaccines delivered periodically in rounds, or “pulse campaign” style.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "In this scenario, a given period is established for delivering and receiving the first and second vaccine doses as separate “rounds”.When schools are used to deliver HPV vaccine, the timing often coincides with appropriate moments in the school calendar year, and the same period is used to vaccinate girls who do not attend school.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "For example, the first dose may be scheduled for the beginning of the school year (e.g., September or October in many countries), and the second dose towards the end of the school year (e.g., April or May).",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "In this case, the flow of HPV vaccination data will not be continuous.It will instead take place only during the months in which first and second dose are delivered, and the two vaccination “rounds” may fall in different reporting years.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Immunization registers and home-based records to track individual vaccination status become very important to determine who is due for a second dose in each round (see Sections 2.3 and 2.4).Also, it is important to note that the total target population will be used as the denominator to calculate coverage for each round.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "“While recognizing that a mix of delivery strategies for HPV vaccination exists, the rest of this document focuses on the design and use of a monitoring system that is based on the routine delivery of the vaccine in health facilities, given than several developing countries are using this strategy.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "” ![](images/202fcec7b291cc4e657f5603d28c12f14dd7893cf7faf846e6ac820cbe2d536a.jpg) \u0007A note about reporting by round instead of by calendar year: A monitoring system that reports HPV vaccination by round has advantages and disadvantages.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "One advantage is that it may align the reporting of HPV vaccination with that of other vaccines targeting school-aged children, such as tetanus-diphtheria-containing vaccines, or other school-based health interventions such as deworming.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "In this case, reporting can be integrated with these other vaccines and health interventions.Among the disadvantages, creating HPV vaccination forms that record and report by round may introduce a parallel reporting system (e.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "g., a new tally or reporting sheet), making it harder to integrate HPV vaccination data into the monitoring system for other childhood vaccines.It is important not to equate the first round of vaccination with the first dose of HPV vaccine.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Every round of vaccination is an opportunity for girls to receive a first or a second dose of HPV vaccine, and should thus be considered an opportunity to vaccinate any girl who was missed earlier or has not yet been fully vaccinated.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Monitoring forms should be designed to enable the delivery and recording of both HPV1 and HPV2.# Determining denominators for monitoring HPV vaccination As noted earlier, identifying accurate denominators for HPV vaccination poses challenges.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The denominator for HPV vaccination differs from the one used for infant and childhood vaccination, being dependent on the eligibility criteria for the HPV vaccine.A country that chooses “all 12 year-old girls or girls born in year $\\mathsf { X } ^ { \\prime \\prime }$ to be eligible for vaccination may be able to obtain an estimate from the National Statistics Office for that single age cohort or use available United Nations population estimates or will have to estimate them (see appendix 3).",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "When the eligibility criteria include a population attending a specific class or grade, such as “Primary Grade $5 , \"$ then the Statistics Office may not be an adequate source for this information and data will need to be collected from the Ministry of Education.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Experiences from several countries, especially from low-income countries with rapidly improving enrol­ ment rates for girls, indicate the need to verify enrolment data with actual attendance in school through enumeration, i.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "e., head-counts.Challenges that have arisen include the fact that some schools, often private schools, have not yet been registered with the Ministry of Education, and enrolment numbers do not always match actual school attendance, among others.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Several countries have used field identification of every school and pre-registration of each eligible girl during the weeks preceding the vaccination as a way to establish more accurate denominators, especially when the vaccination has just been introduced.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Estimating the denominator can be particularly challenging when a country uses eligibility criteria that combine a grade with an age target for out-of-school girls.For example, “All girls in school attending Primary Grade 5 and 10 year-old girls not attending school” can be used as a proxy for the denominator of a single age cohort.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "In these cases, establishing the size of the out-of-school target population can be difficult.In some settings, Ministries of Education may be a good source of information on the size of the out-of-school population.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Also, some countries have conducted pre-registration activities to identify and count eligible girls not attending school, using village health workers or community organizations.WHO, in collaboration with UNESCO, has developed reports for Gavi-eligible countries8 that provide estimates on out-of-school populations.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "9 Experience in several countries has shown that denominator data for HPV coverage calculation are often less readily available and sometimes less accurate than data for younger children.The accuracy of target population estimates at the subnational level can be problematic.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "For example, they can be affected by population movements, including migration of adolescents from rural to urban areas for work or education (e.g., boarding at secondary and private schools).While no good solutions exist for better estimating target populations for HPV vaccination, having these challenges in mind will help better interpret coverage data.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "![](images/4f5137c026ec558e4e4dacb93a755e9fc4f15ac967cba7ea041d7520061159ef.jpg) Tools for recording and reporting HPV vaccination ![](images/100d1170efe70698e423b8dddc2cc2e37bf30b2ad33a30d4335c89e047036fb4.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "jpg) # Types of data and reporting tools needed # Required tools When introducing HPV vaccine, the existing recording tools used for immunization activities should be either adapted to include HPV vaccination, or new forms and data flows may be needed.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The latter may be the case in settings where other vaccines or interventions targeting the same or a similar age group (e.g., young girls) do not exist.If a country uses an electronic aggregated information system, such as a health management information system (HMIS), or and electronic immunization registry that captures individual immunization data, it will be important to update these to include HPV vaccination.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The main recording and reporting tools that will need to be adapted or created for HPV vaccination include: ![](images/e7fa4851b67ad5b4033e460aa4a5ec38a226d5188f5ed581ba777aadfe8d4b9d.jpg) ![](images/5d0e0b69be6b077040bf72c45bc6a9b1a47734e55763f7d94ac5585c51a3fd1a.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "jpg) ![](images/18811fbe51097c771bd86817182aa141761229b30302d39294fe9489777bebb9.jpg) Tally sheets Immunization registers Home-based records10 ![](images/44537d05620e6cfe998ee09162aac48e39fe7b29c89a56f571602da3c455fb06.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "jpg) ![](images/66803d3a53149bf162e448d67105d4650ef8abcd0c431c526383fadcb816d9f8.jpg) ![](images/83968528be59799427cd6b17460ec6fcf1a76381b029cce1b60b618e9166f1da.jpg) # Stock records for vaccines and related supplies Monthly summary reports Monitoring charts The tools will need to be designed based on the vaccination strategy in the country.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "For example, different tools will be needed if vaccination is done at health facilities continuously, or periodically at schools.# Data to collect Decisions must be made about the types of information and performance indicators that will be used to monitor HPV vaccination performance and guide action.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "This will serve as the basis for determining the data requirements.In this manual we focus on the minimum requirements needed to calculate HPV vaccination coverage and drop-out rates, i.e., sex, date/year of birth or age, date of vaccine administration, and dose number.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The immunization records should be modified to include a space for entering the date of HPV vaccine administration and to allow disaggregation by sex, if HPV vaccination is offered to females and males, by age and dose.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "In settings where age is not always known, the country may have to decide whether to create an age category of “unknown” to record, and then report and aggregate, doses given to girls whose exact age is not known, but which likely is within the target age group for HPV vaccination.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "It may be preferable to instruct vaccinators to estimate, based on available information, the girls likely age, as doses reported in an unknown age category are likely to be disregarded in national reporting and in estimating global coverage data, since as no denominator can be assigned to this category.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "In some of the examples below the “unknown” category is not used.For school vaccination, the name of the school and grade level should also be routinely recorded to ensure that all eligible schools have been enumerated and included in the aggregated reports.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "In settings where other interventions or other vaccines, such as tetanus-diphtheria (Td), are already targeting a similar age group, HPV vaccine should be added to the existing data collection forms to reduce the reporting burden of health workers.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Forms should be designed with the vaccinator in mind (using user-centered design approaches11) and piloted before their printing and widespread use.Finally, it is good practice to always include the date or version of the data recording and reporting tools on the form, in order to monitor and avoid the use of outdated forms, which can create problems for monitoring.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "![](images/1263e71c59528048ccc7466a67ae9d16ec586acab13cff822ec4b6733f76ae62.jpg) It may be preferable to instruct vaccinator to estimate the girls’ likely age, based on available information, than to report these doses in the category “unknown age” !",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "[](images/95c36466069a0a84e1bba6763802bd38803da1d42981d7ea34332233e9559b7b.jpg) # Tally sheets Tally sheets or tally booklets are the forms that health workers use to document an immunization session by making a record of every dose of vaccine administered.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "They are used to enumerate doses administered at the time of vaccination, and each vaccination should therefore be marked (“tallied”) immediately following its administration.Tally sheets are often completed at the same time as the immuni­ zation register (see Section 2.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "3 below).Tally sheets can be kept by session or by month.They are useful because, unlike an immunization register, they make it easy to rapidly sum up the doses administered for preparing summary reports or monthly reports (see Section 2.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "6 below).Tally sheets should be used for all HPV vaccinations, whether at the health centre, fixed outreach site, school, or when conducted by mobile teams.It is recommended that the HPV vaccine tally sheet track the doses given by school and grade, dose number (1 or 2), age (which is particularly important if using a school class or grade as the target population), and sex (in case males and females are targeted or when the tally is integrated with other vaccines such as Td).",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "There are a variety of tally sheet designs (with , IIII, zeros or circles as tally marks), most of them are preprinted.If preprinted sheets are not used, all vaccinators in a health facility should use the same type of tally mark to make it easier to count the totals.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Tally sheets can also be useful in tracking vaccine doses that are wasted.# Completing the tally sheets 1.\u0007Fill out one sheet for each vaccination day.2.\u0007Write the date.3.\u0007Write down the geographical/ administrative area and the service delivery site (which can also be the school and grade).",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "4.\u0007Mark the tally sheet for each dose received in the appropriate category (and sex, if vaccine is also offered to boys), right after the dose is given.5.\u0007At the end of each immunization session, add up the number of marks recorded during the session.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "This gives the total number of immunizations given for each dose, i.e., HPV1 and HPV2.6.\u0007At the end of the reporting period (usually month), total all doses given by age to complete the monthly report.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Note that this step does not apply for HPV vaccines given in vaccination rounds.7.\u0007Keep the tally sheets for the supervisor to review.Archive them safely and in an orderly manner and keep for as long as required in the country (usually 3-5 years).",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Avoid these common mistakes in tallying the vaccine doses: \u0007Tallying before the vaccination is given, as the person may not receive the vaccination (if, for example, the vaccine runs out or the person or parent/caregiver refuses); \u0007Filling out the sheet at the end of a session based on the number of doses contained in the used vials, since wasted doses may be counted; \u0007Marking vaccinations under the wrong dose or age (or birth year).",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "This will result in inaccurate coverage data.As this process might be new for some national immunization programmes, it is advised that standard operating procedures (SOPs) be developed and that health worker trainings conducted prior to the introduction of HPV vaccine carefully review the proper method for using the HPV vaccine tally sheet.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "It is also worthwhile for supervisors to routinely spend time reviewing tally sheets with staff, in order to improve the quality of reporting.Below are two examples of tally sheets for HPV vaccination – one using the child’s age and the other, the year of birth.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "District: Town/Village Service Delivery Site: Example 1: Tally sheet, using age in years <html><body><table><tr><td>Age (years)</td><td colspan=\"2\">No.of HPV1 doses given</td><td colspan=\"2\">No.of HPV2 doses given</td><td>Optional Check Column (sum up rows)</td></tr><tr><td>9</td><td>00000 00 0 00000</td><td>9yrHPV1= 8</td><td>00000 00000 0 00 00000 00000</td><td>9yrHPV2= 10</td><td></td></tr><tr><td>10</td><td>00000 00000 00000 00000 00000 00000 00000</td><td>10yrHPV1= 0</td><td>00000 00000 00000 00000 00000 00000</td><td>10yrHPV2= 15 </td><td></td></tr><tr><td>11</td><td>00000 00000 00000 00000 00000 00000 00000</td><td>11yrHPV1=</td><td>00000 00000 00000 00000 00000 00000 00000</td><td>11yrHPV2=</td><td></td></tr><tr><td>12</td><td>00000 00000 00000 00000 00000 00000 00000 00000</td><td>12yrHPV1=</td><td>00000 00000 00000 00000 00000 00000 00000</td><td>12yrHPV2=</td><td></td></tr><tr><td>13</td><td>00000 00000 00000 00000 00000 00000 00000</td><td>13yrHPV1=</td><td>00000 0000 00000 00000 00000 00000 00000 00000</td><td>13yrHPV2=</td><td></td></tr><tr><td>14</td><td>00000 00000 00000 00000 00000 00000</td><td>14yrHPV1=</td><td>00000 00000 00000 00000 00000 00000</td><td>14yrHPV2=</td><td></td></tr><tr><td>≥15</td><td>00000 00000 00000 00000 00000 00000 00000 00000</td><td>15yrHPV1=</td><td>00000 00000 00000 00000 00000 00000 00000 00000</td><td>15yrHPV2=</td><td></td></tr><tr><td colspan=\"2\">Optional Check row (sum up columns)</td><td></td><td></td><td>=</td><td>Grand total=</td></tr></table></body></html> District: Town/Village Service Delivery Site: Example 2: Tally sheet, using birth year <html><body><table><tr><td>Birth year</td><td colspan=\"2\">No.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "of HPV1 doses given</td><td colspan=\"2\">No.of HPV2 doses given</td><td>Optional Check Column (sum up rows)</td></tr><tr><td>2009</td><td>00000 00000 00 00000 00000</td><td>9yrHPV1= 8</td><td>00000 00000 00 0.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "0 00000 00000</td><td>9yrHPV2= 10</td><td></td></tr><tr><td>2008</td><td>00000 00000 00 00000 00000</td><td>10yrHPV1= 0</td><td>0000 00000 09 00000 00000</td><td>10yrHPV2= 15 </td><td></td></tr><tr><td>2007</td><td>00000 0000 00000 00000 00000 00000 00000 00000</td><td>11yrHPV1=</td><td>0000 0000 00000 00000 00000 00000 00000</td><td>11yrHPV2=</td><td></td></tr><tr><td>.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": ".(add years)</td><td>00000 00000 00 00</td><td>(.) yrHPV1=</td><td>00000 00000 00 0 00000</td><td>(..) yrHPV2=</td><td></td></tr><tr><td>2003</td><td>0000 00000 00000 00000 00000 00000 00000</td><td>15yrHPV1=</td><td>00000 0000 00000 00000 00000 00000 00000</td><td>15yrHPV2=</td><td></td></tr><tr><td colspan=\"2\">Optional Check row (sum up columns)</td><td></td><td></td><td></td><td>Grand total=</td></tr></table></body></html> # Immunization registers # 2.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "3 Immunization registers record doses given to an individual and help health workers keep track of each dose that has been administered to each person.It is the basis for determining a person’s immunization status, if, for example, her home-based record, such as an immuni­ zation card, is lost, as well as for tracking defaulters.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "12 Most often immunization registers are organized as books in which individuals are registered in a line listing according to date of birth, some identifier (e.g., national ID number, health ID) or even barcodes linked to the home-based record, or the date of the person’s first visit for an immunization included in the register.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "In well-organized registers, when the person comes back, it is usually quite easy to locate and update her record with the next vaccine dose.In paperbased registers, it is unlikely that the same register that is available for early childhood vaccination is available for vaccinations given to older children and adolescents and thus, new registers for older persons may need to be established.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "# Completing the immunization register for HPV If the register includes addresses and/ or other contact information, such as a mobile phone number, then it can be used to actively find individuals who are overdue for their vaccinations.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "1.\u0007Identify the geographical/administrative area and the service delivery site or school, where appropriate.2.\u0007Register the person’s name, sex (in case males and females are targeted or when the registry is integrated with other vaccines such as Td), address and phone number, and date of birth.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "3.\u0007Write the date for each vaccine adminis­ tered in the column corresponding to the dose number (HPV1 or HPV2), as well as the age of the person at the time the vaccine is given.Enter the age that is reported by the person, the parent/ caregiver or teacher)13.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "4.\u0007Write down any other data of relevance to the immunization programme, such as adverse events or a vaccine contraindica­ tion in the Comment column).5.\u0007When a girl returns for the second dose of HPV, ask for the home-based record (e.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "g., immunization card) and look for a corresponding entry in the register.If the home-based record is not available, ask for the person’s name, age and the month and/or other details of the first immunization, then locate her line in the register.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Once the information is located in the immunization register, verify her eligibility for HPV2.6.\u0007Keep the immunization registers safe and stored in an orderly manner and for as long as required by the country (usually 3-5 years).",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Please note that a new entry in the register should not be created each time a girl comes to a clinic for the immunization or a session is held in the school, unless the girl received the first dose in another facility.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "In such cases, the register can be updated based on the infor­ mation available in the home-based record.For school vaccination, establishing school registers, which may or may not be by grade or age, may be useful.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Such registers should be similar in content to immunization registers used by health facilities, but they are organized by school instead of by health facility.Since there will always be girls who miss the second dose, even if given in the same school year, the registers or other similar tools should allow their easy identification to ensure follow-up.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "An example, is to check for unvaccinated girls in higher grades to see if mop-up vaccination is needed.# Example 1: Immunization register for HPV District: Town/Village Service Delivery Site: <html><body><table><tr><td>ID</td><td>Name</td><td>Address and phone number</td><td>Date of birth (dd/mm/yyy) Date given</td><td>HPV1</td><td>Age of girl</td><td>HPV2</td><td>Comments Age of girl</td></tr><tr><td></td><td></td><td></td><td></td><td>(dd/mm/yyy) (years)</td><td></td><td>Date given (dd/mm/yy) (years)</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table></body></html> !",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "[](images/6cc5cb2575cfd4d3f2226db36743a4c34fd31e0829134aae74d5951c9ae477cf.jpg) Example 2: Human Papillomavirus vaccination register South Africa uses a written consent form that pupils have signed at home before vaccination hence the register includes a column to register whether consent is provided.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "According to the WHO guidance note on consent, consenting practices differ between countries and many counties use implicit consent approaches in which case this column would not be needed.WHO recommends that the consent procedure for HPV vaccination follows the same process as for other vaccines as a way to encourage uptake.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Link: https://www.who.int/immunization/programmes_systems/policies_strategies/consent_note/en/) ![](images/a13daa24be603226bd86d85a3ed43a62d4afbf75d8d289a6e9dddfc577e4eb69.jpg) # Home-based records Home-based immunization or health records are cards or booklets that are given to the child or her parent or caregiver.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Home-based records (HBRs), which are easily modified to include HPV vaccination, keep track of all vaccinations provided and often other health interventions as well.There a several uses and advantages of HBRs, including that they: \u0007Enable health workers to determine which doses are due; \u0007Serve as a reminder for the next visit/dose; Facilitate coverage surveys; \u0007Serve as documented proof of immu­ nization status if required for school enrolment or for other reasons e.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "g., for cervical cancer screening later in life); \u0007Serve as a communication tool with the child and parents, if the card includes information about the vaccines and their recommended schedule, including when to go back for a subsequent dose.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The style and functionality of home-based records differ from country to country.Examples of vaccination cards for HPV are shown below and included in the WHO guidance document on home-based records (See Key Resource box below).",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "In addition, a repository with samples from around the world can be found online14 and specific examples of HBRs, including ones for HPV, are available on the TechNet-21 website (https://www.technet-21.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "org/en/topics/hpv).# Completing home-based records for HPV vaccination ![](images/afb119fd2cbc127abd58e5a72b25caa818db53247fc2357951f536035ba42de6.jpg) 1.\u0007Clearly write the name of the girl and all other general information required in the card.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "2.\u0007Clearly write the date for each vaccine administered in its corre­ sponding section on the card.3.\u0007After HPV1, indicate the date for the second dose of HPV on the card, following the country schedule, and ensure that the girl and/or parent/ caregiver understands when and where to return for HPV2.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "4.\u0007Use the HBR to identify the girl in the immunization register, or to update the register if needed (see Section 2.3 above).5.\u0007Return the immunization card to the girl or parent/caregiver.A copy may also be kept in the school.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "6.\u0007Explain that the immunization card must be kept in good condition, safe and in a dry place, and that it should be brought for future health care visits, particularly to receive the second HPV dose.7.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "\u0007Remind the caregiver or the girl herself that the card should be taken to all of health care visits for review.# Example 1: comprehensive adolescent health card, including information on other health interventions (eg.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Nutrition) and other vaccines besides HPV — Mexico ![](images/f5d73f25791899071c749c8dfb353722585376d385e210fe9af0b6841427bb39.jpg) # Example 2: a dedicated HPV card including messages on cervical cancer and vaccination HP—V Zccinatimon Cbarda_HbPVwVaccein ti2on0Car1d 287/ !",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "[](images/8784a489f60c044442a84484e5016449bf258ec16c4eae2ef23382b814ea1574.jpg) ![](images/d80648dff08509f9b1ef4d761c5d989b0dfb905594b1a23159461292b2dad335.jpg) ![](images/e987f23e0039d35b07a5a9cc1118daad37d8524548b1c647b691407028240492.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "jpg) Cervical Cancer Prevention is everyone's responsibility.Get girls vaccinated against HPV!!!![](images/08bdf59062baf7449c4747f8b0f247c122b5ab5e22ab1de96cbf9f43014b505c.jpg) # LEARNER INFORMATION FOR OFFICIAL USE ONLY continued <html><body><table><tr><td>In the past, did the girl have:</td><td>Yes / No</td><td></td></tr><tr><td>An allergic reaction to a vaccine?",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "</td><td></td><td>NO</td></tr><tr><td>A severe illness in the last 7 days?</td><td></td><td>NO</td></tr><tr><td rowspan=\"3\">Completed by vaccinator</td><td colspan=\"2\">Dose1</td></tr><tr><td>YES No</td><td></td></tr><tr><td>Dose2</td><td></td></tr><tr><td></td><td>YESNO</td><td></td></tr></table></body></html> <html><body><table><tr><td>Dose</td><td>Batch No.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "</td><td>Date</td><td>Signature of vaccinator</td></tr><tr><td>HPV1</td><td></td><td></td><td></td></tr><tr><td>HPV 2</td><td></td><td></td><td></td></tr></table></body></html> <html><body><table><tr><td colspan=\"2\">Date of the next HPV vaccination</td></tr><tr><td></td><td>HPV2</td></tr></table></body></html> Notes !",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "[](images/2d742b7348a3ffdac5d5c0c2f0f49fffb71372c4478397243ce7bb571318cfdf.jpg) # KEY RESOURCE \u0007Practical guide for the design, use and promotion of home-based records in immunization programmes \u0007This document provides guidance to national immunization programmes on how to improve the design of home-based records and how to promote their use among health workers and caregivers.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "\u0007http://www.who.int/immunization/monitoring_ surveillance/routine/homebasedrecords/en/ To avoid missing any opportunity to vaccinate with HPV, health workers should get in the habit of asking for and reviewing home-based records for adolescent girls at each visit, regardless of the reason for coming.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "In some cases when HPV is delivered through schools, the vaccination card will be kept at school and given to take home only after both doses have been administered.In other cases, a separate school health record will be maintained serving a similar function as the immunization record kept at health facilities.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Nevertheless, as girls may change school or seek vaccination elsewhere the home-based record should always be given so that the person can carry her record.While it is always desirable to have an immunization card that includes vaccinations over a lifetime, following the “life-course” approach towards immunization, it is recognized that many countries use vaccination cards only for childhood vaccinations.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "In these cases, it will be necessary to create a new vaccination card for adolescent vaccinations that includes HPV.Even if HPV is the only vaccine currently administered to this age group, it may make sense to include options for other vaccines that can be added (e.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "g.Td).# Stock records and wastage monitoring Stock records or ledgers are books used to record all stock transactions (receipts, dispatches, physical stock counts, and spoilage) for all vaccines, including HPV, and related supplies (e.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "g., syringes) and to keep a running balance of the number of available doses by product and lot number (see the vaccine stock manage­ ment guidelines).15 Monthly stock reports are needed to ensure adequate supplies and avoid stock-outs.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The same function is performed by bin cards or inventory control cards, which are often kept at the refrigerator or cold room.Below is a sample a health centre stock report, which provides an estimated monthly consumption requirement based on expected vaccination activities.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The vaccine consumption figures in these records should correlate with the total number of doses used at immunization sessions held during the month.Each health centre should then report these figures according to national guidelines.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Stock report data may also be added to the monthly summary report (see Section 2.6 below) Example: Vaccine and Injection Materials Stock Register <html><body><table><tr><td>Received</td><td></td><td></td><td></td></tr><tr><td>Date</td><td></td><td></td><td></td></tr><tr><td>Name in Unit</td><td></td><td></td><td></td></tr><tr><td>Stock at hand</td><td></td><td></td><td></td></tr><tr><td>Doses received</td><td></td><td></td><td></td></tr><tr><td>Batch number</td><td></td><td></td><td></td></tr><tr><td>Expiry Date</td><td></td><td></td><td></td></tr></table></body></html> <html><body><table><tr><td>Issued</td><td></td><td></td><td></td></tr><tr><td>Doses issued</td><td></td><td></td><td></td></tr><tr><td>Batch number</td><td></td><td></td><td></td></tr><tr><td>Expiry date</td><td></td><td></td><td></td></tr><tr><td>Doses used</td><td></td><td></td><td></td></tr><tr><td>Doses wasted</td><td></td><td></td><td></td></tr><tr><td>Doses returned</td><td></td><td></td><td></td></tr><tr><td>Total balance</td><td></td><td></td><td></td></tr></table></body></html> <html><body><table><tr><td>Remarks</td></tr><tr><td></td></tr><tr><td></td></tr></table></body></html> # Monthly Summary Reports # Data to include The monthly immunization report contains critical data on most of the components of the immunization system in summary format for both easy recording and easy tracking.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "It is a valuable tool for managing the programme’s achievements and to monitor progress throughout the year.In general, an integrated monthly report that contains summary data on all immu­ nization, should contain the following elements with regards to HPV vaccination: \u0007The number of HPV1 and HPV2 doses by age or year of birth administered in the month (and by sex if males are also targeted); \u0007Stocks received and used, including vaccines and injection equipment, and wastage; \u0007The number of adverse events following immunization (AEFI) reported or identified.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Below are examples of the HPV section of monthly reports – it should be decided if the report will be by age or by year of birth.![](images/758a126b0e30bd4d34986e23f6b2a6c22e4808fed27b0ccc41fe892d29402ebb.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "jpg) # Quality checking of the reports Quality checking of reporting needs to happen at all levels of the health system, starting with health workers, and then up the chain to supervisors, district managers up to national immunization programme staff.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "# Reports should be: 1.\u0007Complete.All sections of the summary reports should be filled in and no parts left blank.All reports due from different services and/or outreach sites should be received and their data included in the summary report.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "2.\u0007Submitted in a timely fashion.All summary reports should be submitted to the next level by the assigned deadline.A standard procedure must be defined to deal with delayed reporting.3.\u0007Accurate.All summary reports should contain figures that correspond to the actual figures from health facilities.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "These figures should be double-checked to ensure that the calculations and totals are correct.# Example 1: Monthly report by age in years District: Town/Village: Service delivery site: Vaccination strategy: <html><body><table><tr><td>Year of birth/ Age</td><td colspan=\"6\">No.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "of HPV1 doses given</td><td colspan=\"5\">No.of HPV2 doses given</td><td rowspan=\"2\">Comments</td></tr><tr><td rowspan=\"2\">2009/ 9 years</td><td colspan=\"6\">9yrHPV1:</td><td colspan=\"5\">9yrHPV2:</td></tr><tr><td>8</td><td></td><td></td><td></td><td></td><td>Total </td><td>10</td><td></td><td></td><td></td><td></td><td>Total </td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=\"3\">2008/ 10 years</td><td colspan=\"6\"></td><td colspan=\"5\">10yrHPV2:</td><td></td></tr><tr><td>10yrHPV1:</td><td></td><td></td><td></td><td></td><td></td><td>15</td><td></td><td></td><td></td><td></td><td rowspan=\"2\"></td></tr><tr><td>0</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=\"2\">2007/ 11 years</td><td colspan=\"6\"></td><td colspan=\"5\">11yrHPV2:</td><td></td><td rowspan=\"2\"></td></tr><tr><td>11yrHPV1:</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=\"2\">2006/</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td rowspan=\"2\"></td></tr><tr><td>12yrHPV1:</td><td></td><td></td><td></td><td></td><td></td><td>12yrHPV2:</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=\"2\">12 years</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=\"2\">2005/ 13 years</td><td>13yrHPV1:</td><td></td><td></td><td></td><td></td><td></td><td>13yrHPV2:</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=\"3\">2004/ 14 years</td><td>14yrHPV1:</td><td></td><td></td><td></td><td></td><td></td><td></td><td>14yrHPV2:</td><td></td><td></td><td></td><td></td><td></td><td rowspan=\"3\"></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=\"3\">2003 or earlier/ 15 + years</td><td>15yrHPV1:</td><td></td><td></td><td></td><td></td><td></td><td></td><td>15yrHPV2:</td><td></td><td></td><td></td><td></td><td></td><td rowspan=\"3\"></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table></body></html> Completeness and timeliness of reporting refer to (1) the level to which facility data is aggregated (i.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "e., usually a district); (2) receiving all reports expected and by a set date; (3) and whether HPV vaccines were administered or not.These can be useful indicators for measuring the performance of the information system.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Completeness requires mecha­ nisms to ensure that all providers who administer HPV vaccines report all doses given.As with tally sheets and registers, supervisors must carefully check monthly report forms systematically.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "If the HPV vaccine delivery strategy is periodic vaccination only, for example every 6 months or annually and not continuously throughout the year, then “zero” reporting will be necessary for the months when HPV vaccine is not given.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Alternatively, summary reports may be used to quantify HPV doses by age or birth year (and by school and grade, where appropriate) for only those months when the vaccine is provided.# Flow of data up the health system Monthly reports should be submitted by all health facilities providing HPV vaccination, noting the delivery strategy used (health facility, school, outreach).",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Health facilities will follow their normal reporting procedures.Copies of reports with dates and signatures are usually sent to the next level (e.g., district, province) and the originals stored at the health facility (Figure 1).",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The reports should be archived in an orderly manner for as long as required by the country (usually 3-5 years).It will be important to ensure that private and other non-public providers are integrated into the existing reporting structure and data flow.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "![](images/15787464c6abae83cd5979bc6df5a040dada47c7cc8aee25c97c8bbb752a930d.jpg) Figure 1.Examples of vaccination data flow using health management information systems.The exception to this type of data flow is the Electronic Immunization Registry (EIR)16.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "In these systems, the immunization records of each person are maintained in an electronic database, and all the data needed for monitoring can be extracted from this database at any time, including monthly reports if they are set to do so.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "# Tracking doses and defaulters As with other vaccinations, it is important to follow-up eligible girls who fail to present for either the first or second dose of HPV vaccine.A system to track dropouts is an integral part of the Reach Every District (RED) or Reach Every Community (REC) strategy.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "17 There are a number of tools to identify, track and follow up persons due for vaccination or “drop outs”.These include: ![](images/fb94ce6cd7f28dd3d7996674d31cd1218d8e54fb24bee66befb34f67b346cc66.jpg) (i) \u0007The immunization register.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Regularly review the immunization register to identify girls who may have failed to receive their second dose of HPV vaccine when due.(ii) \u0007Reminder cards or “tickler boxes”.Make copies of the vaccination card for HPV vaccine and file the copies in a box with dividers by month as shown below.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The reminder card is placed in the month that the missed dose of vaccine is due.(iii) \u0007Electronic immunization registries (EIRs).More and more countries will be developing and implementing computerized registries that include records for each person with personal information as well as vaccination data.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "EIRs allow auto­ mating the generation of lists of persons who are due for a vaccine or who have missed a dose.These lists can be used to send recall/ reminders by phone, email or letter.Some systems can also send auto­ matic reminders directly from the EIR to consenting users.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "18 Once defaulters are identified through these tools, health workers can use com­ munity messaging, reminders to parents, mobile phone texts, or other mechanisms to send reminders of the need to come back to the vaccination site to receive the missed vaccine dose.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Tracking on a monthly basis will provide consistency and make the exercise a regular part of the work of the health centre staff.The use of recall/reminders, for example via SMS, has also proven to be a good tool to improve compliance and completion of the vaccination series.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "![](images/733fcb0c00182e7bf6dff5940d7975edd4dbaeba7352944d7a99b4dff2252b5f.jpg) # Monitoring Coverage Calculating HPV vaccine coverage is necessary: 1) to evaluate the performance of a vaccine programme towards meetings its objectives and 2) to monitor the impact of vaccine on a population.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "As with other EPI vaccines, administrative coverage can be supplemented by coverage surveys.# Administrative coverage In this method, the number of targeted persons (for HPV, often girls of a certain age) that have been vaccinated with a certain dose of vaccine (in this case HPV2) over a certain time (usually 1 calendar year) is obtained from facility reports.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "This number (the numerator), is then divided by an estimate of the target population in that same time period (the denominator).In many cases, aggregated data is entered into an electronic information system either at the level of district (or another intermediate administrative level) or at the level of health facility (at least in large ones).",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "These systems allow the automated aggregation of numerator data by health facility and/or district, and then province/state and finally at the national level.In some systems, denominators are fed to the system and the coverage calculation is done automatically, this should include calculation of HPV vaccination coverage by age.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "To calculate annual coverage, the consolidated number of HPV doses given, by age and dose, during the year is used as the numerator.Estimates of the target population19 are used as the denominator.As mentioned earlier, single-age estimates of the target population by district can usually be obtained from the National Statistics Office or when better options are not available derived from population estimates of five-year age groups.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "An alternative to estimate denominators is included in Appendix 3.WHO has a guide for the assessment of target population that can help assess the “quality” of available target population estimates.20 Grade-based estimates of the target population often cover multiple age cohorts (i.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "e.9-12 year olds).These numbers – including estimates of the out of school population – can be obtained from the Ministry of Education.To obtain potentially more accurate denominators to calculate coverage by school and grades, during the planning phase of a school vaccination activity, the target numbers can be verified with the schools in the relevant catchments areas when registers are developed (see see Section 2.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "3).# Example: Summary Table for a Year.Both birth year and age are presented in this example.Choose one of the other when preparing a summary table.Month/Year District: Town/Village: of report: Service delivery site: <html><body><table><tr><td rowspan=\"3\">Year of birth/ Age</td><td colspan=\"11\"></td></tr><tr><td rowspan=\"2\">No.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "of HPV1 doses given</td><td></td><td>Mar</td><td>Apr</td><td>May</td><td>Jun</td><td></td><td></td><td></td><td></td><td></td><td></td><td>Annual total</td></tr><tr><td>Jan </td><td>Feb </td><td></td><td></td><td></td><td>Jul </td><td>Aug </td><td>Sep </td><td>Oct</td><td>Nov</td><td>Dec</td><td>(by age, sum</td></tr><tr><td>2009/ 9 years</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>across months)</td></tr><tr><td>2008/ 10 years 2007/</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>11 years 2006/</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>12 years 2005/</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>13 years 2004/</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>14 years 2003 or</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>earlier/ 15 + years Total num-</td><td></td><td></td><td>(by mpnth, sum across ages)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>ber of HPV1 doses given to all girls</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan=\"12\"></td></tr><tr><td rowspan=\"2\">Year of birth/ Age</td><td colspan=\"4\">No.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "of HPV2 doses given</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Jan </td><td>Feb</td><td>Mar</td><td>Apr</td><td>May</td><td>Jun </td><td>Jul</td><td>Aug</td><td>Sep </td><td>Oct</td><td>Nov</td><td>Dec</td><td>Annual total</td></tr><tr><td>2009/ 9 years</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>2008/ 10 years</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>2007/ 11 years</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>2006/ 12 years</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>2005/ 13 years</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>2004/ 14 years 2003 or</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>earlier/ 15 + years</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table></body></html> \\*Total annual No.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "of HPV1 doses given to all girls.$\\star \\star$ Total annual No.of HPV2 doses given to all girls Obtaining an accurate estimate of HPV vaccination coverage by age may be difficult for the year of vaccine introduction, particularly if multiple age cohorts are initially targeted.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "One option to calculate the annual age-specific HPV vaccine coverage rates21 is presented below.The number of doses given by the age-specific population is divided by the estimates target population (Columns 4-5 below).",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Table: Calculating annual coverage by HPV dose <html><body><table><tr><td colspan=\"6\">Year of report (YYYY): Country:</td></tr><tr><td rowspan=\"2\">Age (years)</td><td rowspan=\"2\">Column 1 Total annual no.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "of HPV1 doses given</td><td rowspan=\"2\">Column 2 Total annual no.of HPV2 doses given</td><td rowspan=\"2\">Column 3 Estimated size of target population</td><td colspan=\"2\">Coverage (%)</td></tr><tr><td>HPV1 (Column 1÷ Column 3)*100</td><td>HPV2 (Column 2÷ Column 3)*100</td></tr><tr><td>9</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>10</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>11</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>12</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>13</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>14</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Total doses by <15 yrs (Sum of previous rows)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>≥15</td><td></td><td></td><td colspan=\"4\" rowspan=\"2\"></td></tr><tr><td>Total no.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "of doses (all girls)</td><td></td><td></td></tr></table></body></html> Table A: Example District Health Office Annual Reporting Form for a country vaccinating a single age cohort – eligible girls 10 years old.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "(filled out) <html><body><table><tr><td colspan=\"4\">Year of report (YYYY): _ 2014 Country:</td><td colspan=\"3\"></td></tr><tr><td>Age (years)</td><td>Column 1 Total annual no.of HPV1</td><td>Column 2 Total annual no.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "of HPV2</td><td>Column 3 Estimated size of target</td><td colspan=\"3\">Coverage (%) HPV1 HPV2</td></tr><tr><td></td><td>doses given</td><td>doses given</td><td>population</td><td>(Column 1÷ Column 3)*100</td><td></td><td>(Column 2÷ Column 3)*100</td></tr><tr><td>10</td><td>13.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "529</td><td>11.872</td><td>15.200</td><td>89%</td><td>78%</td><td></td></tr><tr><td>11</td><td>876</td><td>799</td><td></td><td></td><td></td><td></td></tr><tr><td>Other</td><td>2</td><td></td><td></td><td></td><td>No data here</td><td></td></tr><tr><td>Total doses by <15 yrs (Sum of previous rows)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table></body></html> Note 1: coverage level is only calculated for the eligible age group (10 years old).",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Note 2: Eligibility can be based on actual age (on day of vaccination) or year of birth (any girl that will become age 10 in 2018).The choice for one or the other will have implications for the programme delivery and the best approach needs to be identified in the country and clearly com­ municated to each health worker during the training Table B: Example District Health Office Annual Reporting Form for a country vaccinating a combination of age cohorts – girls in a grade VI (filled out) <html><body><table><tr><td colspan=\"6\">Country:</td></tr><tr><td colspan=\"2\">Year of report (YYYY):</td><td colspan=\"4\">Column3 Coverage (%)</td></tr><tr><td>Age (years)</td><td>Column 1 Total annual no.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "of HPV1 doses given</td><td>Column 2 Total annual no.of HPV2 doses given</td><td>Estimated size of target population</td><td>HPV1 (Column 1÷ Column 3)*100</td><td>HPV2 (Column 2÷ Column3)*100</td></tr><tr><td>9</td><td>20</td><td>18</td><td></td><td colspan=\"2\"></td></tr><tr><td>10 11</td><td>1000</td><td>900</td><td colspan=\"2\"></td><td></td></tr><tr><td>12</td><td>800</td><td>700</td><td rowspan=\"2\"></td><td colspan=\"2\" rowspan=\"2\">No data to be entered here, Calculation of coverage rates challenging if accurate target population by age is not available</td></tr><tr><td></td><td>200</td><td>200</td></tr><tr><td>13</td><td>２</td><td>1</td><td></td><td colspan=\"2\"></td></tr><tr><td>(.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": ")</td><td></td><td></td><td></td><td colspan=\"2\">83%</td></tr><tr><td>Total nal girls</td><td>2022</td><td>1819</td><td colspan=\"2\">2430</td><td>75%</td></tr></table></body></html> The examples above illustrate how to calculate cumulative coverage levels by cohorts over a several years in order to have an estimated coverage by age 15.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Nevertheless, over time, a country will likely be targeting one cohort per year and as such the estimated denominator will become relatively stable, thus allowing for simplifying the calculation to number of doses given divided by the average size of a cohort of girls aged between 9 and 14.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "A coverage monitoring wall chart for HPV vaccination could be maintained and displayed in the health facility and/or at the district level.This chart should include the target population of girls at the health facility or catchment area, and record the number of girls vaccinated per month, per dose, over time, until the target is reached.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "If periodic or campaign-style delivery is used, e.g., concentrated usually in two periods a year, then setting up the charts showing two time points, with full denominators, can be used to provide a visual record of the administrative coverage (per outreach per dose).",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "![](images/f36366325a852e6ef7f16d5aa9621b5c952584e881faa1805babfc9da15a8fe0.jpg) “A coverage monitoring wall chart for HPV vaccination could be maintained and displayed in the health facility and/or at the district level.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "” # Coverage surveys Coverage surveys estimate vaccine coverage based on the vaccination status of individuals in a randomly selected and representative sample, according to their vaccination record or recall.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "For the HPV vaccination, recall can be provided by the girl or her parents/ caregiver.It provides actual vaccination coverage; it is not an estimate.Surveys usually complement the administrative vaccination coverage estimates and provide an independent assessment of HPV vaccination.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Periodic immunization coverage surveys can assess HPV vaccination coverage, administration (completeness and timeliness), drop-out rates and knowledge, attitudes, practices and barriers related to HPV vaccination.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "They can also help differentiate immunization coverage by strategy (school, health facility, outreach) and provider (public, private, other).Ascertaining whether vaccination occurred may be an important challenge.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Traditionally, for infant vaccination, mothers or caregivers provide the card and/or recall on the doses received by their child.For pre-adolescents and adolescents, the interview may have to include the mother or caregiver, plus the girl, as the latter may provide better recall information.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "It may be useful to include more than one age group to monitor vaccine uptake over time, but interpretation must be careful as HBR availability and recall may vary depending on time since vaccination.If the survey is interviewing girls aged 15, to ascertain “vaccination with one and two HPV doses by age $1 5 \"$ , the availability of cards may be low, and recall of vaccination that took place up to 5 years before may not be reliable.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Furthermore, if the archiving of records is not good, going to health facilities to trace those doses may prove futile.The 2018 WHO Vaccination Coverage Cluster Survey Reference Manual includes provisions to estimate HPV coverage22 and both the Demographic and Health Surveys (DHS)23 and the Multiple Indicator Cluster Surveys $( { \\mathsf { M } } { \\mathsf { I C S } } ) ^ { 2 4 }$ are also starting to assess HPV coverage.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "It is important to ensure alignment between the year of vaccine introduction and target age groups, and the survey eligibility criteria and questionnaire.![](images/9091897f1423053630c997c5196aa9cc50198e9102c67240d2f8111fb5c38f99.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "jpg) # Monitoring drop-out from HPV1 to HPV2 Monitoring HPV drop-out rates, i.e., girls that received the first but not the second HPV dose, is important to flag potential problems.High levels of drop-out or defaulting could indicate systemic problems in the community, such as lack of confidence or trust in the vaccine, a negative experience with the first dose, problems in service delivery, such as stock outs, or a failure to convey the need to receive two doses to be fully vaccinated against HPV.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The drop-out monitoring system in a district or higher level could resemble the standard wall monitoring chart that tracks DTP1 to DTP3 drop out with the important difference that it would likely refer to different birth cohorts.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Practical concerns such as printing of such monitoring charts – a new recurrent cost – and the added workload for health workers, as well as the usefulness of this method to monitor drop-out must be considered in deciding whether to do introduce such a chart.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Other approaches include exploring drop-out through surveys or using EIRs.“High levels of drop-out – or defaulting – could be an indication of more systemic problems with HPV vaccination in the community.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "” ![](images/503b12ffe5e3a0964faed2359bd29852088425f485b1a967096fc1e9a274b56b.jpg) # Final observations ![](images/025ffa448232551acae1d1493f93d7c4f0c554997938df9ea22d2bd92a17a0c4.jpg) “Information about coverage levels when collected, analysed and disseminated in a timely manner can be a powerful tool to assess the overall performance of the HPV vaccination programme.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "” This Manual provides guidance to immunization managers, mid-level managers, sub-national and national health officers on how to develop tools and SOPs to collect and record information on HPV vaccine coverage.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Countries need to adapt the coverage forms and reporting sheets to reflect national recommendations for the target population, vaccination schedule and administrative levels etc.As data is aggregated up, it is important to ensure coverage data is consistently reported by age and dose.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "This will enable the calculation of immunization coverage by birth cohort regardless of the age at vaccination.Collecting HPV vaccine coverage information by age and dose is therefore even more important when the vaccine is targeting multiple age cohorts and when all girls in a particular school grade are eligible for vaccination.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "In order to monitor trends in vaccine coverage among vulnerable populations, such as girls not attending school or girls in nomadic populations, and girls who are at increased risk of cervical cancer, specific adaptations in the monitoring system can be made to allow clear identification of these populations – particularly at the services delivery level.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Similarly, surveys will need to take these populations into consideration when designing the sampling strategy.Information about coverage levels when collected, analysed and disseminated in a timely manner can be a powerful tool to assess the overall performance of the HPV vaccination programme.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "First dose coverage at different ages indicates how well HPV is accepted in the community and how well the particular delivery strategy is reaching the eligible population.High dropout rates between first and second dose may indicate poor performance in one or several components of the vaccination programme or in case of HPV vaccination it can indicate problems with chosen delivery strategy (e.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "g.school absenteeism and drop-out during school year).In order for this information to influence future performance, timely feedback on the reported coverage from the national to district level and from the district to service delivery level is essential.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Supportive supervision is essential for establishing and maintaining a well-functioning HPV coverage monitoring system.This should include careful supervision of HPV coverage monitoring, particularly during the first year(s) after HPV vaccine’s introduction.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Key indicators on HPV vaccination coverage should be included in graphs and vaccination dashboards such as the annual charts at the various levels.This will help ensure HPV vaccination is successfully integrated as part of the routine vaccination programme.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "It is crucial to explain any changes in scheduling, delivery strategy or data collection, and to present metadata (i.e., a set of data describing the variables collected).HBRs play an important role in the delivery and monitoring of vaccination programmes.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "They are also essential for ensuring data quality in the recommended, periodical country-based coverage surveys.In addition, they also serve to document an individual’s vaccination status.In many countries the HPV vaccine is not included in HBRs that focus on childhood vaccines.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "A HRB for adolescents is often produced at the time of HPV vaccine introduction, or adapted if a HBR already exists for other vaccines.WHO guidance exists on how to develop practical HRBs.25 “Indicators on HPV vaccination cover­age should be included in coverage graphs and vaccination dashboards such as the annual charts at the various levels.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "This will be a step to ensure HPV vaccine successfully integrated as part of the routine vaccination system.” Appendix 1.# Data collection for HPV vaccination included in the WHO/UNICEF Join Reporting Form (JRF) HPVVaccineDosesadministered:2o18 [Tahle instructions) <html><body><table><tr><td rowspan=\"2\"></td><td colspan=\"4\">Females</td><td colspan=\"3\">Males</td></tr><tr><td>Vaccine administered (age in years)</td><td>A.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "1stdose</td><td>B.2d dose</td><td>c.3ddose*</td><td>A.1stdose</td><td>B.2ddose</td><td>c.3ddose</td></tr><tr><td>4440</td><td>9</td><td></td><td></td><td>NR </td><td>NR </td><td>NR</td><td>NR</td></tr><tr><td>4450</td><td>10</td><td></td><td></td><td>NR </td><td>NR</td><td>NR </td><td>NR </td></tr><tr><td>4460</td><td>11</td><td></td><td></td><td>NR </td><td>NR </td><td>NR </td><td>NR </td></tr><tr><td>4470</td><td>12</td><td></td><td></td><td>NR</td><td>NR</td><td>NR</td><td>NR</td></tr><tr><td>4480</td><td>13</td><td></td><td></td><td>NR </td><td>NR</td><td>NR </td><td>NR</td></tr><tr><td>4490</td><td>14</td><td></td><td></td><td>NR</td><td>NR</td><td>NR</td><td>NR</td></tr><tr><td>4500</td><td>15+</td><td></td><td></td><td>NR </td><td>NR </td><td>NR </td><td>NR </td></tr><tr><td>4510</td><td>unknown age</td><td></td><td></td><td>NR</td><td>NR</td><td>NR</td><td>NR</td></tr></table></body></html> WHrendhffPsblhdluse !",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "[](images/8ce74201f527d17fa784fe08e9bc4085bcd3dc0cea2b9b6625aa8a82cd4c66c5.jpg) # Appendix 2.# Use of a summary indicator of HPV vaccine coverage One of the indicators used by the World Health Organization to monitor HPV vaccine coverage is a summary indicator that measures the proportion of females vaccinated with a complete series of HPV vaccine doses or “fully vaccinated” by 15 years of age.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "This summary indicator may be used to compare coverage estimates across countries, as well as within countries over time, particularly if the target population changes from year to year.It is also useful for monitoring the vaccine impact by comparing incidence rates of cervical cancer and other HPV disease outcomes to HPV vaccine coverage rates.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "This approach can be used at an earlier age, depending on a country’s recommendations of target age for the HPV vaccine.Information from national annual reporting forms from previous years are needed to calculate this indicator.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The number of girls vaccinated with complete doses of HPV vaccine by age 15 in the current reporting year is calculated as: $^ +$ the number of HPV2 doses given to 14-year-old girls in the current reporting year $^ +$ the number of HPV2 doses given to 13-year-old girls in the previous reporting year $^ +$ \u0007the number of HPV2 doses given to 12-year-old girls 2 years prior to the current reporting year, etc.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "If recording is done by year of birth, the aggregation by 15 years of age becomes more intuitive.For example, if the reporting year is 2018, add the number of girls born in 2003 and vaccinated in 2017, 2016 and 2015 to obtain the numerator.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The proportion of girls vaccinated with two doses of HPV vaccine by age 15 in the current reporting year (e.g., 2018) would be this total divided by the estimated number of 15-yearolds in the current reporting year (e.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "g., 2018).Note that all data collection tools need to be adapted and aggregation processes revised if more than one age group is targeted and/or if changes occur over time.Appendix 3.# Generating estimates of the target population for HPV vaccination # Estimating the target population or the denominator for coverage calculations The target population is the total number of girls of each age for whom the HPV vaccine is recommended.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "This is also the denominator for calculating vaccine coverage for either of the two doses in the vaccine series.The number of girls vaccinated with the previous dose of HPV should not be used as the denominator for calculating the coverage for the next dose; i.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "e., the proportion completing dose 2 after dose 1 is the completion rate and NOT the population coverage rate.A potential resource available are the WHO Projected national annual population 9-14 years of age by sex and single year of age, 2019-203026 # Estimating population by single year of age Calculating age-specific coverage requires estimates of the population of females by single year of age.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "In many instances, these data are available from the National Statistical Office and they should be used whenever possible.In some instances, particularly at lower sub-national levels, estimates may be available only by five-year age groups.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The following describes a simple method for roughly estimating population by single year of age from five-year age groups.Assume that the true, but unknown, population of females 0-24 years of age is given in Table A1.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Table A1: Females, 0-24 years of age <html><body><table><tr><td>Age</td><td>Females</td><td>Age</td><td>Females</td></tr><tr><td>0</td><td>3,829</td><td>13</td><td>3,175</td></tr><tr><td>1</td><td>3,687</td><td>14</td><td>3,079</td></tr><tr><td>2</td><td>3,817</td><td>15</td><td>2,435</td></tr><tr><td>3</td><td>3,512</td><td>16</td><td>2,607</td></tr><tr><td>4</td><td>3,694</td><td>17</td><td>2,445</td></tr><tr><td>5</td><td>3,575</td><td>18</td><td>1,626</td></tr><tr><td>6</td><td>3,769</td><td>19</td><td>1,888</td></tr><tr><td>7</td><td>3,666</td><td>20</td><td>1,375</td></tr><tr><td>8</td><td>3,270</td><td>21</td><td>1,834</td></tr><tr><td>9</td><td>2,810</td><td>22</td><td>1,673</td></tr><tr><td>10</td><td>2,597</td><td>23</td><td>1,866</td></tr><tr><td>11</td><td>3,354</td><td>24</td><td>1,773</td></tr><tr><td>12</td><td>2,937</td><td></td><td></td></tr></table></body></html> However, suppose we only have available population estimates of females by five-year age groups as shown in Table A2.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Table A2: Females, 0-24 years of age <html><body><table><tr><td>Age Group</td><td>Females</td></tr><tr><td>0-4</td><td>18,539</td></tr><tr><td>5-9</td><td>17,090</td></tr><tr><td>10-14</td><td>15,142</td></tr><tr><td>15-19</td><td>11,001</td></tr><tr><td>20-24</td><td>8,521</td></tr></table></body></html> Because there are five years of age in the 15-19 age group, it seems reasonable to simply divide the number of females 15-19 by 5 to estimate the number of girls who are 15 years old ( $1 1 , 0 1 1 / 5 = 2 , 2 0 0 )$ .",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "We see from Table A1 that the actual number of 15-year old girls is 2,435, so we have underestimated the number by 235.A method that provides more accurate estimates is to add the number of females in the age group that includes the single year of age being estimated (in this case, the group 15-19 years) to the number of females in the next younger age group (10-14 years) and the next older age group (20-24 years), then divide the resulting total by the total number of years included in these three age groups (fifteen in this case).",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Thus, to estimate the number of girls fifteen years of age: (females $1 5 - 1 9 +$ females $1 0 - 1 4 +$ females 20-24) / number of years in the three groups, or ( $1 1 , 0 0 1 + 1 5 , 1 4 2 + 8 , 5 2 1 ) / 1 5 = 2 , 3 1 \\$ females age 15.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "The difference between the estimated 2,311 females and the actual number, 2,435 is 124, much closer to the actual number than first estimate above.One important drawback to this method is that the single-year age estimate will be the same for each year of age in the five-year age group.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "In the example above, the estimate for the number 15-year old girls will be the same for 16-year old girls, 17-year old girls and so forth.More sophisticated methods such as the Sprague fifth-difference, Karup-King third-difference and other interpolation methods provide more realistic estimates.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "27 # Summary: 1.I\u0007f available, use single year of age population estimates from the National Statis­ tical Office.2.I\u0007f these data are not available, seek assistance from the National Statistical Office, the Ministry of Planning, or the statistics, demography or sociology departments of a university to produce such estimates.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "Or use the WHO population estimates cited above.3.I\u0007f estimates of the number of females are only available by five-year age groups, use the method described above to estimate the number of females by single years of age.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "4.I\u0007f necessary, use more sophisticated methods such as the Sprague fifth-difference, Karup-King third-difference or other interpolation methods.In most instances, the accuracy of the initial estimates or projections does not warrant this addi­ tional complexity.",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "This document was published by the Department of Immunization, Vaccines and Biologicals.Copies of this document, as well as additional materials on immunization, vaccines and biologicals may be requested from: World Health Organization Department of Immunization, Vaccines and Biologicals CH-1211 Geneva 27 Switzerland Email: vaccines@who.int Web: www.who.int/immunization/en",
    "source": "Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual/Human Papillomavirus(HPV) Vaccine Coverage Monitoring Manual.md"
  },
  {
    "text": "# WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention Use of dual-stain cytology to triage women after a positive test for human papillomavirus (HPV) !",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "[](images/e0708725dfd6ecd4f3e548f6f5efd49460446f3c6a07099ffc194520c8ce89a6.jpg) # WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention Use of dual-stain cytology to triage women after a positive test for human papillomavirus (HPV) # WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention: use of dual-stain cytology to triage women after a positive test for human papillomavirus (HPV) (WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition) ISBN 978-92-4-009165-8 (electronic version) ISBN 978-92-4-009166-5 (print version) # $\\circledcirc$ World Health Organization 2024 Some rights reserved.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services.The use of the WHO logo is not permitted.If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO).WHO is not responsible for the content or accuracy of this translation.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The original English edition shall be the binding and authentic edition”.Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (http://www.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "wipo.int/amc/en/mediation/rules/).Suggested citation.WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention: use of dual-stain cytology to triage women after a positive test for human papillomavirus (HPV).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Geneva: World Health Organization; 2024 (WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition).Licence: CC BY-NC-SA 3.0 IGO.ataloguing-in-Publication (CIP) data.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "CIP data are available at https://iris.who.int/.Sales, rights and licensing.To purchase WHO publications, see https://www.who.int/publications/book-orders.To submit requests for commercial use and queries on rights and licensing, see https://www.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "who.int/copyright.Third-party materials.If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.General disclaimers.The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.All reasonable precautions have been taken by WHO to verify the information contained in this publication.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "However, the published material is being distributed without warranty of any kind, either expressed or implied.The responsibility for the interpretation and use of the material lies with the reader.In no event shall WHO be liable for damages arising from its use.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Design: Studio FFFOG Layout: Green Ink Publishing Services Ltd # Contents Acknowledgements v Abbreviations vii Executive summary viii ![](images/dcce4b0dad5f46499e482d3517461b62db22ec73457b62714d1ac7f660e4eb6b.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "jpg) 1.Introduction 1 1.1 Background 1 1.2 Dual-stain cytology and interpretation of test results 3 1.3 Phased approach for development of updated recommendations and purpose of this guideline 3 1.4 Previous and existing WHO recommendations for screening and treatment to prevent cervical cancer, and definitions 5 1.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "5 Target audience 8 # 2.Methods for development of recommendations on HPV mRNA testing 9 2.1 Groups contributing to the guideline development process 9 2.2 Priority questions for review of evidence 10 2.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "3 Priority algorithms 11 2.4 Outcomes 12 2.5 Syntheses of evidence 13 2.6 Development of the recommendations 16 2.7 Management of the external peer review 17 ![](images/9bd1b4229054c16108f7ae5993f815fa522b7e0b27dbda1edf565715ced4b95c.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "jpg) 3.Recommendations on dual-stain cytology to triage women after a positive HPV nucleic acid test (NAT) result 18 4.Research gaps and further considerations for dual-stain cytology 22 5.Dissemination and updating of the guideline 23 5.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "1 Guideline dissemination and impact 23 5.2 Guideline update 24 ![](images/86504f29e773828a475f9582dac50734ad64fb086c898e9658de53af04d27f13.jpg) References 25 Annexes 28 Annex 1.Guideline groups 29 Annex 2.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Evidence-gathering teams and guideline task groups 37 Annex 3.Declarations of interests 38 Annex 4.Algorithms for use of dual-stain cytology as a triage test in the general population of women 40 Annex 5.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Recommendations for the use of HPV DNA tests and HPV mRNA tests and other cervical screening methods 43 Web Annex A.Syntheses of evidence.Available at: https://iris.who.int/handle/10665/342366 (includes IARC handbook materials and Supplementary materials 1–13) Web Annex B.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Evidence summaries.Available at: https://iris.who.int/handle/10665/376493 Web Annex C.Evidence-to-decision framework for dual-stain cytology to triage women after a positive test for human papillomavirus (HPV).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Available at: https://iris.who.int/ handle/10665/376494 # Acknowledgements The Department of Sexual and Reproductive Health and Research, the Department of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes and the Department of Noncommunicable Diseases, Rehabilitation and Disability at the World Health Organization (WHO) would like to thank members of the Guideline Development Group (GDG) for their consistent availability and commitment to making this guideline possible, and the members of the External Review Group (ERG) and all other external contributors for their work.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The Departments are also grateful to the International Agency for Research on Cancer (IARC) for the literature reviews performed in the context of the updating of the IARC handbooks of cancer prevention: cervical cancer screening, Vol.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "18 (2021), which were extremely useful for this guideline development process.Special thanks go to Nancy Santesso, the guideline methodologist from McMaster University.The names of the members of the GDG and the ERG and those of the other contributors, in particular systematic reviewers, modellers and costing teams, are listed below, with full details provided in Annexes 1–3.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "We appreciate the overall support of the WHO Guidelines Review Committee (GRC) Secretariat during the guideline development process, with grateful thanks to Rebekah Thomas Bosco, who is leading the GRC Secretariat.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The WHO Steering Group was composed of Nathalie Broutet, Shona Dalal, Linda Eckert (who also supported the GDG, the working groups for specific aspects of the guideline, and the WHO Secretariat), Morkor Newman and Ajay Rangaraj.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "This group was assisted by Myriam Cortes and Jane Werunga-Ndanareh.Nathalie Broutet and Shona Dalal also led the guideline development process.The members of the GDG were Claire Achieng, Silvina Arrossi, Muhammad Atif Waqar, Ruth Awori, Ruanne Barnabas, Itamar Bento Claro, Neerja Bhatla, Marie-Claude Boily, Laia Bruni, Joanna Cain, Lameck Chinula, Z.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Mike Chirenje (GDG Co-Chair), Michael Chung, Flavia Miranda Correa, Miriam Cremer, Teresa Darragh, Lynette Denny, Silvia de Sanjosé, Mamadou Diop, Wachara Eamratsameekool, Julia Gage, Ali Ghanbari-Motlagh, Patti Gravitt, Margaret Happy, Tarek Hashem, Rolando Herrero, Priscilla Ingbian, Ebony Johnson, Bayarsaikhan Luvsandorj, Anne Mackie, Mauricio Maza, Kelle Moley, Sebitloane Motshedisi, Nelly Mugo, Raul Murillo, Laura Muzingwani, Ashrafun Nessa, Dorcas Obiri-Yeboah, Gina Ogilvie, Patrick Petignat, Maria Alejandra Picconi, Leeya Pinder, Walter Prendiville, Veronica Reis, Gracia Violetta Ross Quiroga, Vikrant Sahasrabuddhe, Pete Sasieni, Netsanet Shiferaw, Rose Slavkovsky, Myint Myint Thinn, Kerry Thomson, Julie Torode (GDG Co-Chair), Nicolas Wentzensen and Fanghui Zhao.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The members of the ERG were Raveena Chowdhury, Heather Cubie, Suzanne Garland, Sarita Ghimire, Zaki El Hanchi, Ha Hyeong In, Oh Jin Kyoung, Alejandra Meglioli, Mohammed Moawia, Lim Myong Cheol, Angélica Nogueira, Mark Schiffman, Saritha Shamsunder, Vanita Suri, Carolina Teran, Ted Trimble, Gino Venegas and Heather White.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "External contributors to the evidence profiles were Marc Arbyn, Karen Canfell, Michael Caruana, Owen Demke, Cindy Gavreau, Michaela Hall, Adam Keane, James Killen, Beatrice Lauby-Secretan, Gigi Lui, Diep Nguyen and Kate Simms.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The following individuals acted as observers at the GDG meeting: Benjamin Anderson, Danielle Engel, J.(Hans) Berkhof, Michelle Chevalier, Smiljka de Lussigny, Eduardo Franco, Lisa Pei-Ching Huang, Krishna Jafa, Jose Jeronimo, Somesh Kumar, Ilana Lapidos-Salaiz, David Mesher, Jasantha Odayar, Groesbeck Parham, Carmen Perez Casas and Felipe Roitberg, Anna Shakarishvili and Petra ten Hoope-Bender.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The WHO Secretariat included Maribel Almonte Pacheco, Prebo Barango, Partha Basu, Paul Bloem, Nathalie Broutet, Gary Clifford, Marilys Corbex, Myriam Cortes, Shona Dalal, Jean-Marie Dangou, Maeve De Mello, Gampo Dorji, Linda Eckert, Fayad El Sheikh, Elena Fidarova, Massimo Ghidinelli, Karima Gholbzouri, Rodolfo Gómez Ponce de León, Sami Gottlieb, Joumana George Hermez, Raymond Hutubessy, Andre Ilbawi, Naoko Ishikawa, Chandani Anoma Jayathilaka, Sharon Kapambwe, Rajat Khosla, Stephanie Yetunde Kuku, Hugues Lago, Beatrice Lauby-Secretan, Silvana Luciani, Priya Mannava, Dara Masoud, Manjulaa Narasimhan, Elick Narayan, Morkor Newman, Leopold Ouedraogo, Tina Purnat, Neena Raina, Ajay Rangaraj, Leanne Margaret Riley, Anita Sands, Catherine Sauvaget, Tshidi Sebitloane, Mukta Sharma, Hai-rim Shin, Slim Slama, Vitaly Smelov, Howard Sobel, Ute Ströher, Josaia Tiko, Huong Tran, Adriana Velazquez Berumen, Lara Vojnov and Hongyi Xu.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Funding for the preparation, development and printing of the guideline was provided by the UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), with the support of the United States President’s Emergency Plan for AIDS Relief (PEPFAR) through the United States Agency for International Development (USAID), and Unitaid.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# Abbreviations AIS adenocarcinoma in situ CIN cervical intraepithelial neoplasia CKC cold knife conization DOI declaration of interest ERG External Review Group EtD evidence-to-decision GDG Guideline Development Group GRC Guidelines Review Committee GRADE Grading of Recommendations Assessment, Development and Evaluation HPV human papillomavirus HRP UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction IARC International Agency for Research on Cancer LBC liquid-based cytology LEEP loop electrosurgical excision procedure (also known as LLETZ) LLETZ large-loop excision of the transformation zone (also known as LEEP) mRNA messenger ribonucleic acid (referring to HPV E6/E7 messenger RNA) NAAT nucleic acid amplification test NAT nucleic acid test1 PEPFAR The United States President’s Emergency Plan for AIDS Relief PICO population (P), intervention (I), comparator (C), outcome (O) SDG Sustainable Development Goal UNDP United Nations Development Programme UNFPA United Nations Population Fund UNICEF United Nations Children’s Fund USAID United States Agency for International Development VIA visual inspection with acetic acid WHO World Health Organization # Executive summary # Background In 2022, cervical cancer was the fourth most commonly occurring cancer among women globally and also the fourth leading cause of cancer deaths among women, accounting for around 662 000 new cases and around 349 000 deaths.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "It is the most common cancer in women in 25 countries, many of which are in sub-Saharan Africa.Even while recognizing varying incidence levels, cervical cancer can be eliminated as a public health problem, through the scale-up of the World Health Organization (WHO) Cervical Cancer Elimination Initiative.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In May 2018, Dr Tedros Adhanom Ghebreyesus, Director-General of WHO, issued a call to action for the elimination of cervical cancer.In November 2020, the Director-General launched the Global Strategy to accelerate the elimination of cervical cancer.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The targets of the Global Strategy are to achieve by 2030: • $90 \\%$ of girls fully vaccinated with human papillomavirus (HPV) vaccine by age 15 years; $70 \\%$ of women screened with a high-performance test by 35 years of age and again by 45 years of age; and $90 \\%$ of women identified with cervical disease receive treatment.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Following the launch of the Global Strategy, a large panel of experts met to define the key areas of focus to increase access to screening and treatment to reach the 2030 targets.One of the agreed areas of focus was to update the existing 2013 WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention, and to simplify the algorithms.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "It was decided that WHO’s updated cervical cancer screening and treatment guidance would be developed in four phases.The output of the first phase was a large set of recommendations and good practice statements on screening and treatment, with a primary focus on the use of HPV DNA tests, and key clinical algorithms for screening and triage strategies (primary screening with HPV DNA-based tests, VIA or cytology, and triage tests after a positive primary screen, including partial genotyping, colposcopy, VIA or cytology) for both the general population of women (i.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "e.women who are presumed or confirmed to be HIV-negative) and those living with HIV.This output was published in July 2021.1 # Two approaches to screening and treatment are distinguished: In the “screen-and-treat approach”, the decision to treat is based on a positive primary screening test only.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In the “screen, triage and treat approach”, the decision to treat is based on a positive primary screening test followed by a positive second test (a “triage” test), with or without histologically confirmed diagnosis.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The second phase was to develop recommendations for the use of HPV mRNA (messenger ribonucleic acid) tests as a primary screening test and dual-stain cytology as a triage test to detect cervical pre-cancer and prevent cervical cancer.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The recommendations for the use of HPV mRNA tests were published in December 2021.2 This current guideline presents the recommendations for dual-stain cytology as a triage test, thus completing the second phase.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Dual-stain cytology can be used as a triage test in the “screen, triage and treat approach” to cervical cancer prevention.It is performed on liquid-based cytology (LBC) slides (not on conventional Pap smears) to detect the presence of two proteins: p16 and Ki-67.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "These two proteins are co-expressed in cells that have been transformed by high-risk HPV.When both proteins are detected in the same cell(s), this is interpreted as a positive dual-stain cytology result, meaning that there is an increased risk that cervical intraepithelial neoplasia 2/3 (CIN 2/3) lesions, also referred to as high-grade squamous intraepithelial lesions, are present.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# Methods The guideline has been developed according to the WHO handbook for guideline development, second edition (2014).The Guideline Development Group (GDG) for this guideline was formed in early 2019 and, based on their clinical expertise, research and knowledge of tests in development, identified 13 clinical algorithms (involving several different screening tests) for screening and treatment that could be evaluated.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Seven of these algorithms were addressed in the July 2021 edition of the updated guideline and another four were addressed in the December 2021 edition, while the final two algorithms are addressed in this current guideline publication.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The GDG, WHO Steering Group and WHO Secretariat, methodologists and technical groups (see Annex 1) met several times to discuss the evidence pertaining to the previously established PICO (population, intervention, comparator, outcome) questions related to the algorithms using dual-stain cytology as a triage test.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "A review of published and unpublished data from cross-sectional and longitudinal studies, and a systematic review and meta-analysis of the accuracy of dual-stain cytology as a triage test were conducted.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "A natural-history-based population simulation model was used to estimate the risk of important outcomes (e.g.primary and recurrent high-grade CIN and cervical cancer) with the use of different triage tests used in screening and treatment strategies.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In addition, modelling evaluated the number of treatments and the cost-effectiveness of the different strategies.Due to the paucity of data for the acceptability, feasibility, resources and equity aspects of the use of dual-stain cytology as a triage test, the views of the GDG were used to inform decisions.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "During the GDG meetings, the GDG members reviewed the evidence and made the recommendations presented in this guideline, applying the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# Summary of recommendations for the use of dual-stain cytology as a triage test to prevent cervical cancer In this publication, only recommendations for the use of dual-stain cytology as a triage test are presented.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Please refer to the previous edition of the guidelines for recommendations on screening and treatment to prevent cervical cancer with a focus on HPV DNA testing published in July 2021, and for recommendations with a focus on HPV mRNA testing published in December 2021.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "When using the term HPV NATs, we are referring to molecular nucleic acid tests (NATs) for the detection of high-risk (i.e.cancer-causing or oncogenic) HPV types, including the two types of tests, such as HPV DNA-based molecular NATs or HPV mRNA-based molecular NATs.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "3 # Recommendation for the general population of women: In a screen, triage and treat approach using HPV NATs as the primary screening test among the general population of women, WHO suggests using partial genotyping, colposcopy, VIA, cytology or dual-stain cytology to triage women after a positive HPV NAT result.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "![](images/c76822e241bf324ddb69b7145675e485c63389e939c5b15c27f7ea3c7c31460d.jpg) When providing dual-stain cytology to triage women after a positive HPV NAT, WHO suggests: using samples collected by the health worker; and retesting with HPV NAT 24 months after a negative dual-stain cytology result.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "These are conditional recommendations based on low-certainty evidence for dual-stain cytology as a triage test.# Remarks: The benefits and harms of the triage options are similar; therefore, the choice of triage method will be dependent on feasibility, training, programme quality assurance, capacity for follow-up testing and resources in countries.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Dual-stain cytology and the other triage options are used in the context of screening algorithms using HPV NATs as the primary screening test, which recommend screening intervals of 5–10 years for HPV DNA tests and 5 years for HPV mRNA tests.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# Recommendation for women living with HIV: No recommendation was made for using dual-stain cytology to triage women living with HIV after a positive HPV DNA test, because evidence on the outcomes of using dual-stain cytology applicable to this population was minimal.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Therefore, the following recommendation remains current for the use of triage tests for this population.In a screen, triage and treat approach using HPV DNA detection as the primary screening test among women living with HIV, WHO suggests using partial genotyping, colposcopy, VIA or cytology to triage women after a positive HPV DNA test.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# Programme implementation considerations Considering the implications for programme implementation, dual-stain cytology is most similar to LBC, among existing screening and triage options.Dual-stain cytology has been developed and validated for LBC slides, not for conventional Pap smears.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Hence, dual-stain cytology requires an LBC infrastructure.Dual-stain cytology also requires infrastructure for immunostaining, which may include an autostainer, and training is required for correct interpretation of dual-stain slides.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Proficiency in reading dual-stain cytology can be achieved faster than for Pap cytology, and reproducibility of dual-stain cytology results is higher than that of cytology.Being a cytological method needing specific laboratory infrastructure, dual-stain cytology cannot be implemented as a point-of-care test, but can be implemented in centralized, high-standard laboratories that serve multiple screening sites.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Experience implementing this technology in low-resource settings is lacking.Dual-stain cytology has not yet been validated in self-collected samples.It is critically important that dual-stain cytology is implemented within a health system that ensures adequate laboratory infrastructure, quality assurance, management and monitoring of follow-up testing for those women referred to 24-month follow-up surveillance after a negative dual-stain result.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# Introduction # 1.1 Background In 2022, cervical cancer was the fourth most commonly occurring cancer among women globally and also the fourth leading cause of cancer deaths among women, accounting for around 662 000 new cases and around 349 000 deaths.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "It is the most common cancer in women in 25 countries, many of which are in sub-Saharan Africa $( 7 )$ .Even while recognizing varying incidence levels, cervical cancer can be eliminated as a public health problem, through the scale-up of the World Health Organization (WHO) Cervical Cancer Elimination Initiative.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In May 2018, Dr Tedros Adhanom Ghebreyesus, Director-General of WHO, issued a call to action for the elimination of cervical cancer.A WHO Global Strategy to accelerate the elimination of cervical cancer as a public health problem was presented and unanimously endorsed by the Seventy-third World Health Assembly in August 2020.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Subsequently, WHO officially launched the Global Strategy to accelerate the elimination of cervical cancer on 17 November 2020 (2).The targets of the Global Strategy are to achieve, by 2030: 90% of girls fully vaccinated with human papillomavirus (HPV) vaccine by age 15 years; $70 \\%$ of women screened with a high-performance test by 35 years of age and again by 45 years of age; and $90 \\%$ of women identified with cervical disease receive treatment ( $90 \\%$ of women with pre-cancer treated, and $90 \\%$ of women with invasive cancer managed) $( 2 )$ In the context of this Global Strategy, countries are updating their protocols for the prevention of cervical cancer and for the care and treatment of affected women.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Cervical cancer prevention also plays an integral role in reaching the Sustainable Development Goals (SDGs), both for health (SDG 3) and gender equality (SDG 5).To prevent cervical cancer, women can be screened using various tests to identify those who have or are at risk of cervical pre-cancer (see Table 1.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "1).Cervical intraepithelial neoplasia (CIN) is characterized by cellular changes in the transformation zone of the cervix.CIN is typically caused by infections with HPV, especially the high-risk HPV types such as types 16 and 18 (these two types cause more than $70 \\%$ of cervical cancers) $( 3 ,$ 4).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "CIN1 lesions – also referred to as low-grade squamous intraepithelial lesions – are morphological correlates of HPV infections.CIN2/3 lesions – also referred to as high-grade squamous intraepithelial lesions – are correlates of cervical pre-cancers that, if left untreated, may progress to cervical cancer (for further details, refer to Chapter 1 of WHO’s Comprehensive cervical cancer control guidance $[ 5 ]$ ).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "![](images/25fca34f28ddebf6498771f490d3ea5ca5ec2fa261f42446c06afa1e07b2c80c.jpg) Table 1.1 Three approaches to cervical cancer screening and future tests <html><body><table><tr><td>Molecular</td><td>Cytologic</td><td>Visual inspection</td></tr><tr><td>Nucleic acid tests (NAT)a 》 HPV DNA</td><td>Conventional Pap smeara</td><td>Visual inspection with acetic acid (VIA)a or with</td></tr><tr><td rowspan=\"3\">》 HPV mRNA</td><td>Liquid-based cytology</td><td>Lugol's iodine (VILI)</td></tr><tr><td>(LBC)a</td><td>》 naked eye</td></tr><tr><td>Dual-stain cytology to</td><td>》 magnified by colposcope or camera</td></tr><tr><td>Protein biomarkersb</td><td>identify p16 and Ki-67a</td><td>Automated visual</td></tr><tr><td>》 HPV antibodies</td><td></td><td>evaluation of digital</td></tr><tr><td>》 oncoproteins</td><td></td><td>imagesb</td></tr></table></body></html> a Current tests b Tests under evaluation (future tests).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The traditional method to screen women for cervical cancer has been cytology.The Papanicolaou (Pap) smear or liquid-based cytology (LBC) smear test checks whether cells in the cervix are abnormal.Cells are collected via speculum examination with a brush and swab, and placed either directly onto a slide to which a fixative is added (conventional cytology) or in a bottle with a liquid storage medium (LBC).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Abnormal cervical cells testing as “atypical squamous cells of undetermined significance (ASCUS), low grade to high grade” may mean that there are pre-cancer changes in the cervix that may lead to cervical cancer.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "When cytology results are positive, the diagnosis is confirmed by colposcopy, and appropriate treatment is informed by biopsy of suspicious lesions for histological diagnosis.In this guideline, “cytology” refers to either conventional cytology or LBC.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Newer screening tests introduced in the last 15 years include visual inspection with acetic acid (VIA) and molecular tests – mainly high-risk HPV DNA-based tests,4 which are suitable for use in all settings (Table 1.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "1).More recently, additional tests and techniques have been developed: (i) molecular tests such as those based on HPV mRNA (messenger ribonucleic acid), oncoprotein detection or DNA methylation; (ii) tests performed on cytological samples, such as p16/Ki-67 dual-stain cytology; and (iii) visual tests based on artificial intelligence/machine learning platforms (e.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "g.automated visual evaluation of digital images) (6–9).# 1.2 Dual-stain cytology and interpretation of test results The focus of this edition of the updated guideline is the use of dual-stain cytology as a triage test.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Dual-stain cytology is performed on liquid-based cytology (LBC) slides (not on conventional Pap smears) to detect the presence of two proteins: p16 and Ki-67.p16 protein is expressed in cells that have been transformed by high-risk HPV due to actions of the HPV oncoprotein E7.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "p16 overexpression is shown in most cervical pre-cancer lesions and cancers, but it is rarely observed in normal tissue.Co-expression of the antiproliferative p16 protein and the proliferation marker Ki-67 within the same cervical epithelial cell can be used as a surrogate marker of cell-cycle deregulation mediated by HPV oncoproteins.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "When dual-stain cytology slides show cervical epithelial cells with brown cytoplasmic p16 immunostaining and red nuclear Ki-67 immunostaining in the same cell(s), this is interpreted as a positive dual-stain cytology result, meaning there is an increased risk that CIN2/3 lesions are present.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# 1.3 Phased approach for development of updated recommendations and purpose of this guideline Following the 2020 launch of the Global Strategy to accelerate the elimination of cervical cancer as a public health problem $( 2 ) ,$ a large panel of experts met to define the key areas of focus to increase access to screening and treatment to reach the 2030 targets.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "One of the agreed areas of focus was to update the existing 2013 WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention (10), and to simplify the algorithms.# Guideline objective: To improve national strategies for screening and treatment to prevent cervical cancer in all women, including women living with HIV.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "![](images/361147af4755d9731051704ed900b1018cd08861f44446a856e53eff27fb7848.jpg) It was decided that WHO’s updated cervical cancer screening and treatment guidance would be developed in four phases: # Phase 1 Updated recommendations on screening and treatment and the clinical algorithms for the most commonly used primary screening tests (HPV DNA tests, VIA and cytology) and triage strategies (partial genotyping, colposcopy, VIA and cytology) for both women in general (i.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "e.women who are presumed or confirmed to be HIV-negative) and those living with HIV.Phase 1 also addresses routine screening programmes, the ages at which to initiate and stop screening, and the frequency of screening.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# Phase 2 Evaluate the evidence and develop recommendations for the clinical algorithms using (a) HPV mRNA tests and (b) dual-stain cytology as a triage test in women testing HPV-NAT positive for the general population of women and for women living with HIV.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Phase 3 Develop recommendations for the implementation of these screening and treatment strategies.# Phase 4 Establish a consolidated “living guideline” for screening and treatment tests and algorithms (combining all the output from Phases 1–3), which will allow the recommendations to be updated as new evidence becomes available and is evaluated.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The output of Phase 1 was a guideline that was published and launched in July 2021, WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition, presenting a large set of recommendations and good practice statements on screening and treatment, with a primary focus on the use of HPV DNA tests, and key clinical algorithms for screening and triage strategies for both the general population of women (i.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "e.women who are presumed or confirmed to be HIV-negative) and those living with HIV.For the rationale for the development of the new edition of recommendations for screening and treatment to prevent cervical cancer, please refer to section 1.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "3 of that guideline (11).In December 2021, recommendations for the use of HPV mRNA tests as a primary screening test were published as part of the output of Phase 2, in WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention: use of mRNA tests for human papillomavirus (HPV) (12).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "A policy brief summarizing the use of HPV DNA and HPV mRNA tests to screen for cervical pre-cancer was also published in 2022 (13).Summary tables of the July/HPV DNA and December/HPV mRNA 2021 recommendations are provided in Annex 5.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The objective of this second part of Phase 2 was to develop recommendations for the use of dual-stain cytology as a triage test for cervical cancer prevention – both in the general population of women and in women living with HIV.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In addition to evidence gathered for the first two sets of recommendations, this guideline is also supported by evidence compiled in the IARC handbooks of cancer prevention: cervical cancer screening, Vol.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "18, and by Bouvard et al.in a special report in the New England Journal of Medicine (14, 15).The clinical flowcharts for the algorithms presented in this guideline include strategies using dual-stain cytology as a triage test in women who have received a positive HPV NAT result (HPV DNA or mRNA test).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In the near future, the recommendations in this guideline will be integrated with the recommendations recently published in the two 2021 guidelines mentioned above, on the use of HPV DNA tests $( 7 7 )$ and the use of HPV mRNA tests $( 7 2 ) .",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "$ along with the forthcoming recommendations on the implementation of screening and treatment strategies (Phase 3), to develop a full consolidated “living guidelines” version of this guidance (Phase 4).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# 1.4 Previous and existing WHO recommendations for screening and treatment to prevent cervical cancer, and definitions In 2006, WHO published Comprehensive cervical cancer control: a guide to essential practice (C4GEP), which was updated in a second edition in 2014 $( 5 ) ,$ consolidating all the recommendations for screening and treatment to prevent and treat cervical cancer up to that year.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The consolidated C4GEP included the WHO recommendations for HPV vaccination, treatment of cervical cancer and pre-cancer lesions, and palliative care, as well as the recommendations from the previous edition (2013) of this guideline, then titled WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention (10).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In 2019, WHO published guidance on the use of thermal ablation for treatment of cervical pre-cancer lesions (16) and in 2020, WHO published guidance documents to support the introduction and scale-up of screening and treatment interventions, specifically relating to HPV testing and relevant medical devices $( 7 7 )$ .",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In the updated second edition of the recommendations on screening and treatment for cervical cancer prevention, two populations of women are referred to: women living with HIV and the general population of women, which refers to women who are presumed or confirmed to be HIV-negative, or whose HIV status may be unknown.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In addition, two approaches to screening and treatment are distinguished, the “screen-and-treat approach” and the “screen, triage and treat approach”.# Screening and treatment approaches In the “screen-and-treat approach”, the decision to treat is based on a positive primary screening test only.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "![](images/2fc2b075d873463b83e14d87181b2cde4dbb580fb84769390af240d6a89b7f54.jpg) In the “screen, triage and treat approach”, the decision to treat is based on a positive primary screening test followed by a positive second test (a “triage” test), with or without histologically confirmed diagnosis.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "![](images/3e4f02ae485d0e12b8fc01bade41e4ce5a9a45ec675ffe2717f697502443caa9.jpg) In a screen-and-treat approach, treatment is provided based on a positive primary screening test alone, without triage (i.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "e.no second screening test and no histopathological diagnosis).• When the patient is eligible for ablative treatment, this should ideally be done immediately, at the same visit as the screening test (the single-visit approach).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "At some facilities, this is not feasible and a second visit is needed (the two-visit approach).Women who are not eligible for ablation can have excisional treatment on the same day if the clinic has the capacity for large-loop excision of the transformation zone (LLETZ).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "5 If LLETZ is not available on-site, women need to be referred for the excisional treatment or for further evaluation.In a screen, triage and treat approach, the triage test is done if the primary screening test is positive, and the decision to treat is made when both the primary test and the triage test are positive.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "• A positive triage test can lead to colposcopy with biopsy and histopathological examination for diagnosis to determine the appropriate treatment.The implementation of colposcopy and biopsy can be challenging, however, so this guideline also considers triage strategies that are not dependent on the availability of colposcopy.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "• When the primary screening test is positive, and the triage test is negative, women need appropriate follow-up evaluation at a specified interval in accordance with the recommendations.If the triage test is visual, a single visit combining screening, triage and treatment is also feasible.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The publication of the output of Phase 1 of the update of the recommendations for screening and treatment to prevent cervical cancer (in July 2021) presented 23 recommendations and 7 good practice statements (11).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Those recommendations focused mainly on the use of HPV DNA testing as the primary screening test.In addition, one recommendation addressed the types of triage tests that could be used after a positive primary screening test.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Later, in December 2021, the output of the first part of Phase 2 was published, presenting one recommendation on the use of HPV mRNA testing as the primary screening test (12).Table 1.2 provides a summary of those recommendations.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Table 1.2 Summary recommendations from the WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition: (i) HPV DNA tests and (ii) HPV mRNA tests <html><body><table><tr><td>General population of women</td><td>Women living with HIV</td></tr><tr><td>WHO suggests using either of the following strategies for cervical cancer prevention among the general population of women: 》 HPV DNA detection in a screen-and-treat approach starting at the age of 30 years</td><td>WHO suggests using the following strategy for cervical cancer prevention among women living with HIV: 》 HPV DNA detection in a screen, triage</td></tr><tr><td>with regular screening every 5 to 10 years.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "》 HPV DNA detection in a screen, triage and treat approach starting at the age of 30 years with regular screening every 5 to 10 years.</td><td>and treat approach starting at the age of 25 years with regular screening every 3 to 5 years.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td></tr><tr><td>WHO suggests that HPV mRNA detection using samples taken by the health worker may be used as a primary screening test, either with or without triage, to prevent cervical cancer in the general population of women with regular screening every 5 years.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>No recommendation was made for using HPV mRNA in women living with HIV.</td></tr><tr><td>In a screen, triage and treat approach using NATs for HPV detection as the primary screening test among the general population of women, WHO suggests using partial genotyping, colposcopy, VlA or cytology to triage women after a positive HPV test.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>In a screen, triage and treat approach using HPV DNA detection as the primary screening test among women living with HIv, WHO suggests using partial genotyping, colposcopy, VlA or cytology to triage women after a positive HPV DNA test.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td></tr></table></body></html> Sources: WHO, 2021 (11), WHO, 2021 $( 1 2 )$ .The full set of recommendations, along with relevant remarks, is provided in the guidance published in 2021 focused on the use of HPV DNA tests and the use of HPV mRNA tests (11, 12), and also in Annex 5 of this guideline.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# 1.5 Target audience This document is intended primarily for policy-makers, programme managers, programme officers and other professionals in the health sector who have responsibility for choosing strategies for cervical cancer prevention, at country, regional and district levels.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Health workers – such as doctors, nurses and community health workers working in reproductive health programmes, antenatal and postnatal services, family planning services, HIV/AIDS control programmes and in clinics that care for women at the district and primary health care levels – may also consult this document to understand how recommendations are developed and why it is vitally important to select and implement evidence-based strategies to prevent cervical cancer.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "This document could be used as the basis for developing an adapted publication for women and their families to support them in making decisions about cervical cancer screening and treatment.All individuals have the right to equality and non-discrimination in sexual and reproductive health care.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In this guideline, we recognize that most of the available evidence on cervical cancer is based on study populations of cisgender women, and we also recognize that cisgender women, transgender men, non-binary, gender fluid and intersex individuals born with a female reproductive system require cervical cancer prevention services.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "However, to be concise and facilitate readability, we use the term “women” to refer to all gender diverse people at risk for cervical cancer.Sexual and reproductive health service providers and cervical cancer prevention services must consider the needs of – and provide equal care to – all individuals independently of gender identity or its expression.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# 2.Methods for development of recommendations on HPV mRNA testing This updated guideline has been developed in accordance with the methods described in the WHO handbook for guideline development, second edition (18).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "More detailed methods are described in the recent publication of the outputs of the first phase of the guideline update (11).Information in this section focuses on methods specific to this phase of the guideline update: dual-stain cytology as a triage test.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# 2.1 Groups contributing to the guideline development process Lists of all members of the Guideline Development Group (GDG), External Review Group (ERG), systematic review teams, modelling teams and other contributors are provided in Annex 1, with details of their expertise and affiliations.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The WHO Secretariat consisted of staff from various relevant WHO departments, and staff from the International Agency for Research on Cancer (IARC).The Steering Group of the WHO Secretariat led the coordination of the development of this guideline.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Members of the Secretariat who were not part of the Steering Group were kept informed of the guideline development process and participated in the discussions, in particular during meetings of the various teams.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "For the evaluation of the evidence and formulation of recommendations relating to dual-stain cytology, the GDG comprised 53 members (35 women, 18 men), from across all six WHO regions, including representatives from civil society organizations and women’s groups, and women living with HIV.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The members brought to the table their varied expertise on cervical screening and treatment.Two members acted as co-chairs and moderated the GDG meetings.Observers who attended the GDG meetings did not participate in the GDG discussions or vote on recommendations.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The ERG provided peer review for the guideline document.Its 18 members, none of whom was also a member of the GDG, had expertise in research, policy development, programme implementation and clinical care.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Once the GDG had agreed on the recommendations, the ERG reviewed the full draft of the guideline and provided feedback.Multiple teams prepared evidence relevant to dual-stain cytology (see details in Annex 2).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Two teams conducted evidence reviews relevant to dual-stain cytology – one on test accuracy of dual-stain cytology as a triage test to detect $\\mathsf { C l N } 2 +$ and ${ \\mathsf { C l N } } 3 + ,$ and one on longitudinal evidence for the use of dual-stain cytology.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "One team adapted a pre-existing comprehensive natural history microsimulation model to simulate the use of dual-stain cytology in the general population of women.A guideline methodologist with experience of using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach (19) coordinated the presentation of evidence and decision-making processes that facilitated the development of the recommendations, as stipulated in the WHO handbook for guideline development, second edition (18).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# 2.1.1 Declarations and management of conflicts of interest Each invited GDG member completed a written declaration of interest (DOI) form (including those who had completed them prior to participation in the first phase of the guideline update).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The DOIs were reviewed by two members of the WHO Secretariat and no conflicts of interest were identified (see Annex 3).At the beginning of every GDG meeting, members were asked to declare any potential new conflicts of interest.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# 2.1.2 Confidentiality Each GDG member also signed a confidentiality agreement at the beginning of the guideline development process, and the WHO Secretariat restated at the start of each GDG meeting that all discussions and draft recommendations were to remain confidential until publication.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# 2.2 Priority questions for review of evidence The questions for dual-stain cytology are based on the scoping review and the prioritization of research questions and algorithms for screening and treatment, which were performed by GDG members in 2019 at the start of the process of updating the WHO recommendations on this topic.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The key questions relating to dual-stain cytology (see Table 2.1) followed a similar format to those assessed for the first phase of the guideline update (11), referring to both the general population of women and women living with HIV.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Table 2.1 PICO questions for the recommendations in women <html><body><table><tr><td>PICO1</td><td>After a positive HPV NAT result, should dual-stain cytology be used as a triage test versus the use of partial genotyping, colposcopy, VIA or cytology as a triage test?",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td></tr><tr><td>PICO2</td><td>Should women be followed up after 12 or 24 months after a positive HPV NAT and a negative dual-stain cytology result?</td></tr></table></body></html> NAT: nucleic acid test; VIA: visual inspection with acetic acid.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# 2.3 Priority algorithms Since screening and treatment can be done using different primary screening and triage tests, there are numerous possible combinations or algorithms.In December 2019, GDG members were surveyed to prioritize the screening and/or triage tests and the treatments that should be evaluated.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Following this prioritization exercise, a subgroup of GDG members met to review the results from the survey and to agree on the algorithms to be prioritized.They reached a consensus to address seven priority algorithms in the first phase of the guideline update (see Annex 4 in that publication) (11), and to address four algorithms relevant to HPV mRNA testing as part of the second phase of the guideline update (see Annex 4 in that publication) (12).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "It was also decided to address two algorithms for this continuation of the second phase of the guideline update, related to triage testing using dual-stain cytology after a positive result on primary screening using an HPV DNA or HPV mRNA nucleic acid test (NAT).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "A positive dual-stain cytology result is followed by colposcopy to determine further management; a negative dual-stain cytology result is followed by a repeat HPV test after 24 months, as presented in Table 2.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "2.Post-treatment follow-up remains as in the first phase of the guideline update (11); the algorithm for this follow-up is presented in Annex 4, along with a combined algorithm flow chart for the two algorithms relating to triage using dual-stain cytology.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Table 2.2 The two algorithms considered <html><body><table><tr><td colspan=\"2\">Screen, triage and treat approachesa</td></tr><tr><td>1</td><td>HPV DNA as the primary screening test, followed by triage using dual-stain cytology, then further followed by colposcopy to determine further management </td></tr><tr><td>2</td><td>HPV mRNA as the primary screening test, followed by triage using dual-stain cytology, then further followed by colposcopy to determine further management</td></tr></table></body></html> # 2.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "4 Outcomes The GDG agreed that the critical outcomes previously identified for the 2013 first edition of this guideline (10) and for the 2021 guideline which presented the output of the first phase of the guideline update $( 7 7 )$ continued to be the critical outcomes for the new PICO questions; they are listed below.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# Critical outcomes for the screening and treatment recommendations cervical cancer mortality high-grade cervical intraepithelial neoplasia or worse $( C l N 2 + )$ HPV infection preterm birth pre-cancer treatments adverse events (direct consequence of pre-cancer treatment): – major infections or bleeding procedure-associated pain cervical stenosis infertility spontaneous abortion perinatal deaths premature rupture of membrane unnecessary interventions – increased viral shedding in women living with HIV costs equity acceptability feasibility.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Adverse events were defined as outcomes that were a direct consequence of pre-cancer treatment and were grouped as one category, with the exception of preterm birth, which was considered a critical outcome.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "For additional details and definitions, see Annex 5 in the previous 2021 edition of the guideline providing the output of the first phase of the guideline update $( 7 7 )$ .# 2.5 Syntheses of evidence Evidence was synthesized according to the methods in the WHO handbook for guideline development (18), and the Cochrane handbook for systematic reviews of interventions (20).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The literature review performed for the development of the IARC handbooks of cancer prevention: cervical cancer screening, Vol.18 (14) was also part of the evidence synthesized for the development of this guideline – details of this review and its methods were published in a special report in 2021 (15).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "It should be noted that both published and unpublished data from studies were included in the literature review.Many longitudinal studies are currently under way.Unpublished longitudinal studies were identified as expansions of previously published cross-sectional studies.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Additional unpublished longitudinal studies were identified through presentations at scientific meetings.Primary data from longitudinal studies were analysed individually using prevalence–incidence mixture models that can account for undiagnosed prevalent disease and interval censoring.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Triage testing using dual-stain cytology was evaluated alone or in combination with partial HPV genotyping.A systematic review of the relative diagnostic accuracy of dual-stain cytology compared with cytology as a triage test for detecting $\\mathsf { C l N } 2 +$ and $\\mathsf { C l N 3 + }$ was also performed.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The literature search was conducted from 1994 up to December 2021 in PubMed/MEDLINE, Embase and Scopus, and the references of included studies were also searched for additional sources of evidence.Random effects meta-analyses were conducted on the absolute clinical sensitivity and specificity of dual-stain cytology and of the relative sensitivity and specificity of dual-stain cytology compared with conventionally stained cytology, considering cytology at the cut-off of or exceeding atypical squamous cells of undetermined significance (ASCUS) and considering $\\mathsf { C l N } 2 +$ or $\\mathsf { C l N 3 + }$ as disease outcome.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Further details about the methods are provided in Web Annex B.Evidence summaries.The certainty of the evidence from the systematic reviews and modelling was assessed using the GRADE methodology.The four levels of certainty of evidence are summarized in Table 2.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "3.![](images/0a7238d05949ef7510bf3768de9224464659673f417a7e8108e78857106b35e0.jpg) Table 2.3 Interpretation of the GRADE levels of certainty of evidence Source: Schünemann et al., GRADE handbook (GRADEpro, 2013) (19) # 2.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "5.1 Mathematical modelling We used the Policy1-Cervix platform (developed by the Daffodil Centre, a joint venture between the University of Sydney and Cancer Council NSW, Australia), an extensively validated dynamic model of HPV transmission, vaccination, type-specific natural history, cancer survival, screening, diagnosis and treatment (21–29) to predict outcomes in the general population of women across 78 low- and lower-middle-income countries.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The Policy1-Cervix model was one of three models used by the Cervical Cancer Elimination Modelling Consortium (CCEMC) to evaluate the impact of cervical cancer prevention interventions in the 78 countries (21, 23).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "For the baseline analysis, we assumed that $70 \\%$ of women attended screening at each routine screening event and $90 \\%$ of women complied with follow-up at 12 months.Outcomes were assessed over the lifetime of birth cohorts eligible for screening starting in 2030, and included cervical cancer incidence and mortality, pre-cancer treatments, additional preterm deliveries as a result of pre-cancer treatment and costeffectiveness.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The cost of dual-stain cytology used as a triage test was assumed to be equivalent to cytology as a triage test in the baseline.In the sensitivity analysis, we varied the performance of dual-stain cytology, considered a higher cost, and considered the impact of rescreening women 24 months after a negative dual-stain cytology result with a $70 \\%$ compliance rate for returning instead of the base-case assumption of 12 months with a $90 \\%$ compliance rate for returning.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "For the analysis of dual-stain cytology, a specific validation exercise was performed to demonstrate that the Policy1-Cervix model predictions matched the available longitudinal information on the performance of dual-stain cytology as a triage test in HPV-positive women.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "We also performed a validation against emerging unpublished data on longitudinal outcomes of dual-stain cytology as a triage test for HPV-positive women stratified by 16/18 positivity.Detailed methods for the simulation modelling are presented in Supplementary material 13a, in Web Annex A (pp.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "173–190), which accompanied the publication of the outputs of the first phase of the guideline update (11).# 2.5.2 Values and preferences A systematic review was performed for the first phase of the guideline update to address, among other considerations, the values and preferences of end-users, health workers and other stakeholders for cervical cancer screening and treatment strategies.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The results of the literature review were compiled according to study design and methodology, location and population, and presented to the GDG.The evidence was assessed using the GRADE-CERQual approach (Confidence in the Evidence from Reviews of Qualitative Research)6 and confidence in the evidence was rated from very low to high in the summary of findings.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "A summary is presented in the evidence-to-decision (EtD) framework, which informed the development of the recommendations by the GDG (see Web Annex C), and the evidence tables are presented in Supplementary material 10, in Web Annex A (pp.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "131–144), which accompanied the publication of the outputs of the first phase of the guideline update (11).We also collected primary data from a voluntary and anonymous survey distributed via SurveyMonkey during the first phase of the guideline update.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The survey was open to all women and girls aged 15 years and older, regardless of their prior cervical cancer screening or treatment status.The survey received approval from the WHO Ethics Review Committee and was run in English and French from 22 June to 18 September 2020.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Awareness of the survey had been raised among a wide range of civil society groups through a webinar.The survey was also promoted through the Union for International Cancer Control and the WHO advisory group of women living with HIV, and shared through WHO regional focal points for the WHO Cervical Cancer Elimination Initiative.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "7 The responses from the 561 respondents, including their qualitative responses to open-ended questions, were analysed.The detailed methods and results are available in Supplementary material 9, in Web Annex A (pp.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "119–130), which accompanied the publication of the outputs of the first phase of the guideline update (11).Both the systematic review and the survey considered screening with cytology, VIA and HPV testing.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "There were, however, no data specific to the values and preferences specifically related to different triage tests, and therefore the views of the GDG were used to inform the criteria for values and preferences.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# 2.5.3 Feasibility, acceptability, resources and equity considerations Evidence came from a review of systematic reviews (as presented in Web Annex A), and a survey of the GDG members.A review of systematic reviews of the acceptability, feasibility, resources and equity considerations for the use of different screening tests included systematic reviews published since 2010 that synthesized results from studies with quantitative or qualitative designs.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Evidence about the use of cytology as a triage test was used to inform decisions about the use of dual-stain cytology as a triage test.Further information about the methods and findings are provided in Supplementary material 12, in Web Annex A (pp.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "165–172), which accompanied the publication of the outputs of the first phase of the guideline update (11).The survey of GDG members was administered via SurveyMonkey to assess the implementation feasibility considerations for all of the priority algorithms – this included an algorithm for triage using cytology and this was used to inform the assessment of the feasibility of using dual-stain cytology for triage testing.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The survey was developed using the context and implementation of complex interventions (CICI) framework (30).Each GDG member was asked about their level of concern about each algorithm being able to sustainably meet the large-scale goal of cervical cancer elimination.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The following components of cervical cancer screening and management service delivery were queried separately according to the priority algorithm: demand generation, access to screening and the follow-up management of positives, workforce training, infrastructure development and maintenance, development and maintenance of the screening registry, and cost and integration with other priority health services.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The considerations of the GDG members were assessed for the following eight stakeholder groups: health authorities at the national level, health authorities at the regional level, professional societies, health workers at both the hospital and primary care levels, community health workers, clients (screened women) and the community.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The detailed methods and results of the survey are provided in Supplementary material 11, in Web Annex A (pp.145–164), which accompanied the publication of the outputs of the first phase of the guideline update (11).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "During GDG meetings, the views of the members were gathered to complement the data specific to the use of dual-stain cytology, as there were very limited data specific to dual-stain cytology in the survey and the reviews.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# 2.6 Development of the recommendations All the GDG meetings that focused on formulation of recommendations were held virtually.Tables to facilitate decision-making for recommendations – EtD frameworks – were produced by the guideline methodologist for each recommendation.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "These tables included a summary of the evidence (benefits and harms), information on relevant values and preferences, and information on other issues, including use of resources, cost, feasibility, equity and acceptability.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "During the meeting, the evidence was discussed with the GDG.Following the meeting, the methodologist, systematic reviewers, modellers and WHO Steering Group assessed the GDG input and used it to write the recommendations.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Agreement on the recommendations was made by consensus during the GDG meetings, and the final written recommendations were then approved electronically.The responses solicited via email were either to approve, approve “with the following remarks” or not approve.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The GDG had agreed that, if consensus could not be reached, a majority vote of $5 1 \\%$ would have been accepted to make recommendations – yet the group did reach a consensus on all the recommendations.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Strong recommendations (worded as “WHO recommends”) were made when all the desirable consequences of the intervention clearly outweighed the undesirable consequences in most settings.Conditional recommendations (worded as “WHO suggests”) were made when the desirable consequences of the intervention probably outweighed the undesirable consequences in most settings.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Table 2.4 describes how strong and conditional recommendations should be interpreted.Table 2.4 Interpretation of strong and conditional recommendations <html><body><table><tr><td>Implications</td><td>Strong recommendation (WHO recommends.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "..)</td><td>Conditional recommendation (WHO suggests..)</td></tr><tr><td>For individuals</td><td>Most individuals in this situation would want the recommended course of action, and only a small proportion would not.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Formal decision aids are not likely to be needed to help individuals make</td><td>The majority of individuals in this situation would want the suggested course of action, but some may not.</td></tr><tr><td rowspan=\"2\">For health workers</td><td>and preferences.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Most individuals should receive the recommended course of action.Adherence to this recommendation</td><td>Clinicians should recognize that different choices may be appropriate for different individuals and that clinicians must help each individual</td></tr><tr><td>(when it aligns with national guidelines) could be used as a quality criterion or performance indicator.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>arrive at a management decision consistent with the individual's values and preferences.Decision aids may be useful to help individuals make decisions consistent</td></tr><tr><td>For policy- makers</td><td>The recommendation can be adopted as policy in most situations.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>with their values and preferences.Policy-making will require discussion and involvement of various stakeholders.</td></tr></table></body></html> Source: Schünemann et al., GRADE handbook (GRADEpro, 2013) (19).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "For information on important considerations for the recommendations, please refer to Chapter 3 of the published guideline that delivered the outputs of the first phase of the guideline update (11).# 2.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "7 Management of the external peer review The draft guideline document was circulated to the External Review Group (ERG) for comment.The WHO Secretariat prepared a summary table with all ERG responses and sorted the comments by topic or section.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The WHO Secretariat then reviewed the comments, which were minor wording changes, without any implications for the substance of the recommendations themselves, and the guideline document was finalized.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# 3.Recommendations on dual-stain cytology to triage women after a positive HPV nucleic acid test (NAT) result In this present publication, only recommendations for the use of dual-stain cytology as a triage test are presented.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Please refer to the July 2021 edition of the guideline for recommendations on screening and treatment to prevent cervical cancer, with a focus on HPV DNA testing (11).For recommendations with a focus on HPV mRNA, refer to the recommendations published in the December 2021 edition (12).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Summary tables of the 2021 recommendations are provided in Annex 5.# Recommendations for the general population of women: In a screen, triage and treat approach using HPV NATs as the primary screening test among the general population of women, WHO suggests using partial genotyping, colposcopy, VIA, cytology or dual-stain cytology to triage women after a positive HPV NAT result.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "![](images/e33c7650d4fd5cd16cea81f384fb97e52c3b96bdedd77ae8671ac9ee9a84ca2c.jpg) When providing dual-stain cytology to triage women after a positive HPV NAT, WHO suggests: using samples collected by the health worker; and retesting with HPV NAT 24 months after a negative dual-stain cytology result.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "These are conditional recommendations based on low-certainty evidence for dual-stain cytology as a triage test.# Remarks: The benefits and harms of the triage options are similar; therefore, the choice of triage method will be dependent on feasibility, training, programme quality assurance, capacity for follow-up testing, and resources in countries.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Dual-stain cytology and the other triage options are used in the context of screening algorithms using HPV NATs as the primary screening test, which recommend screening intervals of 5–10 years for HPV DNA tests and 5 years for HPV mRNA tests.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "See Annex 4 for detailed algorithms.# Recommendation for women living with HIV: No recommendation was made for using dual-stain cytology to triage women living with HIV after a positive HPV DNA test, because evidence on the outcomes of using dual-stain cytology applicable to this population was minimal.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Therefore, the following recommendation remains current for the use of triage tests for this population.![](images/b84e886678176413f7e3058198b252c3539bd47a571e0c78916cae5ad1493aad.jpg) In a screen, triage and treat approach using HPV DNA detection as the primary screening test among women living with HIV, WHO suggests using partial genotyping, colposcopy, VIA or cytology to triage women after a positive HPV DNA test.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# Programme implementation considerations Considering the implications for programme implementation, dual-stain cytology is most similar to LBC, among existing screening and triage options.Dual-stain cytology has been developed and validated for LBC slides, not for conventional Pap smears.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Hence, dual-stain cytology requires an LBC infrastructure.Dual-stain cytology also requires infrastructure for immunostaining, which may include an autostainer, and training is required for correct interpretation of dual-stain slides.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Proficiency in reading dual-stain cytology can be achieved faster than for Pap cytology, and reproducibility of dual-stain cytology results is higher than that of cytology.Being a cytological method needing specific laboratory infrastructure, dual-stain cytology cannot be implemented as a point-of-care test, but can be implemented in centralized, high-standard laboratories that serve multiple screening sites.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Experience implementing this technology in low-resource settings is lacking.Dual-stain cytology has not yet been validated in self-collected samples.It is critically important that dual-stain cytology is implemented within a health system that ensures adequate laboratory infrastructure, quality assurance, management and monitoring of follow-up testing for those women referred for 24-month follow-up surveillance after a negative dual-stain result.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# Justification Overall, there is low-certainty evidence for the balance of the benefits, harms and cost-effectiveness of using dual-stain cytology as a triage test after positive HPV NAT testing.The longitudinal evidence for the benefits of dual-stain cytology found that, compared with cytology, the risk of pre-cancers after 3–5 years may be lower in women with a negative result on dual-stain cytology, and higher in women who are dual-stain positive.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Evidence on the sensitivity and specificity of dual-stain cytology is likely non-inferior to evidence on cytology.Sensitivity and specificity results were used for modelling.Modelling data suggest that, at a “whole-of-population” level, and when considered over a lifetime of screening, there may be similar reductions in cervical cancer cases and deaths when using dual-stain cytology as a triage test for HPV-positive women compared with other triage tests (partial genotyping, colposcopy, VIA or cytology).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "At a whole-of-population level, modelling also predicted similar cost-effectiveness outcomes when using dual-stain cytology as a triage test, if it is assumed that the dual-stain cytology costs would be similar to the costs of cytology.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Use of dual-stain cytology as a triage test requires similar infrastructure to LBC, with the additional need for staining kits and equipment.Implementing dual-stain cytology in a programme that does not currently use quality-assured LBC may be challenging.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The cost to perform dual-stain cytology will to a large extent depend on manufacturer pricing, which will likely vary across settings – and the actual price will impact cost-effectiveness.Using dual-stain assays approved by a regulatory agency is appropriate.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "There is a paucity of evidence available on dual-stain cytology in women living with HIV, and data from the general population of women are not applicable to that population.Therefore, no recommendation was made for women living with HIV.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# Summary of the evidence The GDG considered evidence from cross-sectional and longitudinal studies, and from simulation modelling of long-term outcomes (refer to Web Annex B for the evidence summaries and Web Annex C for the EtD framework).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Data from 11 cross-sectional studies at low-to-moderate risk of bias were pooled in a meta-analysis to calculate the sensitivity and specificity of p16 detection alone or dual-stain cytology (for p16 and Ki-67 detection) as a triage test after women test positive for HPV DNA.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The studies were conducted in Australia, China, Italy, Mexico and the United States of America (USA), among the general population of women.There is some heterogeneity among the studies, but the range of variation was narrow for sensitivity and moderate for specificity.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Few studies measured longitudinal outcomes after the use of dual-stain cytology as a triage test: data were used from published and unpublished studies from Italy and the USA that reported longitudinal outcomes.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The follow-up data suggest that women who test negative on dual-stain cytology have a lower risk of pre-cancer after 3–5 years $( 2 - 4 \\% )$ when compared with women who test positive using dual-stain cytology $( 1 2 - 1 5 \\% )$ .",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "These predictors of risk may be better than with cytology as a triage test.There are currently no data from longitudinal studies from low- and middle-income countries (LMICs), and there is a paucity of data for women living with HIV.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The simulation used data extracted from the cross-sectional studies included in the analysis of the 11 cross-sectional studies on sensitivity and specificity (see Web Annexes B and C).For the purposes of the model, the costs of dual-stain triage testing were assumed to be equivalent to those of LBC as a triage, and the model was validated against the available longitudinal evidence.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Real-life costs of dual-stain cytology are currently higher than LBC due to immunostaining, but they may vary across settings, within the high range.Sensitivity analyses were conducted assuming higher cost, and under those conditions the results showed dual-stain cytology to be far less cost-effective than other triage methods (partial genotyping, colposcopy, cytology and VIA).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Long-term outcomes using HPV NATs for primary screening and using VIA, cytology, HPV 16/18 testing (partial genotyping), colposcopy or dual-stain cytology for triage were modelled.Two principal algorithms using dual-stain cytology for triage were considered: primary HPV DNA testing followed by triage using dual-stain cytology; and primary HPV mRNA testing followed by triage using dual-stain cytology.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Both algorithms assumed 12-month follow-up testing for women with negative results on dual-stain cytology used for triage; 24-month follow-up was also explored in the analyses.The findings, which are based on low-certainty evidence, suggest that when comparing the long-term effects of repeated rounds of testing – when implemented programmatically at 5-year screening intervals – algorithms using dual-stain cytology as a triage test for HPV DNA-positive women reduced cervical cancer incidence and mortality by $6 4 \\%$ compared with no screening, and algorithms using dual-stain cytology as a triage test for HPV mRNA-positive women reduced cervical cancer incidence and mortality by $6 0 .",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "3 \\%$ compared with no screening.These ranges are similar to what was reported in earlier analyses involving either primary HPV DNA $( 7 7 )$ or primary HPV mRNA testing $( 7 2 )$ .Compared with cytology triage, algorithms involving dual-stain triage resulted in a $1 \\%$ greater reduction in long-term cervical cancer incidence and mortality (for detailed results, see Web Annex C).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The modelling evidence also suggests that the number of treatments for pre-cancer lesions may be slightly higher using algorithms with dual-stain cytology for triage versus algorithms with cytology for triage, but lower compared with algorithms that use other triage tests.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The lifetime discounted costs of algorithms using dual-stain cytology for triage are similar to algorithms using cytology for triage (if dual-stain cytology costs are assumed to be similar to cytology costs), and higher than algorithms using other triage tests.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Overall, given these cost assumptions, the cost-effectiveness may be similar when using dual-stain cytology for triage compared with other triage tests.When assuming 24-month follow-up for women with a negative result on dual-stain triage, and assuming that compliance with follow-up at the 24-month visit is reduced from $90 \\%$ to $70 \\%$ , the modelling predicted that the reduction in cervical cancer mortality is $6 2 .",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "7 \\%$ compared with no screening, which is less of a reduction $1 .5 \\%$ smaller) than the scenario of 12-month follow-up with $90 \\%$ compliance.Much of this loss in effectiveness was because of the assumption that compliance with follow-up at the 24-month visit was reduced from $90 \\%$ to $70 \\%$ .",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In most studies, samples were taken by health workers and therefore the recommendations are for this sampling method.Because of the paucity of data on dual-stain cytology in women living with HIV, a separate analysis could not be performed.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The GDG agreed that the recommendation presented here does not apply to women living with HIV.The GDG also considered whether there are advantages to using dual-stain cytology for triage rather than other triage tests.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The findings of the surveys and systematic reviews for values and preferences, acceptability, feasibility and equity that were performed for the first phase of the guideline (see Web Annex A) were considered when formulating this recommendation by applying the findings for cytology to dual-stain cytology.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "There was little evidence specific to the use of dual-stain cytology for triage testing, but from the survey and views of the GDG, it was agreed that there could be challenges providing dual-stain cytology as a triage test where LBC services are not currently available, quality controlled and quality assured.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "If available and affordable, dual-stain cytology as a triage test would probably outperform triage with cytology.# 4.Research gaps and further considerations for dual-stain cytology Although cross-sectional accuracy data (e.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "g.sensitivity and specificity of the tests) were available for the general population of women, and were used to inform the evidence on dual-stain cytology presented in this guideline, the GDG noted that longitudinal data, with follow-up for more than 5 years, are needed regarding the impact of dual-stain cytology when used within cervical screening programmes.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The majority of studies have been conducted in high-income settings, and therefore data generation in LMIC settings, where diagnostic and treatment capacities may be different from high-income settings, is needed.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "More studies comparing the accuracy of testing using self-collected samples versus health provider-collected samples are needed.Among women living with HIV, trials assessing the test performance of dual-stain cytology, and trials comparing the screen, triage and treat approach using dual-stain cytology as a triage test versus other triage tests are urgently needed.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "It is also important to conduct studies among this population in LMIC settings, where diagnostic and treatment capacities may be different from high-income settings.Furthermore, longitudinal studies that assess outcomes among women living with HIV over longer periods of time (e.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "g.3–5 years), including with different screening intervals and collection techniques, will be important to ascertain the long-term benefits and risks of different screening tests and strategies.Studies evaluating the implementation of screening and treatment strategies using dual-stain cytology for triage testing are also needed.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The studies should address the feasibility (including training, infrastructure needs and quality assurance) of dual-stain cytology, the acceptability by different stakeholders (including women and health workers) and the effect on accessibility and equity.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# 5.Dissemination and updating of the guideline # 5.1 Guideline dissemination and impact This recommendation will be integrated into a full consolidated version of WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, along with the outputs of the previous and next phases of the guideline update, in the near future.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In brief, the outputs of each phase and the final consolidated guideline will be disseminated using WHO’s worldwide network to make sure that the guideline reaches health workers and programme managers so that the most recent evidence is integrated and accessible for clinical decision-making to prevent cervical cancer.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The full dissemination strategy was approved for the second edition and includes dissemination on the WHO website and in the next edition of HRP News, and printed copies will be disseminated upon request to health ministries, WHO country and regional offices, WHO collaborating centres on cervical cancer, and other cervical cancer collaborators and partners.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Policy briefs and an app will also be produced.The guideline will be translated into the six WHO official languages.Dissemination plans also include partners involved in the implementation and roll-out of cervical cancer screening and treatment programmes.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "These include other United Nations agencies, the United States President’s Emergency Fund for AIDS Relief (PEPFAR), the Global Fund and Unitaid.WHO headquarters will work with WHO regional offices and country offices to ensure that countries will be supported in the adoption, implementation and monitoring of the guideline.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "For this purpose, regional workshops and webinars in different languages will be organized to present, discuss and plan guideline adaptation and implementation, as well as to update current national guidelines.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In addition, impact of the fully updated and consolidated guideline will be measured by developing and disseminating surveys for both health workers and clients, as was done during the guideline development on the topic of values and preferences.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "This will be done a year after release to assess any changes in country policies and national guidelines.This will also assess the reach of the guideline and ultimately its impact in changing practice.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Over the next year, WHO’s Comprehensive cervical cancer control: a guide to essential practice, which was last published in 2014 $( 5 )$ , will be revised to provide an up-to-date and global consolidation of all recommendations to prevent cervical cancer.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# 5.2 Guideline update Evidence for the sensitivity and specificity of the different tests addressed in the full updated guideline (including in this present guidance, focusing on dual-stain cytology) and evidence on the impact of these tests on important outcomes is accumulating, and syntheses of this evidence are needed.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "These syntheses will be used in a continual process to develop new recommendations – as part of the “living guidelines” approach – in the final phase of the guideline update (31).The GDG will continue to work with the WHO Secretariat in an ad hoc manner, so that the research gaps identified during the process can be addressed.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The GDG anticipates that as data and experience with new screening tests and modalities advance, new recommendations will be needed through a living guideline process that is able to rapidly respond and evolve.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# References 1.Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L et al.Global Cancer Observatory: Cancer Today [website].Lyon: International Agency for Research on Cancer; 2024 (https://gco.iarc.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "fr/today, accessed 8 March 2024).2.Global strategy to accelerate the elimination of cervical cancer as a public health problem.Geneva: World Health Organization; 2020 (https://iris.who.int/handle/10665/336583).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "3.Human papillomaviruses.IARC monographs on the evaluation of carcinogenic risks to humans, Vol.90.Lyon: International Agency for Research on Cancer; 2007 (https://publications.iarc.fr/ Book-And-Report-Series/Iarc-Monographs-On-The-Identification-Of-Carcinogenic-HazardsTo-Humans/Human-Papillomaviruses-2007).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "4.de Martel C, Plummer M, Vignat J, Franceschi S.Worldwide burden of cancer attributable to HPV by site, country and HPV type.Int J Cancer.2017;141(4):664–70.doi:10.1002/ijc.30716.5.Comprehensive cervical cancer control: a guide to essential practice, second edition.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Geneva: World Health Organization; 2014 (https://apps.who.int/iris/handle/10665/144785).6.Clarke MA, Gradissimo A, Schiffman M, Lam J, Sollecito CC, Fetterman B et al.Human papillomavirus DNA methylation as a biomarker for cervical precancer: consistency across 12 genotypes and potential impact on management of HPV-positive women.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Clin Cancer Res.2018;24(9):2194–202.doi:10.1158/1078-0432.CCR-17-3251.7.Hu L, Bell D, Antani $\\mathsf { S } , \\mathsf { X u e } \\mathsf { Z } , \\mathsf { Y u } \\mathsf { K } ,$ Horning MP et al.An observational study of deep learning and automated evaluation of cervical images for cancer screening.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "J Natl Cancer Inst.2019;111(9):923–32.doi:10.1093/jnci/djy225.8.Lie AK, Kristensen G.Human papillomavirus E6/E7 mRNA testing as a predictive marker for cervical carcinoma.Expert Rev Mol Diagn.2008;8(4):405–15.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "doi:10.1586/14737159.8.4.405.9.Sorbye SW, Fismen S, Gutteberg TJ, Mortensen ES, Skjeldestad FE.Primary cervical cancer screening with an HPV mRNA test: a prospective cohort study.BMJ Open.2016;6(8):e011981.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "doi:10.1136/bmjopen-2016-011981.10.WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention.Geneva: World Health Organization; 2013 (https://apps.who.int/iris/ handle/10665/94830).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "11.WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition.Geneva: World Health Organization; 2021 (https://apps.who.int/iris/ handle/10665/342365).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "12.WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition: use of mRNA tests for human papillomavirus (HPV).Geneva: World Health Organization; 2021 (https://apps.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "who.int/iris/handle/10665/350652).13.Human papillomavirus (HPV) nucleic acid amplification tests (NAATs) to screen for cervical pre-cancer lesions and prevent cervical cancer: policy brief.Geneva: World Health Organization; 2022 (https://apps.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "who.int/iris/handle/10665/352495).14.International Agency for Research on Cancer.IARC handbooks of cancer prevention: cervical cancer screening, Vol.18.Lyon, France: IARC Press; 2021 (https://publications.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "iarc.fr/Book-AndReport-Series/Iarc-Handbooks-Of-Cancer-Prevention/Cervical-Cancer-Screening-2022).15.Bouvard V, Wentzensen N, Mackie A, Berkhof J, Brotherton J, Giorgi-Rossi P et al.The IARC perspective on cervical cancer screening.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Special report.N Engl J Med.2021;385:1908–18.doi:10.1056/NEJMsr2030640.16.WHO guidelines for the use of thermal ablation for cervical pre-cancer lesions.Geneva: World Health Organization; 2019 (https://apps.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "who.int/iris/handle/10665/329299).17.Introducing and scaling up testing for human papillomavirus as part of a comprehensive programme for prevention and control of cervical cancer: a step-by-step guide.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Geneva: World Health Organization: 2020 (https://apps.who.int/iris/handle/10665/336668).18.WHO handbook for guideline development, second edition.Geneva: World Health Organization; 2014 (https://apps.who.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "int/iris/handle/10665/145714).19.Schünemann H, Brożek J, Guyatt G, Oxman A.GRADE handbook: handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach.GRADEpro; updated October 2013 (https://gdt.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "gradepro.org/app/handbook/handbook.html).20.Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ et al., editors.Cochrane handbook for systematic reviews of interventions, version 6.4 (updated August 2023).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Cochrane; 2023 (www.training.cochrane.org/handbook).21.Brisson M, Kim JJ, Canfell K, Drolet M, Gingras G, Burger EA et al.Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Lancet.2020;395(10224):575–90.doi:10.1016/ S0140-6736(20)30068-4.22.Burger EA, Smith MA, Killen J, Sy S, Simms KT, Canfell K, Kim JJ.Projected time to elimination of cervical cancer in the USA: a comparative modelling study.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Lancet Public Health.2020.5(4):e213–e222.doi:10.1016/S2468-2667(20)30006-2.23.Canfell K, Kim JJ, Brisson M, Keane A, Simms KT, Caruana M et al.Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Lancet.2020;395(10224):591–603.doi:10.1016/S0140- 6736(20)30157-4.24.Hall MT, Simms KT, Lew JB, Smith MA, Brotherton JML, Saville M et al.The projected timeframe until cervical cancer elimination in Australia: a modelling study.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Lancet Public Health.2019;4(1):e19–e27.doi:10.1016/S2468-2667(18)30183-X.25.Kitchener HC, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, Peto J.The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Health Technol Assess.2014;18(23):1–196.doi:10.3310/hta18230.26.Lew J-B, Simms K, Smith M, Lewis H, Neal H, Canfell K.Effectiveness modelling and economic evaluation of primary HPV screening for cervical cancer prevention in New Zealand.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "PLoS ONE.2016;11(5):e0151619.doi:10.1371/journal.pone.0151619.27.Lew J-B, Simms KT, Smith MA, Hall M, Kang YJ, Xu XM et al.Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Lancet Public Health.2017;2(2):e96–e107.doi:10.1016/S2468-2667(17)30007-5.28.Shi JF, Canfell K, Lew JB, Zhao F-H, Legood R, Ning Y et al.Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "BMC Cancer.2011;11:239.doi:10.1186/1471- 2407-11-239.29.Simms KT, Steinberg J, Caruana M, Smith MA, Lew J-B, Soerjomataram I et al.Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020–99: a modelling study.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Lancet Oncol.2019;20:394–407.doi:10.1016/S1470-2045(18)30836-2.30.Pfadenhauer LM, Gerhardus A, Mozygemba K, Lysdahl KB, Booth A, Hofmann B et al.Making sense of complexity in context and implementation: the Context and Implementation of Complex Interventions (CICI) framework.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Implement Sci.2017;12(1):21.doi:10.1186/s13012-017-0552-5.31.Vogel J, Dowswell T, Lewin S, Bonet M, Hampson L, Kellie F et al.Developing and applying a “living guidelines” approach to WHO recommendations on maternal and perinatal health.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "BMJ Glob Health.2019;4(4):e001683.doi:10.1136/bmjgh-2019-001683.![](images/5a48efd133ca1e72be35f007bf0f26c154ca97e743c29078848a8b046b844a6a.jpg) # Annex 1.Guideline groups ![](images/989ae304d829115dd1d6917ff647e4233edd09eb3635aed94ed562ee54d43d46.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "jpg) Guideline Development Group (GDG) members <html><body><table><tr><td>WHO region</td><td>Last name</td><td>First name</td><td>Institution</td><td>Country</td></tr><tr><td>Africa</td><td>Achieng </td><td>Claire Judith Ikate</td><td>Uganda Cancer Society</td><td>Uganda</td></tr><tr><td>Africa </td><td>Awori</td><td>Ruth</td><td>Representative from communities of women living with HIV</td><td>Uganda </td></tr><tr><td>Africa</td><td> Chinula</td><td>Lameck </td><td>Kamuzu Central Hospital </td><td> Malawi</td></tr><tr><td>Africa</td><td>Chirenje</td><td>Z.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Mike </td><td>University of Zimbabwe</td><td>Zimbabwe </td></tr><tr><td>Africa</td><td>Denny </td><td>Lynette </td><td>University of Cape Town</td><td> South Africa</td></tr><tr><td>Africa</td><td>Diop</td><td>Mamadou</td><td>Joliot Curie Cancer Institute</td><td>Senegal</td></tr><tr><td>Africa</td><td>Happy </td><td>Margaret</td><td>Advocacy for Quality Health Uganda</td><td> Uganda</td></tr><tr><td>Africa </td><td>Ingbian</td><td> Priscilla</td><td>Community health support and empowerment initiative </td><td>Nigeria</td></tr><tr><td>Africa</td><td>Motshedisi</td><td>Sebitloane</td><td>University of Kwazulu-Natal</td><td>South Africa</td></tr><tr><td>Africa</td><td>Mugo</td><td>Nelly </td><td>Kenya Medical Research Institute</td><td>Kenya </td></tr><tr><td>Africa</td><td> Muzingwani</td><td>Laura </td><td>I-TECH Namibia</td><td>Namibia</td></tr><tr><td>Africa</td><td>Obiri-Yeboah</td><td>Dorcas</td><td>University of Cape Coast </td><td>Ghana</td></tr><tr><td>Africa</td><td> Shiferaw</td><td>Netsanet </td><td> Pathfinder International </td><td>Ethiopia</td></tr><tr><td>The Americas</td><td>Arrossi</td><td>Silvina</td><td>Centro de Estudios de Estado y Sociedad (CEDES)</td><td>Argentina</td></tr><tr><td>The Americas</td><td>Barnabas</td><td>Ruanne </td><td>University of Washington</td><td>United States of America (USA)</td></tr><tr><td>The Americas</td><td>Bento Claro</td><td>Itamar</td><td>National Cancer Institute José Alencar Gomes da Silva (INCA)</td><td>Brazil</td></tr><tr><td>The Americas</td><td>Chung</td><td>Michael</td><td>Emory University</td><td>USA</td></tr><tr><td>The Americas</td><td>Correa</td><td></td><td>Flavia Miranda Brazilian National Cancer Institute </td><td> Brazil</td></tr><tr><td>The Americas</td><td>Cremer </td><td>Miriam</td><td>Basic Health International</td><td>USA</td></tr></table></body></html> <html><body><table><tr><td></td><td></td><td></td><td></td><td>Country</td></tr><tr><td>The Americas</td><td>Darragh</td><td>Teresa </td><td>Urniersty ofCalfona san</td><td>USA</td></tr><tr><td>The Americas</td><td>de Sanjosé</td><td> Silvia</td><td>National Cancer Institute </td><td>USA</td></tr><tr><td>The Americas</td><td>Gage</td><td>Julia</td><td>National Cancer Institute</td><td>USA</td></tr><tr><td>The Americas</td><td> Gravitt </td><td>Patti</td><td>fortinaar stute ener</td><td>USA</td></tr><tr><td>The Americas</td><td></td><td>Rolando</td><td> Costa Rican Agency for</td><td>USA</td></tr><tr><td>The Americas</td><td></td><td></td><td>Biomedical Research Representatvfrm muniies</td><td></td></tr><tr><td></td><td>Johnson </td><td>Ebony</td><td></td><td>USA</td></tr><tr><td>The Americas The Americas</td><td>Maza Murillo</td><td>Mauricio Raul </td><td>Basic Health International Hospital Universitario San Ignacio</td><td>El Salvador Colombia</td></tr><tr><td>The Americas</td><td>Moley</td><td>Kelle</td><td>BiMein Gete Fuates</td><td>USA</td></tr><tr><td>The Americas</td><td> Ogilvie</td><td></td><td>BC Women's Hospital and Health </td><td></td></tr><tr><td>The Americas</td><td></td><td></td><td>Centre HPV Reference Laboratory.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Maria Alejandra National Institute for Infectious </td><td></td></tr><tr><td>The Americas</td><td></td><td></td><td>Diseases - ANLIS \"Dr Malbran\"</td><td></td></tr><tr><td>The Americas</td><td> Pinder </td><td>Leeya Veronica</td><td>University of Washington Jhpiego</td><td>USA USA</td></tr><tr><td></td><td>Reis</td><td></td><td> Bolivian Network of People Living</td><td></td></tr><tr><td>The Americas</td><td>Ross Quiroga</td><td>Gracia Violetta</td><td>with HIV/AIDS</td><td>Bolivia</td></tr><tr><td>The Americas The Americas</td><td>Sahasrabuddhe</td><td>Vikrant </td><td>National Cancer Institute PATH</td><td>USA USA</td></tr><tr><td>The Americas </td><td>Slavkovsky</td><td>Rose</td><td>PATH</td><td>USA</td></tr><tr><td>The Americas</td><td>Thomson Wentzensen </td><td>Kerry Nicolas</td><td>National Cancer Institute</td><td>USA</td></tr><tr><td>Eastern </td><td>Atif Waqar </td><td>Muhammad</td><td>Aga Khan University Hospital</td><td> Pakistan </td></tr><tr><td>Mediterranean Eastern </td><td>Ghanbari-Motlagh Ali </td><td></td><td>Ministry of Health </td><td>Iran </td></tr><tr><td>Eastern Mediterranean </td><td>Hashem </td><td>Tarek </td><td>Menofyia University</td><td>Egypt </td></tr></table></body></html> <html><body><table><tr><td>WHO region</td><td>Last name</td><td>First name</td><td>Institution</td><td>Country</td></tr><tr><td>Europe</td><td>Bruni</td><td>Laia</td><td>Catalan Institute of Oncology</td><td>Spain</td></tr><tr><td>Europe</td><td>Boily</td><td>Marie-Claude </td><td>Imperial College London</td><td>United Kingdom of Great Britain and Northern Ireland</td></tr><tr><td>Europe</td><td>Cain</td><td>Joanna</td><td>International Federation of Obstetrics and Gynecology (FIGO)</td><td>United Kingdom</td></tr><tr><td>Europe</td><td>Kelly</td><td>Helen </td><td>Trndien SchlofHygie and</td><td>United Kingdom</td></tr><tr><td>Europe</td><td>Mackie</td><td>Anne</td><td>Public Health England Screening and Screening Quality Assurance Service</td><td>United Kingdom</td></tr><tr><td>Europe</td><td>Petignat</td><td> Patrick</td><td>Hopitaux Universitaires de Geneve </td><td>Switzerland</td></tr><tr><td>Europe</td><td>Prendiville</td><td>Walter</td><td>International Agency for Research on Cancer (IARC)</td><td>France </td></tr><tr><td>Europe</td><td>Sasieni</td><td> Peter </td><td>King's College London</td><td>United Kingdom</td></tr><tr><td>Europe</td><td>Torode</td><td>Julie</td><td>King's College London</td><td>United Kingdom</td></tr><tr><td>South-East Asia</td><td>Bhatla</td><td>Neerja</td><td>All India Institute of Medical Sciences</td><td>India</td></tr><tr><td>South-East Asia</td><td>Eamratsameekool </td><td>Wachara</td><td>Phanomphrai Community Hospital Thailand </td><td></td></tr><tr><td>South-East Asia</td><td>Nessa</td><td>Ashrafun</td><td>Bangabandhu shih Mujib</td><td>Bangladesh</td></tr><tr><td>South-East Asia</td><td>Thinn </td><td>Myint Myint </td><td>Central Women's Hospital</td><td>Myanmar </td></tr><tr><td>Western Pacific</td><td>Luvsandorj</td><td>Bayarsaikhan</td><td>National Cancer Center of Mongolia</td><td>Mongolia</td></tr><tr><td>Western Pacific</td><td>Zhao</td><td> Fanghui</td><td>China Cancer Institute</td><td>China</td></tr></table></body></html> # External Review Group (ERG) members <html><body><table><tr><td>WHO region</td><td>Last name</td><td>First name</td><td>Institution</td><td>Country</td></tr><tr><td>The Americas</td><td>Meglioli</td><td>Alejandra</td><td>International Planned Parenthood Federation/Western Hemisphere Region </td><td>USA</td></tr><tr><td>The Americas</td><td>Nogueira</td><td>Angélica</td><td>Federal University of Mina Gerais, Brazilian Society of Medical Oncology</td><td>Brazil</td></tr><tr><td>The Americas</td><td>Schiffman </td><td>Mark</td><td>National Cancer Institute</td><td>USA</td></tr><tr><td>The Americas</td><td>Teran </td><td>Carolina</td><td>Universidad Mayor, Real y Pontificia de San Francisco Xavier de Chuquisaca</td><td>Bolivia</td></tr><tr><td>The Americas</td><td>Trimble</td><td>Ted </td><td>National Cancer Institute</td><td>USA</td></tr><tr><td>The Americas</td><td>Venegas</td><td>Gino</td><td>Facultad de Medicina, Universidad de Piura</td><td>Peru </td></tr><tr><td>The Americas</td><td>White</td><td>Heather</td><td>TogetHER for Health</td><td>USA</td></tr><tr><td>Eastern Mediterranean</td><td>El Hanchi</td><td>Zaki</td><td>National Institute of Oncology, CHU</td><td>Morocco</td></tr><tr><td>Eastern Mediterranean</td><td>Moawia</td><td>Mohammed</td><td>National Cancer Institute, University of Gezira</td><td>Sudan </td></tr><tr><td>Europe</td><td>Chowdhury</td><td>Raveena</td><td>MSI Reproductive Choices UK</td><td>United Kingdom</td></tr><tr><td>Europe</td><td>Cubie</td><td>Heather</td><td>University of Edinburgh</td><td>United Kingdom</td></tr><tr><td>South-East Asia</td><td>Ghimire </td><td> Sarita </td><td>Nepal Cancer Care Foundation</td><td>Nepal </td></tr><tr><td>South-East Asia</td><td>Shamsunder </td><td>Saritha </td><td>Safdarjung Hospital </td><td>India </td></tr><tr><td>South-East Asia</td><td>Suri </td><td>Vanita </td><td>Department of Obstetrics and Gynecology, Postgraduate Institute of Medical Education and Research</td><td>India</td></tr><tr><td>Western Pacific</td><td>Garland </td><td>Suzanne</td><td>University of Melbourne</td><td> Australia</td></tr><tr><td>Western Pacific</td><td>In </td><td>Ha Hyeong</td><td>Center for Gynecologic Cancer, National Cancer Center</td><td>Republic of Korea</td></tr><tr><td>Western Pacific</td><td> Jin-Kyoung</td><td>Oh</td><td>Department of Cancer Control and Population Health Research, National Cancer Center</td><td>Republic of Korea</td></tr><tr><td>Western Pacific</td><td>Myong Cheol </td><td>Lim</td><td>Center for Gynecologic Cancer, National Cancer Center</td><td>Republic of Korea</td></tr></table></body></html> # Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodologist supporting guideline development Nancy Santesso Department of Health Research Methods, Evidence and Impact McMaster University, Hamilton, Canada Area of expertise: guideline development, systematic reviews, clinical epidemiology # Systematic review teams <html><body><table><tr><td>Last name</td><td>Firstname</td><td>Institution</td><td>Country</td></tr><tr><td>Arbyn</td><td>Marc</td><td>Unit Cancer Epidemiology - Belgian Cancer Centre - Sciensano</td><td>Belgium</td></tr><tr><td>Lauby-Secretan</td><td>Beatrice</td><td>IARC</td><td>France</td></tr><tr><td>Wentzensen</td><td>Nicolas</td><td>National Cancer Institute</td><td>USA</td></tr></table></body></html> # Modelling team The modelling team supported the development of these guidelines for women in the general population and women living with HIV.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The modelling work was performed by the team led by Karen Canfell at Cancer Council NSW, Sydney, Australia (now the Daffodil Centre, a joint venture between the University of Sydney and Cancer Council NSW) using the Policy1-Cervix platform.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "The team members are listed in the table below.The modelling team gratefully acknowledges: John Murray from the University of New South Wales, Sydney, who was also involved in the development of the HIV/HPV model used for the evaluation of screening in women living with HIV; Megan Smith from Cancer Council NSW, who contributed to past model development and discussions about model validation for newly emergent technologies; and Susan Yuill from Cancer Council NSW, who contributed to the systematic review of the evidence on HPV triage strategies led by Marc Arbyn of the Belgian Cancer Centre, which was used to inform the modelling.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "<html><body><table><tr><td>Last name</td><td>First name</td><td>Institution</td><td>Country</td></tr><tr><td>Canfell</td><td>Karen </td><td>The Daffodil Centre, a joint venture between the University of Sydney and Cancer Council NSW</td><td>Australia</td></tr><tr><td>Caruana</td><td>Michael </td><td>The Daffodil Centre</td><td>Australia</td></tr><tr><td>Hall</td><td>Michaela</td><td>The Daffodil Centre</td><td>Australia</td></tr><tr><td>Keane</td><td>Adam</td><td>The Daffodil Centre</td><td>Australia</td></tr><tr><td>Killen</td><td>James </td><td>The Daffodil Centre</td><td>Australia</td></tr><tr><td>Lui</td><td>Gigi</td><td>The Daffodil Centre</td><td>Australia</td></tr><tr><td>Nguyen</td><td>Diep </td><td>The Daffodil Centre</td><td>Australia</td></tr><tr><td>Simms</td><td>Kate</td><td>The Daffodil Centre</td><td>Australia</td></tr></table></body></html> # Costing expertise <html><body><table><tr><td>Last name</td><td>First name</td><td>Institution</td><td>Country</td></tr><tr><td>Demke</td><td>Owen</td><td>Clinton Health Access Initiative</td><td>Rwanda</td></tr><tr><td>Gauvreau</td><td>Cindy </td><td>Hospital for Sick Children/University of Toronto</td><td>Canada</td></tr></table></body></html> # Observers <html><body><table><tr><td>Last name</td><td>First name</td><td>Institution</td><td>Country</td></tr><tr><td>Anderson</td><td>Benjamin</td><td>University of Washington</td><td>USA</td></tr><tr><td>Berkhof</td><td>J.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "(Hans)</td><td>Vrije Universiteit</td><td>Kingdom of the Netherlands</td></tr><tr><td>Chevalier</td><td>Michelle</td><td>President's Emergency Plan for AIDS Relief (PEPFAR)</td><td>USA</td></tr><tr><td>de Lussigny</td><td> Smiljka</td><td>Unitaid </td><td>Switzerland </td></tr><tr><td>Engel </td><td>Danielle </td><td>United Nations Population Fund (UNFPA)</td><td>USA</td></tr><tr><td>Franco</td><td>Eduardo</td><td>Division of Cancer Epidemiology, McGill University</td><td>Canada</td></tr><tr><td>Huang</td><td>Lisa Pei-Ching</td><td>Expertise France</td><td>France </td></tr><tr><td>Jafa</td><td>Krishna</td><td>Bill & Melinda Gates Foundation</td><td>USA</td></tr><tr><td>Jeronimo</td><td>Jose</td><td>Cancer Consulting</td><td>USA</td></tr><tr><td>Kumar </td><td>Somesh</td><td>Jhpiego</td><td>USA</td></tr><tr><td>Lapidos-Salaiz</td><td>Illana </td><td>United States Agency for International Development (USAID)</td><td>USA</td></tr><tr><td>Mesher</td><td>David</td><td>Public Health England, International Agency for Research on Cancer (IARC)</td><td>United Kingdom</td></tr><tr><td> Odayar</td><td>Jasantha</td><td>University of Cape Town</td><td>South Africa</td></tr><tr><td> Parham</td><td>Groesbeck</td><td>University of North Carolina</td><td>USA</td></tr><tr><td>Perez Casas</td><td>Carmen </td><td>Unitaid</td><td>Switzerland</td></tr><tr><td>Roitberg</td><td>Felipe</td><td>WHO</td><td>Switzerland </td></tr><tr><td>Shakarishvili</td><td>Anna </td><td>Joint United Nations Programme on HIV/AIDS (UNAIDS)</td><td>Switzerland</td></tr><tr><td>ten Hoope-Bender</td><td>Petra</td><td>UNFPA</td><td>Switzerland</td></tr></table></body></html> WHO Secretariat – headquarters members (Geneva, Switzerland) <html><body><table><tr><td>Last name</td><td>First name</td><td>Departments</td></tr><tr><td>Almnte</td><td>Maribel </td><td>Deatment ofNoncommunicableDiseases eabitation and</td></tr><tr><td>Bloem</td><td> Paul</td><td>Department of Immunization, Vaccines and Biologicals </td></tr><tr><td>Broutet </td><td>Nathalie</td><td>Department of Sexual and Reproductive Health and Research</td></tr><tr><td>Cortes </td><td>Myriam </td><td>Department of Sexual and Reproductive Health and Research </td></tr><tr><td> Dalal</td><td> Shona</td><td>Department of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes </td></tr><tr><td> De Mello</td><td>Maeve</td><td>Department of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes </td></tr><tr><td>Eckert </td><td>Linda </td><td>Department of Sexual and Reproductive Health and Research</td></tr><tr><td> El Sheikh </td><td>Fayad </td><td>Department of Immunization, Vaccines and Biologicals </td></tr><tr><td>Fidarova </td><td>Elena </td><td>Deasblt</td></tr><tr><td>Gottlieb</td><td> Sami</td><td>Department of Sexual and Reproductive Health and Research</td></tr><tr><td>Hutubessy</td><td>Raymond </td><td>Department of Immunization, Vaccines and Biologicals </td></tr><tr><td>lbawi</td><td>Andre</td><td>Department of Noncommunicable Diseases, Rehabilitation and Disability</td></tr><tr><td>Khosla</td><td>Rajat </td><td>Department of Sexual and Reproductive Health and Research </td></tr><tr><td>Kuku </td><td>Stephanie Yetunde</td><td>Department of Digital Health and Innovation</td></tr><tr><td>Narasimhan </td><td>Manjulaa </td><td>Department of Sexual and Reproductive Health and Research</td></tr><tr><td>Newman </td><td>Morkor</td><td>Department of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes</td></tr><tr><td> Purnat </td><td>Tina</td><td>Department of Digital Health and Innovation</td></tr><tr><td>Rangaraj</td><td>Ajay</td><td>Deertmsn ogGobal HIV epatis and eoual Transmited</td></tr><tr><td>Riley</td><td>Lanaret</td><td>Deartmen o loncom uniableDisases ehbitaton andl</td></tr><tr><td>Sands </td><td> Anita</td><td>Department of Regulation and Prequalification</td></tr><tr><td>Stroher</td><td>Ute</td><td>Department of Regulation and Prequalification</td></tr><tr><td>Velazquez Berumen </td><td>Adriana </td><td> Department of Health Product Policy and Standards</td></tr><tr><td>Vojnov</td><td>Lara </td><td>Dptl</td></tr><tr><td>Xu</td><td>Hongyi</td><td>Demenicaiseabit</td></tr></table></body></html> WHO Secretariat – regional advisers and International Agency for Research on Cancer (IARC) staff <html><body><table><tr><td>WHO region</td><td>Last name</td><td>First name</td></tr><tr><td>Africa</td><td>Barango</td><td> Prebo</td></tr><tr><td>Africa</td><td>Dangou </td><td>Jean-Marie</td></tr><tr><td>Africa</td><td>Kapambwe </td><td>Sharon </td></tr><tr><td>Africa </td><td>Lago</td><td>Hugues</td></tr><tr><td>Africa </td><td> Ouedraogo</td><td>Leopold </td></tr><tr><td>Africa</td><td>Sebitloane</td><td>Tshidi</td></tr><tr><td>The Americas</td><td>Ghidinelli </td><td>Massimo</td></tr><tr><td>The Americas</td><td>Gomez Ponce de Leon</td><td>Rodolfo</td></tr><tr><td>The Americas</td><td>Luciani </td><td>Silvana</td></tr><tr><td>Eastern Mediterranean</td><td>Gholbzouri</td><td>Karima</td></tr><tr><td>Eastern Mediterranean </td><td>Hermez </td><td>Joumana George</td></tr><tr><td> Eastern Mediterranean </td><td> Slama</td><td>Slim</td></tr><tr><td>Europe</td><td>Corbex </td><td>Marilys </td></tr><tr><td>Europe</td><td>Masoud</td><td>Dara </td></tr><tr><td>Europe</td><td> Smelov </td><td>Vitaly</td></tr><tr><td>South-East Asia</td><td>Dorji</td><td>Gampo </td></tr><tr><td>South-East Asia</td><td>Jayathilaka</td><td>Chandani Anoma</td></tr><tr><td>South-East Asia</td><td> Raina </td><td>Neena</td></tr><tr><td>South-East Asia</td><td> Sharma</td><td>Mukta</td></tr><tr><td>Western Pacific</td><td>Ishikawa</td><td>Naoko</td></tr><tr><td>Western Pacific</td><td>Mannava</td><td>Priya </td></tr><tr><td>Western Pacific</td><td> Narayan </td><td>Elick </td></tr><tr><td>Western Pacific</td><td>Shin </td><td>Hai-rim </td></tr><tr><td>Western Pacific</td><td>Sobel </td><td>Howard </td></tr><tr><td>Western Pacific</td><td>Tiko</td><td> Josaia</td></tr><tr><td>Western Pacific</td><td>Tran </td><td>Huong</td></tr><tr><td>IARC</td><td>Almonte Pacheco</td><td>Maribel </td></tr><tr><td>IARC</td><td>Basu</td><td> Partha</td></tr><tr><td>IARC</td><td>Clifford </td><td>Gary</td></tr><tr><td>IARC</td><td>Lauby-Secretan</td><td>Beatrice</td></tr><tr><td>IARC</td><td>Sauvaget </td><td>Catherine</td></tr></table></body></html> # Annex 2.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Evidence-gathering teams and guideline task groups <html><body><table><tr><td>Screen-and-treat Screen, triage and treat (follow-up studies)</td><td>Screen-and-treat Screen, triage and treat (diagnostic studies)</td></tr><tr><td>Lead: Nicolas Wentzensen</td><td>Lead: Marc Arbyn</td></tr><tr><td>Nicolas Wentzensen</td><td>Karen Canfell</td></tr><tr><td>IARC handbook Working Group (Lead: Beatrice Lauby-Secretan):</td><td>Silvia de Sanjosé</td></tr><tr><td>Julia Brotherton</td><td>Nicolas Wentzensen</td></tr><tr><td>Marta del Pino Chisato Hamashima</td><td></td></tr><tr><td>Anne Mackie</td><td></td></tr><tr><td>Walter Prendiville</td><td></td></tr><tr><td>Paolo Giorgi Rossi</td><td></td></tr><tr><td>Rengaswamy Sankaranarayanan</td><td></td></tr><tr><td></td><td></td></tr></table></body></html> <html><body><table><tr><td>Values and preferences</td><td>Feasibility and implementation</td><td>Clinical algorithms</td></tr><tr><td>Lead: Ajay Rangaraj</td><td>Leads: Patti Gravitt and</td><td>Lead: Partha Basu</td></tr><tr><td>WHO Advisory Group of Women</td><td>Nancy Santesso</td><td>Maribel Almonte</td></tr><tr><td>Living with HIV </td><td> Prajakta Adsul</td><td>Silvina Arrossi</td></tr><tr><td>Nathalie Broutet</td><td>Maribel Almonte</td><td>Neerja Bhatla</td></tr><tr><td>Shona Dalal</td><td>André Carvalho</td><td>Nathalie Broutet</td></tr><tr><td>Linda Eckert</td><td>Lisa Huang</td><td>Karen Canfell</td></tr><tr><td>Morkor Newman</td><td>José Jeronimo</td><td>Z.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Mike Chirenje</td></tr><tr><td>Nancy Santesso</td><td>Somesh Kumar</td><td>Miriam Cremer</td></tr><tr><td>Julie Torode</td><td>Najat Lahmi</td><td>Shona Dalal</td></tr><tr><td></td><td>Kelly McCrystal</td><td>Lynette Denny</td></tr><tr><td></td><td>Raul Murillo</td><td>Linda Eckert</td></tr><tr><td></td><td>Jasantha Odayar</td><td>Jose Jeronimo</td></tr><tr><td></td><td>Katayoun Taghavi</td><td>Beatrice Lauby</td></tr><tr><td></td><td></td><td>Raul Murillo</td></tr><tr><td></td><td></td><td>Laura Muzingwani </td></tr><tr><td></td><td></td><td>Groesbeck Parham</td></tr><tr><td></td><td></td><td>Walter Prendiville</td></tr><tr><td></td><td></td><td>Nancy Santesso</td></tr><tr><td></td><td></td><td>Nicolas Wentzensen</td></tr></table></body></html> # Annex 3.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Declarations of interests <html><body><table><tr><td>WHO region</td><td>Last name</td><td>First name</td><td>Declaration of interests</td><td>Confidentiality agreement</td></tr><tr><td>Africa</td><td>Achieng </td><td>Claire Judith Ikate</td><td>None </td><td>Received </td></tr><tr><td>Africa</td><td>Awori</td><td>Ruth </td><td>None </td><td>Received </td></tr><tr><td>Africa</td><td>Chinula</td><td>Lameck </td><td>None </td><td> Received </td></tr><tr><td>Africa</td><td>Chirenje</td><td>Z.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Mike </td><td>None </td><td> Received </td></tr><tr><td>Africa</td><td>Denny</td><td>Lynette</td><td>None </td><td>Received </td></tr><tr><td>Africa </td><td>Diop</td><td>Mamadou</td><td>None </td><td> Received </td></tr><tr><td>Africa</td><td>Happy</td><td>Margaret </td><td>None </td><td>Received </td></tr><tr><td>Africa</td><td>Ingbian </td><td>Priscilla</td><td>None </td><td>Received </td></tr><tr><td>Africa</td><td> Motshedisi</td><td>Sebitloane</td><td>None </td><td>Received </td></tr><tr><td>Africa</td><td>Mugo</td><td>Nelly</td><td>None </td><td>Received </td></tr><tr><td>Africa</td><td>Muzingwani</td><td>Laura </td><td>None </td><td>Received </td></tr><tr><td>Africa</td><td> Obiri-Yeboah</td><td>Dorcas</td><td>None </td><td>Received </td></tr><tr><td>Africa</td><td> Shiferaw</td><td>Netsanet </td><td>None</td><td>Received</td></tr><tr><td>The Americas</td><td>Arrossi</td><td>Silvina</td><td>None </td><td> Received</td></tr><tr><td>The Americas</td><td>Barnabas</td><td>Ruanne</td><td>None</td><td>Received </td></tr><tr><td>The Americas</td><td>Bento Claro</td><td>Itamar </td><td>None </td><td> Received </td></tr><tr><td>The Americas</td><td>Chung</td><td>Michael </td><td>None </td><td>Received </td></tr><tr><td>The Americas</td><td>Correa</td><td>Flavia Miranda</td><td>None </td><td>Received </td></tr><tr><td>The Americas</td><td>Cremer</td><td>Miriam</td><td>None </td><td>Received </td></tr><tr><td>The Americas</td><td>Darragh</td><td>Teresa </td><td>None </td><td>Received </td></tr><tr><td>The Americas</td><td>Gage</td><td>Julia</td><td>None</td><td>Received </td></tr><tr><td>The Americas</td><td>Gravitt </td><td> Patti</td><td>None </td><td>Received </td></tr><tr><td>The Americas</td><td>Herrero</td><td> Rolando</td><td>None</td><td>Received </td></tr><tr><td>The Americas</td><td>Johnson</td><td>Ebony</td><td>None</td><td>Received </td></tr><tr><td>The Americas</td><td>Maza</td><td>Mauricio</td><td>None </td><td>Received </td></tr><tr><td>The Americas</td><td>Murillo</td><td>Raul</td><td>None</td><td>Received </td></tr></table></body></html> <html><body><table><tr><td>WHO region</td><td>Last name</td><td>First name</td><td>Declaration of interests</td><td>Confidentiality agreement</td></tr><tr><td>The Americas</td><td>Moley</td><td>Kelle</td><td>None </td><td>Received</td></tr><tr><td>The Americas</td><td>Ogilvie</td><td>Gina </td><td>None</td><td>Received </td></tr><tr><td>The Americas </td><td> Picconi</td><td> Maria Alejandra </td><td>None </td><td>Received </td></tr><tr><td>The Americas</td><td> Pinder </td><td>Leeya</td><td>None</td><td>Received </td></tr><tr><td>The Americas</td><td>Reis</td><td>Veronica</td><td>None </td><td> Received </td></tr><tr><td>The Americas</td><td>Ross Quiroga</td><td>Gracia Violetta</td><td>None</td><td>Received </td></tr><tr><td>The Americas</td><td>Sahasrabuddhe</td><td>Vikrant </td><td>None</td><td>Received</td></tr><tr><td>The Americas</td><td> Slavkovsky</td><td>Rose</td><td>None </td><td>Received </td></tr><tr><td>The Americas</td><td>Thomson</td><td>Kerry</td><td>None</td><td> Received</td></tr><tr><td>The Americas</td><td>Wentzensen</td><td>Nicolas </td><td>None</td><td>Received </td></tr><tr><td>Eastern Mediterranean</td><td>Atif Waqar </td><td>Muhammad</td><td>None </td><td>Received </td></tr><tr><td>Eastern Mediterranean</td><td>Ghanbari-Motlagh</td><td>Ali</td><td>None </td><td>Received </td></tr><tr><td>Eastern Mediterranean </td><td>Hashem </td><td>Tarek </td><td>None</td><td> Received </td></tr><tr><td>Europe</td><td>Bruni</td><td>Laia </td><td>None</td><td>Received </td></tr><tr><td>Europe</td><td>Boily</td><td>Marie-Claude</td><td>None</td><td>Received </td></tr><tr><td>Europe</td><td>Cain </td><td>Joanna</td><td>None </td><td>Received</td></tr><tr><td>Europe</td><td>de Sanjosé </td><td> Silvia</td><td>None </td><td>Received</td></tr><tr><td>Europe</td><td>Kelly</td><td>Helen </td><td>None</td><td>Received</td></tr><tr><td>Europe</td><td>Mackie</td><td>Anne</td><td>None </td><td>Received </td></tr><tr><td>Europe</td><td> Petignat</td><td>Patrick</td><td>None</td><td>Received </td></tr><tr><td>Europe</td><td> Prendiville</td><td>Walter</td><td>None</td><td>Received </td></tr><tr><td>Europe</td><td>Sasieni</td><td> Peter </td><td>None </td><td> Received </td></tr><tr><td>Europe</td><td>Torode</td><td>Julie</td><td>None </td><td>Received </td></tr><tr><td> South-East Asia</td><td>Bhatla </td><td>Neerja </td><td>None </td><td>Received </td></tr><tr><td> South-East Asia</td><td> Eamratsameekool </td><td>Wachara</td><td>None </td><td>Received </td></tr><tr><td>South-East Asia </td><td>Nessa</td><td> Ashrafun </td><td>None</td><td> Received </td></tr><tr><td>South-East Asia </td><td>Thinn </td><td>Myint Myint </td><td>None </td><td> Received </td></tr><tr><td>Western Pacific</td><td>Luvsandorj</td><td>Bayarsaikhan</td><td>None</td><td>Received </td></tr><tr><td>Western Pacific</td><td>Zhao</td><td>Fanghui</td><td>None</td><td>Received </td></tr></table></body></html> # Annex 4.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Algorithms for use of dual-stain cytology as a triage test in the general population of women Screening and treatment approaches In the “screen-and-treat approach”, the decision to treat is based on a positive primary screening test only.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "![](images/842c1c9dfb7d3d43e4737c2cd33f18250497958567473f0cefdab6676b635512.jpg) In the “screen, triage and treat approach”, the decision to treat is based on a positive primary screening test followed by a positive second test (a “triage” test), with or without histologically confirmed diagnosis.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "![](images/df1050454230f5ebef34e7a7e98db7e769614486904e4228b65edd6bbdc09d4e.jpg) # Screen-and-treat approach: Dual-stain cytology was not assessed as part of a screen-and-treat approach.# Two algorithms for screen, triage and treat approach: 1.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "HPV DNA as the primary screening test, followed by triage using dual-stain cytology, then further followed by colposcopy to determine further management 2.HPV mRNA as the primary screening test, followed by triage using dual-stain cytology, then further followed by colposcopy to determine further management These two algorithms have been combined into one flow chart as presented on the next page.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In addition, on p.42, an algorithm is presented for follow-up testing at 12 months post-treatment.# Algorithm for primary HPV DNA or HPV mRNA screening and dual-stain cytology as a triage test (screen, triage and treat approach) For the general population of women This flow chart combines the two algorithms that were assessed (see Table 2.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "2).![](images/a94aae00e3b665a999c13624f5cf8df0078a7a173facfb56ea8051a77d2a7952.jpg) a If using an HPV DNA nucleic acid test (NAT), rescreen in 5–10 years.If using an HPV mRNA NAT, rescreen in 5 years.# Algorithm for follow-up testing at 12 months post-treatment For the general population of women !",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "[](images/171edc463f252401ad898a25c837b932a036948416e40b3fa448e63653bfe3c2.jpg) # Annex 5.Recommendations for the use of HPV DNA tests and HPV mRNA tests and other cervical screening methods1 <html><body><table><tr><td>Recommendations for the general population of womena</td><td>Strength of recommendation and certainty of evidence</td><td>Recommendations for women living with HiVa</td><td>Strength of recommendat and certainty evidence</td></tr><tr><td>1.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "WHO recommends using HPV DNA detection as the primary screening test rather than VIA or cytology in screening and treatment approaches among both the general population of women and women living with HIV.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Remarks: Existing programmes with quality-assured cytology as the primary screening test should be continued until HPV DNA testing is operational; existing programmes using VIA as the primary screening test should transition rapidly</td><td>Strong recommendation, moderate-certainty evidence </td><td>21.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "WHO recommends using HPV DNA detection as the primary screening test rather than VIA or cytology in screening and treatment approaches among both the general population of women and women living with HIV.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Remarks: Existing programmes with quality-assured cytology as the primary screening test should be continued until HPV DNA testing is operational; existing programmes using VIA as the primary screening test should transition rapidly</td><td>Strong recommendatic moderate certa of evidence </td></tr><tr><td>2.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "WHO suggests using an HPV DNA primary screening test either with triage or without triage to prevent cervical cancer among the general population of women.</td><td>Conditional recommendation, moderate-certainty evidence</td><td>22.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "WHO suggests using an HPV DNA primary screening test with triage rather than without triage to prevent cervical cancer among women living with HIV.</td><td>Conditional recommendatic moderate certa of evidence</td></tr></table></body></html> a Rows shaded in pink indicate that the recommendation or good practice statement is identical for both the general population of women (left column) and women living with HIV (right column).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In other rows, the wording of the recommendations differs for each population.四 <html><body><table><tr><td>Recommendations for the general population of women a</td><td>Strength of recommendation and certainty of evidence Conditional</td><td> Recommendations for women living with HIVa</td><td>Strength recomme and certa evidence Condition</td></tr><tr><td>3a.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In a screen-and-treat approach using HPV DNA detection as the primary screening test, WHO suggests treating women who test positive for HPV DNA among the general population of women.3b.In a screen, triage and treat approach using HPV DNA detection as the primary screening test among the general population of women, WHO suggests using partial genotyping, colposcopy, VIA</td><td>recommendation, moderate-certainty evidence </td><td>23.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In a screen, triage and treat approach using HPV DNA detection as the primary screening test among women living with HIV, WHO suggests using partial genotyping, colposcopy, VIA or cytology to triage women after a positive HPV DNA test (Annex 4).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Remarks: The benefits, harms and programmatic</td><td>recommel moderate evidence </td></tr><tr><td>feasibility, training, programme quality assurance and resources in countries.HPV16/18 genotyping could be integrated into the HPV DNA test (refer to Annex 4 for specific details of the algorithms).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "4.When providing HPV DNA testing, WHO suggests using either samples taken by a health-care provider or self-collected samples among both the general population of women and women living with HIV.</td><td>Conditional recommendation, low-certainty evidence</td><td>feasibility, training, programme quality assurance and resources in countries.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "HPV16/18 genotyping could be integrated into the HPV DNA test (refer to Annex 4 for specific details of the algorithms).24.When providing HPV DNA testing, WHO suggests using either samples taken by a health-care provider or self-collected samples among both the general population of women and women living with HIV.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>Condition recommei low-certai evidence </td></tr></table></body></html> a Rows shaded in pink indicate that the recommendation or good practice statement is identical for both the general population of women (left column) and women living with HIV (right column).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In other rows, the wording of the recommendations differs for each population.<html><body><table><tr><td>Recommendations for the general population of womena</td><td>Strength of recommendation and certainty of evidence</td><td> Recommendations for women living with HIVa</td><td>Strength of recommendati and certainty evidence</td></tr><tr><td>5.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "WHO recommends starting regular cervical cancer screening at the age of 30 years among the general population of women.</td><td>Strong recommendation, moderate-certainty evidence</td><td>25.WHO suggests starting regular cervical cancer screening at the age of 25 years among women living with HIV.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Remarks: Low-certainty evidence found that there are likely to be small numbers of women living with HIV with cervical cancer who are below the age of 25.This recommendation applies to women living with HIV regardless of when they first tested positive for HIV.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>Conditional recommendatic low-certainty evidence</td></tr><tr><td>6.After the age of 50 years, WHO suggests screening is stopped after two consecutive negative screening results consistent with the recommended regular screening intervals among both the general population of women and women living with HIV.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Remarks: Neither VIA nor ablative treatment are suitable for screening or treatment of women in whom the transformation zone is not visible.</td><td>Conditional recommendation, low-certainty evidence </td><td>26.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "After the age of 50 years, WHO suggests screening is stopped after two consecutive negative screening results consistent with the recommended regular screening intervals among both the general population of women and women living with HIV.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Remarks: Neither VIA nor ablative treatment are suitable for screening or treatment of women in whom the transformation zone is not visible.</td><td>Conditional recommendatic very low-certair evidence </td></tr><tr><td>Inadequate visualization is typical after the menopause.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "7.Priority should be given to screening women aged 30-49 years in the general population of women.When tools are available to manage women aged 50-65 years, those in that age bracket who have never been screened should also be prioritized.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>Good practice statement</td><td>Inadequate visualization is typical after the menopause.27.Priority should be given to screening women living with HIV aged 25-49 years.When tools are available to manage women living with HIV aged 50-65 years, those in that age bracket who have never been screened should also be prioritized.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>Good practice statement </td></tr></table></body></html> a Rows shaded in pink indicate that the recommendation or good practice statement is identical for both the general population of women (left column) and women living with HIV (right column).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In other rows, the wording of the recommendations differs for each population.<html><body><table><tr><td>Recommendations for the general population of womena</td><td>Strength of recommendation and certainty of evidence</td><td>Recommendations for women living with Hiva</td><td>Strength of recommendation and certainty of evidence</td></tr><tr><td>8.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "WHO suggests a regular screening interval of every 5 to 10 years when using HPV DNA detection as the primary screening test among the general population of women.</td><td>Conditional recommendation, low-certainty evidence</td><td>28.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "WHO suggests a regular screening interval of every 3 to 5 years when using HPV DNA detection as the primary screening test among women living with HIV.</td><td>Conditional recommendation, low-certainty evidence</td></tr><tr><td>9.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Where HPV DNA testing is not yet operational, WHO suggests a regular screening interval of every 3 years when using VIA or cytology as the primary screening test, among both the general population of women and women living with HIV.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>Conditional recommendation, low-certainty evidence </td><td>29.Where HPV DNA testing is not yet operational, WHO suggests a regular screening interval of every 3 years when using VIA or cytology as the primary screening test, among both the general population of women and women living with HIV.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>Conditional recommendation, low-certainty evidence</td></tr><tr><td>10.While transitioning to a programme with a recommended regular screening interval, screening even just twice in a lifetime is beneficial among both the general population of women and women living with HIV.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>Good practice statement </td><td>30.While transitioning to a programme with a recommended regular screening interval, screening even just twice in a lifetime is beneficial among both the general population of women and women living with HIV.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>Good practice statement </td></tr><tr><td>11.WHO suggests that the general population of women who have screened positive on an HPV DNA primary screening test and then negative on a triage test are retested with HPV DNA testing at 24 months and, if negative, move to the recommended regular screening interval.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>Conditional recommendation, low-certainty evidence</td><td>31.WHO suggests that women living with HIV who have screened positive on an HPV DNA primary screening test and then negative on a triage test, are retested with HPV DNA testing at 12 months and, if negative, move to the recommended regular screening interval.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>Conditional recommendation, low-certainty evidence</td></tr></table></body></html> a Rows shaded in pink indicate that the recommendation or good practice statement is identical for both the general population of women (left column) and women living with HIV (right column).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In other rows, the wording of the recommendations differs for each population.HPV: human papillomavirus; VIA: visual inspection with acetic acid.<html><body><table><tr><td>Recommendations for the general population of womena</td><td>Strength of recommendation and certainty of evidence</td><td> Recommendations for women living with HIVa</td><td>Strength of recommendatio and certainty of evidence</td></tr><tr><td>12.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "WHO suggests that women from the general population and women living with HIV who have screened positive on a cytology primary screening test and then have normal results on colposcopy are retested with HPV DNA testing at 12 months and, if negative, move to the recommended regular screening interval.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>Conditional recommendation, low-certainty evidence</td><td>32.WHO suggests that women from the general population and women living with HIV who have screened positive on a cytology primary screening test and then have normal results on colposcopy are retested with HPV DNA testing at 12 months and, if negative, move to the recommended regular screening interval.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>Conditional recommendation low-certainty evidence </td></tr><tr><td>13.WHO suggests that women from the general population who have been treated for histologically confirmed CIN2/3 or adenocarcinoma in situ (AIS), or treated as a result of a positive screening test are retested at 12 months with HPV DNA testing when available, rather than with cytology or VlA or co-testing, and, if negative, move to the recommended regular screening interval.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>Conditional recommendation, low-certainty evidence </td><td>33.WHO suggests that women living with HIV who have been treated for histologically confirmed CIN2/3 or adenocarcinoma in situ (AlS), or treated as a result of a positive screening test are retested at 12 months with HPV DNA testing when available, rather than with cytology or VIA or co-testing, and, if negative, are retested again at 12 months and, if negative again, move to the recommended regular screening interval.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>Conditional recommendation low-certainty evidence </td></tr><tr><td>14.As programmes introduce HPV DNA testing, use this test at the woman's next routine screening date regardless of the test that was used at prior screening.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "In existing programmes with cytology or VIA as the primary screening test, rescreening with the same test should be continued until HPV DNA testing is operational among both the general population of women and women living with HIV.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>Good practice statement </td><td>34.As programmes introduce HPV DNA testing, use this test at the woman's next routine screening date regardless of the test that was used at prior screening.In existing programmes with cytology or VIA as the primary screening test, rescreening with the same test should be continued until HPV DNA testing is operational among both the general population of women and women living with HIV.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>Good practice statement </td></tr></table></body></html> Source: WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition.Geneva: World Health Organization; 2021 <html><body><table><tr><td>For both the general population and women living with Hiv</td><td>Strengthofrecommendation and certainty of evidence</td></tr><tr><td>41.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Once a decision to treat a woman is made - whether from the general population of women or women living with HIV - it is good practice to treat as soon as possible within six months to reduce the risk of los to follow-up.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "However, in women who are pregnant, good practice includes deferral until after pregnancy.In circumstances when treatmentis not provided within this time frame,it is good practice to re-evaluate the woman before treatment.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>Good practice statement </td></tr><tr><td>42.WHO suggests large-loop excision of the transformation zone (LLETZ) or cold knife conization (CKC) for women from the general population and women living with HiV who have histologically confirmed adenocarcinoma in situ (AIS).",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "</td><td>Conditional recommendation, low-certainty evidence </td></tr><tr><td>Remarks: Loop excision may be preferred in women of reproductive age, in setings with greater availability of LLETZ and by providers with greater expertise performing LLETZ.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "CKC may be prefeed when interpretation of the margins of the histological specimen is imperative.</td><td></td></tr></table></body></html> # Summary recommendation for the general population of women WHO suggests using either of the following strategies for cervical cancer prevention among the general population of women: HPV DNA detection in a screen-and-treat approach starting at the age of 30 years with regular screening every 5 to 10 years.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "HPV DNA detection in a screen, triage and treat approach starting at the age of 30 years with regular screening every 5 to 10 years.![](images/6177e7e584e5ce08e1c7a0cab3ea92dc8161fe81fbe3a0f45f58e7f5b2552981.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "jpg) Summary recommendation for women living with HIV WHO suggests using the following strategy for cervical cancer prevention among women living with HIV: HPV DNA detection in a screen, triage and treat approach starting at the age of 25 years with regular screening every 3 to 5 years.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "![](images/3657f20f41f4b516e908ea15e57151ffa9cacc4294ce6b8150a9c4db2cbe94bf.jpg) Table 3.Recommendation on HPV mRNA testing <html><body><table><tr><td>Recommendation for the general population of women</td><td>Strength of recommendation and certainty of evidence</td></tr><tr><td>WHO suggests that HPV mRNA detection using samples taken by the health worker may be used as a primary screening test, either with or without triage, to prevent cervical cancer in the general population of women with regular screening every 5 years.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "Remarks: HPV DNA is the recommended screening test.Choosing the alternative option of HPV mRNA testing implies having the capacity to provide follow-up screening at 5-year intervals.</td><td>Conditional recommendation, low-certainty evidence</td></tr></table></body></html> Recommendation for women living with HIV: No recommendation was made for using HPV mRNA in women living with HIV because evidence on the outcomes of using HPV mRNA detection applicable to this population was not identified.",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "For more information, please contact: World Health Organization Department of Noncommunicable Diseases, Rehabilitation and Disability 20 Avenue Appia 1211 Geneva 27 Switzerland Email: NCDdepartment@who.int Website: https://www.who.int/teams/surveillance-of-noncommunicable-diseases/about/ncds www.who.int",
    "source": "who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention/who guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.md"
  },
  {
    "text": "# Contrast Analysis of CT Perfusion Imaging Staging and FIGO Staging and Pathological Staging of Cervical Carcinoma 论 著 # 宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析 CHEN Hui, HUANG Wen-qi, ZHU Ai-peng.Department of Radiology, Shangqiu First People's Hospital, Shangqiu 476100, Henan Province, China # 河南省商丘市第一人民医院放射科(河南 商丘 476100) 陈 辉 黄文起 褚爱鹏【摘要】目的 研究宫颈癌CT灌注成像分期与FIGO分期及病理分期的比较。",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "方法 采用GE Lightspeed UItra 16排多层螺旋CT扫描仪对我院148例宫颈癌患者进行增强扫描，图像传输至PACE系统并进行多平面重建(MPR)，得到冠状位、矢状位、斜冠状位图像，比较CT分期、FIGO分期及术后病理分期的差异。结果 148例宫颈癌患者CT分期诊断Ⅰa期27例、Ⅰb期41例、Ⅱa期28例、Ⅱb期18例、Ⅲa期6例，分期正确120例，占81.08%，其中7例CT、FIGO分期显示无病变，漏诊率4.",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "73%，后经术后脱落细胞学检出，CT诊断过低分期8例，占5.41%，过高分期20例，占13.51%，FIGO分期过低分期31例，过高分期28例，诊断准确率60.14%。结论 CT灌注成像分期准确率高于FIGO分期，并可提供更多的病理信息，可作为FIGO分期后的纠错检查措施，CT对术前分期、手术方案选择及预后有重要的指导意义。【关键词】宫颈癌；CT灌注成像；FIGO分期；病理分期 【中图分类号】R711.",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "74 【文献标识码】A D O I : 1 0 .3 9 6 9 / j .i s s n .1 6 7 2 - 5131.2017.04.035 通讯作者：陈 辉 [Abstract] Objective To compare CT perfusion imaging staging and FIGO staging and pathological staging of cervical carcinoma.",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "Methods 148 patients with cervical carcinoma were scanned with GE Lightspeed UItra 16 slice spiral CT scanner.The images were transmitted to the PACE system and were processed by multi planar reconstruction (MPR) to obtain coronal, sagittal and oblique coronal images.",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "The differences of CT staging, FIGO staging and postoperative pathological staging were compared.Results CT staging diagnosis of 148 patients with cervical carcinoma showed 27 cases of stageⅠa, 41 cases of stageⅠb, 28 cases of stageⅡa, 18 cases of stage $\\mathbb { I } \\mathrm { b }$ and 6 cases of stageⅢa.",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "Staging was correct in 120 cases, accounting for $8 1 .0 8 \\%$ , in which CT and FIGO staging showing no lesions in7 cases.The rate of missed diagnosis was $4 .7 3 \\%$ which was detected by postoperative exfoliative cytology.",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "CT diagnosed excessive low staging in 8 cases, accounting for $5 .4 1 \\%$ and excessive high staging in 20 cases, accounting for $1 3 .5 1 \\%$ .For FIGO staging, there was excessive low staging in 31 cases and excessive high staging in 28 cases.",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "The diagnostic accuracy was $60 .1 4 \\%$ .Conclusion The accurate rate of CT perfusion imaging staging is higher than that of FIGO staging and it can provide more information.It can be used as an error correction test after FIGO staging.",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "CT is of important guiding significance in preoperative staging, the selection of operation scheme and prognosis.[Key words] Cervical Carcinoma; CT Perfusion Imaging; FIGO Staging; Pathological Staging 宫颈癌在妇科恶性肿瘤中排名第三，在我国发病率仅次于乳腺癌，宫颈癌术前分期是治疗方案疗效保障的基本前提，国际妇产科联合会(FIGO)将宫颈癌分为四期，并认为Ⅱa期以下患者适用放疗及根治性手术治疗，而Ⅱb期或Ⅱ期以上患者则采取放疗[1]。",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "目前术前分期方式主要包括影像学分期及FIGO分期，但FIGO为单纯临床诊断，主要通过触诊、阴道镜、子宫镜或X线检查，准确率较低[2]，有研究调查发现，FIGO对Ⅰa期-Ⅱa期、Ⅱb期或更晚期的检出率分别为 $5 4 .7 \\%$ 、$2 1 \\%$ ，均处于较低水平[3]。而随着CT诊断技术的不断成熟，其用于宫颈癌术前诊断具有可能性，尤其是多层螺旋CT有较高的空间分辨率及强大的图像后处理技术，有利于提高分期准确性，但目前有关CT术前分期与FIGO分期、病理分期比较的研究较少，本次研究选取我院148例经病理证实为宫颈癌的患者为研究对象，观察CT灌注成像技术在宫颈癌术前分期中的应用价值，结果如下。",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "# 1 资料与方法 1.1 患者资料 选取我院2009年11月至2014年12月148例病理确诊为宫颈癌的患者为研究对象，均拟进行手术治疗，年龄 $2 6 \\sim 7 1$ 岁，平均( $( 4 3 .1 6 \\pm 4 .4 9 )$ )岁，入院时阴道分泌物增多73例，阴道出血或接触性出血55例，20例同时伴有阴道出血及分泌物增多。1.2 方法 收集所有患者FIGO分期结果，FIGO分期参照2009年19届国际妇产科联盟(International Federation of Gynecology and Obstetrics，FIGO)[1]制定的分期标准，并记录术后病理分期结果，以手术病理学检查为金标准。",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "行CT扫描，检测仪器为GE Lightspeed UItra 16排多层螺旋CT扫描仪，扫描时指导患者摒气，148例患者均进行增强扫描，电胍: $1 2 0 \\mathrm { k V }$ ，电流: $5 0 \\mathrm { m A }$ ，矩阵 $5 1 2 \\times 5 1 2$ ，高压注射器注入非离子造影剂碘海醇(国药准字H20084434，生产单位：江苏晨牌药业有限公司) $3 0 0 \\mathrm { { m g i / m l } }$ ，剂量视患者体重，约 $2 \\mathrm { m l / k g }$ ，3ml/s速率，延迟1min进行扫描，后进行薄层重建，阴道内放置阴道栓，1周后进行手术。",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "增强扫描图像传输至PACE系统并进行MPR重建，包括冠状位、矢状位、斜冠状位(长轴与宫体长轴、阴道长轴相同的平面)，阅片由我院2名高资历影像科医师共同阅片，阅片前不知FIGO分期结果，进行CT分期判断。1.3 统计学分析 比较CT分期与FIGO分期、术后病理分期结果，以术后分期为金标准，观察 表1 CT灌注成像分期与FIGO分期、术后病理分期结果对照 <html><body><table><tr><td>分期方式</td><td>0期</td><td>Ia期</td><td>Ib期</td><td>ⅡIa期</td><td>ⅡIb期</td><td>Ⅲla期</td><td>总数</td></tr><tr><td>CT分期</td><td>0</td><td>27</td><td>41</td><td>28</td><td>18</td><td>6</td><td>120</td></tr><tr><td>FIGO分期</td><td>0</td><td>22</td><td>35</td><td>16</td><td>13</td><td>3</td><td>89</td></tr><tr><td>术后分期</td><td>7</td><td>34</td><td>48</td><td>33</td><td>20</td><td>6</td><td>148</td></tr></table></body></html> CT、FIGO分期的准确性。",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "# 2 结 果 ![](images/6140e557b9a37bb8270cc9cbb041089c9db0f6cbe280b02e38bfe6a4d68f205a.jpg) 图1-3为同一患者的轴位、矢状位、冠状位图像，轴位可见子宫颈处有较大的软组织肿物，约7×4cm，且有不均匀坏死，子宫颈癌确诊。矢状位对病灶体积、边界的显像更清晰，可见不均匀坏死，冠状位同可观察处以上信息；图4可见子宫颈处有不均匀低密度影，且边界模糊，子宫颈癌；图5轴位可见子宫颈处不均匀低密度影，边界模糊，确诊为子宫颈癌；图6是非图5患者的轴位图像，同可见子宫颈处有低密度软组织肿物，且边界模糊。",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "2.1 CT灌注成像结果与术后病理分期结果对照 CT分期诊断Ⅰa期27例、Ⅰb期41例、Ⅱa期28例、Ⅱb期18例、Ⅲa期6例，分期正确120例，占 $8 1 .0 8 \\%$ ，其中 7 例 C T 、 F I G O 分 期 显 示 无 病变，漏诊率 $4 .7 3 \\%$ ，后经术后脱落细胞学检出，CT诊断过低分期8例，占 $5 .4 1 \\%$ ，过高分期20例，占 $1 3 .5 1 \\%$ ，FIGO分期过低分期31例，过高分期28例，诊断准确率$6 0 .",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "\\ 1 4 \\%$ ，各分期诊断准确率见表1。# 2.2 CT图像观察 见图1-6。# 3 讨 论 目前临床的宫颈癌患者大多采取化疗干预，尚未采取手术病理分期，因此需统一的分期标准，FIGO是术前分期的一种，最早应用1989年，需在一切治疗前完成判断，如治疗导致分期改变，则仍保留最初诊断结果，如无法做出分期判断，则以最早1级分期确定[4]，此种分期对医师技术、经验的要求较高，如操作不当则容易误判，众多研究均认为其判断分期的准确性较低[5]。",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "本次研究中FIGO准确率为 $6 0 .1 4 \\%$ ，明显低于CT分期，其原因是FIGO仅可分析病理表象，无法观察病灶大小、对周围组织的侵犯情况。本次研究显示CT对Ⅰa期、Ⅰb期的分期准确例数分别为27例、41例，尽管高于FIGO分期，但仍不够满意，考虑CT对早期子宫颈癌的显示不佳，主要因病灶多呈等密度，尽管可通多平面重建提高图像质量，但子宫颈增粗仍为主要征象，而对体积较大的肿瘤CT则检出率明显较高，因病灶呈低血供，且病变处可见溃疡、坏死，且病灶边界清晰，可通过上述征象完成确诊[6]。",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "同时CT可判断宫旁侵袭，这是FIGO无法做到的，且病变越晚，则检出率越高，如宫旁侵袭仅局限在宫旁组织、子宫韧带等处，CT则可能出现误诊。另外多排螺旋CT可实现阴道侵犯的观察，假阳性常见外生性子宫颈瘤，因此可作为FIGO的补充措施。宫颈癌有相对特殊C T 征象 ， 成 人 正 常 宫 颈 长 度 约$2 .3 { \\sim } 3 .0 \\mathrm { c m }$ ，而宫颈处于子宫下部[7]，CT通过扫描双侧股骨水平可完成宫颈的扫描，增强扫描后子宫体与宫颈的强化程度基本一致，且强化扫描后血管因强化可清晰显像。",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "CT主要通过肿瘤体积、宫旁侵袭、阴道侵犯实现分期判断[8]。CT对肿瘤体积的判断相对较差，主要因为与正常宫颈组织比较，肿瘤组织无较大的差异性，病灶多呈等密度变化，增强扫描后可见差异，本次研究中患者病灶大多为等、低密度，等密度时仅可依靠宫颈管增粗判断，对肿瘤大小判断较困难，而低密度时则提示病变坏死、血供减少等因素导致，但部分患者增强扫描后出现明显强化，病灶边缘清晰，对病灶的显像效果提高，对肿瘤体积的判断良好[9]。",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "宫旁侵袭程度的判断主要用于鉴别Ⅱa、Ⅱb期[10]，CT诊断后如见宫颈边缘毛躁、不规则，条纹不规则形影或周围脂肪间隙消失则需考虑为出现宫旁侵袭，而冠状位图像的表现更为明确，总的来说，CT通过宫旁侵袭进行分期判断的价值较高。阴道侵犯可区分Ⅲ、Ⅱ期，如侵犯至阴道下1/3处则为Ⅲ期，反之则为Ⅱ期，阴道侵袭的判断需在检查前放置阴道栓使阴道形态更加明确，从而提高阴道侵袭判断的准确性[11]。CT多平面重建可避免单纯横断面检测的局限性，本次研究后期进行冠状位、矢状位、斜冠状位的图像重建，可全面显示阴道和子宫颈的空间关系，显示肿瘤对阴道的侵袭程度，具有高度的准确性，肿瘤侵袭阴道的CT征象主要包括阴道上段可见软组织肿物，且肿物边缘和阴道壁贴合密切无分界限，阴道壁增厚且不规则[12]。",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "综上，通过与术后病理分期及FIGO分期的比较可知，CT分期准确性高于FIGO分期，可作为FIGO分期的补充措施完善治疗依据，可作为宫颈癌手术、放化疗前的常规检测方式进行推广。# 参考文献 [ 1 ] P e c o r e l l i S .R e v i s e d F I G Os t a g i n g f o r c a r c i n o m a o ft h e v u l v a , c e r v i x , a n dendometrium [J].",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "Int J GynaecolObstet,2009,105(2):103-104.[2]邱书珺,陆晓兰,蒋小平，等.MSCT和M R I 对浸润性宫颈癌术前分期 的 价 值 对 比 [ J ] .放 射 学 实践,2012,27(1):77-80.[3]郭强蕊.CT诊断在卵巢癌和宫颈癌放射治疗前后的临床运用价值[J].西部中医药,2015,19(1):125-128.[4]靳宏星,张建新,杜笑松，等.",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "MSCT与 多 平 面 重 组 诊 断 不 同 分 期宫 颈 癌 [ J ] .中 国 医 学 影 像 技术,2012,28(3):543-547.[5]张海燕,宋迪.多层螺旋CT与MRI对 宫 颈 癌 术 前 分 期 的 诊 断 价值 比 较 [ J ] .中 国 妇 幼 健 康 研究,2014,25(1):111-113.[6]姚铭,刘桂锋,王永亮,等.多排螺旋CT对宫颈癌影像诊断的价值[J].",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "中国老年学杂志,2012,32(10):2169-2170.[ 7 ] P a r k J M , C h a r n s a n g a v eC,Yoshimitsu K,et al.Pathwayo f n o d a l m e t a s t a s i sf r o m p e l v i c t u m o r s : C Td e m o n s t r a t i o n [ J ] .",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "R a d i o g -raphics,1994,16(14):1309-1321.[8]叶斌强,孙鹏飞.宫颈癌诊断及疗效评价的影像学研究进展[J].中国CT和MRI杂志,2014,14(2):109-112.[9]邱书珺,陆晓兰,蒋小平，等.16层 螺 旋 C T 在 宫 颈 癌 临 床 分 期中 的 价 值 [ J ] .实 用 放 射 学 杂志,2010,26(7):990-992.[10]孙瑞瑞,胡尔西旦·尼牙孜,赵化荣，等.",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "早期宫颈癌FIGO分期与手术病理分期的差异性及淋巴结转移危险因素的分析[J].临床肿瘤学杂志,2015,21(8):704-708.[11]孟建超,李宇光,刘玉虎,等.宫颈癌CT影像分析[J].中国美容医学,2012,21(z2):347.[12]钱跃龙.螺旋CT多期增强扫描及三维重建在宫颈癌诊断中的临床研究[J].河北医学,2012,18(9):1209-1211.(本文编辑: 刘龙平) # （上接第 105 页） [ 4 ] H a n s - J o r g W i t t s a c k , R i t z l A,Gereon Retal．MR Imaging in Acute Stroke: Diffusionw e i g h t e d a n d P e r f u s i o n I m a g i n g P a r a m e t e r s f o r Predicting Infarct Size1[J].",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "Radiology,2002,222(2):397-403.[5]靳瑞娟,马强华,杨晓萍,等.卵巢 良恶性病变的磁共振扩散加权成 像分析及应用[J].实用放射学杂 志,2009,25(6):825-828.[6]梁长松,陈忠,李伟峰.磁共振扩散加 权成像在卵巢囊腺癌与囊腺瘤鉴别 诊断中的价值[J].中国CT和MRI杂 志,2015(3):83-86 [ 7 ] S i e g e l m a n E S , O u t w a t e r E K.",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "Tissue characterization i n t h e f e m a l e p e l v i s b y m e a n s o f M R i m a g i n g [ J ] .Radiology,1999,212(1):5-18 [ 8 ] T h o m a s s i n - Naggara,IToussaint,NPerrot， et al.Characterization of complex adnexal masses:value o f a d d i n g p e r f u s i o n a n d diffusion-weighted MR imaging to conventional MR Imaging[J].",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "Radiology,2011,258(3):793-803.[9]Shu H Z，Jin W Q，Guo F Z， et al.Diffusion-weighted MR imaging for differentiating borderline from malignant e p i t h e l i a l t u m o u r s o f t h e o v a r y ： p a t h o l o g i c a l c o r r e l a t i o n [ J ] .",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "E u r o p e a n Radiology,2014,24(9):2292- 2299.[10]Thomassin-Naggara I,Bazot M E，Callard P，et al.Epithelial o v a r i a n t u m o r s : v a l u e o f dynamic contrast-enhanced MR imaging and correlation with tumor angiogenesis[J].",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "Radiology,2008,248(1):148-159.[11]Sohaib S A,Mills T D,Sahdev A，et al．The role of magnetic r e s o n a n c e i m a g i n g a n d ultrasound in patients with adnexal masses[J].Clinical Radiology,2005,60(3):340-348.(本文编辑: 刘龙平)",
    "source": "宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析/宫颈癌CT灌注成像分期与FIGO分期及病理分期的对照分析.md"
  },
  {
    "text": "# 宫颈癌的临床病理研究进展 陈丽鹃1\\*，华媛媛2# 1重庆医科大学第二临床学院，重庆 2重庆医科大学附属第二医院妇科，重庆 收稿日期：2024年3月11日；录用日期：2024年4月4日；发布日期：2024年4月11日 # 摘 要 宫颈癌是全球各国中妇女发病率和死亡率最高的恶性肿瘤之一。近些年，宫颈癌的患病年龄呈现出年轻化的趋势。近期发现的Silva分型相比于目前的传统诊断依据，可更有效地预见宫颈腺癌的预后和指导临床处理。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "许多免疫组织化学标志物对宫颈癌发病各个时期的作用目前仍不明确。本文就宫颈癌的组织病理学和免疫组化标志物相关问题进行综述。# 关键词 宫颈癌，组织病理学，Silva分型，免疫组化标志物 # Clinical and Pathological Research Progress in Cervical Cancer Lijuan Chen1\\*, Yuanyuan Hua2# 1The Second Clinical College of Chongqing Medical University, Chongqing 2Department of Gynecology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing Received: Mar.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "11th, 2024; accepted: Apr.$4 ^ { \\mathsf { t h } }$ , 2024; published: Apr.11th, 2024 # Abstract Cervical cancer is one of the most common malignant tumors with the highest incidence and mortality rates among women worldwide.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "In recent years, there has been an increasing trend of cervical cancer incidence among younger age groups.The recently discovered Silva classification is a more effective predictor of prognosis and guide for clinical management of cervical adenocarcinoma compared to traditional diagnostic criteria.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "The role of many immunohistochemical markers in the development of cervical cancer is still unclear.This article provides a comprehensive review of the issues related to the histopathology and immunohistochemical biomarkers of cervical cancer.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "# Keywords # Cervical Cancer, Histopathology, Silva Classification, Immunohistochemical Markers Copyright $\\circledcirc$ 2024 by author(s) and Hans Publishers Inc.This work is licensed under the Creative Commons Attribution International License (CC BY 4.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "0).http://creativecommons.org/licenses/by/4.0/ # 1.组织病理学特点 # 1.1.病理分级 上皮癌变常起源于化生。化生是指一种已分化组织转化为另一种相似性质的分化组织的过程。宫颈由两部分组成，包括宫颈管的柱状上皮和宫颈阴道部的鳞状上皮，鳞状上皮细胞和柱状上皮细胞之间的过渡区域称为鳞柱交界处，是宫颈的移行区，此区域是子宫颈鳞状上皮内病变及宫颈癌的好发部位[1]。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "当宫颈长期处于 HPV 病毒感染、炎症等危险因素的长期刺激下，柱状上皮下未分化的储备细胞开始增生，并逐渐发生鳞状上皮化生，继之取代柱状上皮。未成熟的化生鳞状上皮细胞继续被 HPV 感染持续刺激后容易出现细胞异常分化，最后形成子宫颈鳞状上皮内病变(SIL) [2]。子宫颈鳞状上皮内病变(SIL)既往称为“子宫颈上皮内瘤变”(CIN)，CIN 根据瘤变程度分为3 级：CIN1，不成熟的异型细胞局限于上皮的下1/3；CIN2，不成熟非典型细胞局限于上皮的下1/3 至2/3；CIN3，增生的异型细胞超过上皮层的 2/3，包含原位癌。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "CIN 逐级发展，突破上皮下基底膜，进而浸润间质，进一步发展为宫颈浸润癌。2014 年，世界卫生组织发表了宫颈癌前病变的新分类，即二分类法，分为低级别鳞状上皮内病变(LSIL)和高级别鳞状上皮内病变(HSIL)，LSIL 包括 CIN1 及相关的 HPV 感染，HSIL 包括 CIN3 和大部分 CIN2。# 1.2.组织学分类 宫颈癌的组织学分类主要包括鳞癌、腺癌、腺鳞癌和其他少见类型[3]。起源于宫颈外口的宫颈癌通常为鳞状细胞癌，约占宫颈癌的 $70 \\%$ [4]，是最常见的组织病理类型。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "而起源于宫颈内口的通常为腺癌，近年来宫颈腺癌的发病率有上升趋势，从 $5 \\%$ 增加至 $20 \\% { \\sim } 2 5 \\%$ 。其他比较少见的组织学亚型包括宫颈浆液性乳头状癌、小细胞或神经内分泌癌、透明细胞癌等。对于宫颈鳞癌，2014 年 WHO 指南根据形态学进行分类，包括角化型、非角化型、乳头状鳞癌、基底样癌、湿疣性癌、疣状癌、鳞状–移行细胞癌、淋巴上皮样瘤样癌。而新版 2020 年 WHO 指南更注重发病机制及预后，分为 HPV 相关性、HPV 非相关性、非特指类型。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "对于宫颈腺癌，2014 年 WHO 指南将其分为普通型、黏液性癌(包括非特殊型 NOS、肠型、胃型、印戒细胞型)、绒毛管状腺癌、子宫内膜样癌、透明细胞癌、浆液性癌、中肾管癌及混合性腺癌–神经内分泌癌。日益增多的研究结果证实宫颈腺癌是一组异质性肿瘤，在组织学、流行病学、预后因素和治疗结局等方面与宫颈鳞癌存在差异[5]。为此 2020 年 WHO 指南以 2018 年首次提出的国际宫颈腺癌标准和分类(IECC) [6]为基础，根据是否与 HPV 相关将宫颈腺癌分为 HPV 相关性与 HPV 非依赖性两大类。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "总体来讲，HPV 相关性宫颈腺癌的特征为低倍镜下可见显著的顶端核分裂和凋亡小体；HPV非依赖性宫颈腺癌病灶广泛，组织学上看不到显著的凋亡小体及核分裂象，其发病年龄大，预后差，无 病生存期短。# 1.3.Silva 分型 # 1.3.1.Silva 分型的概述 美国妇产科病理学家 Silva 所带领的科研小组于 2013 年率先提出了一个针对宫颈腺癌风险分级的新系统模型，并于 2015 年证实了这种分型体系，遂将其定名为Silva 分型体系[7] [8] [9]。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "此系统以浸润模式为基础对宫颈腺癌进行了分级，可较好预估淋巴结转移、复发的危险性和预后情况，其分级重复性较强、切实可行，有助于更好地进行临床医学工作。Silva 分型可分为Silva A、B、C 三种模式：Silva A 型肿瘤的特点表现为腺体边界清楚、轮廓完整，有时小叶结构保存较好，无破坏性间质浸润，无肿瘤硬化性间质，无脉管侵犯；Silva B 型肿瘤的特点是以A 型腺体特点为基础，间质中可见单个或小簇肿瘤细胞，有时可见脉管内瘤栓侵犯；Silva C 型肿瘤的特点主要表现为弥漫性的间质浸润破坏，出现广泛的硬化性肿瘤间质，常见脉管内瘤栓侵犯，腺体常呈棱角状或破碎状，呈融合性生长。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "# 1.3.2.Silva 分型的临床应用 与传统的 2014 版 WHO 组织学分类、2020 版 WHO 病因学分类和 FIGO 临床病理分期相比，Silva分型通过肿瘤的生长方式来估计肿瘤的生物学行为，为临床工作提出新的治疗策略并指导手术方式。2016年 Roma 等人根据 Silva 分型对宫颈腺癌提出了新的分层治疗策略:Silva A 型患者预后较好，无瘤生存期较长，淋巴结转移和复发风险相对较低，在宫颈锥切标本切缘阴性时可以考虑保守治疗，不需切除子宫和淋巴结清扫。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "Silva B 型患者需要冷刀锥切、LEEP 术或宫颈切除术，同时进行前哨淋巴结取样；在切缘阴性的前提下，若前哨淋巴结阳性或重新评估为 Pattern C 型，则选择根治性子宫切除术，并酌情进行淋巴清扫术和术后放、化疗。Silva C 型患者由于预后较差，发生复发和转移的风险极高，则行子宫广泛性切除术及淋巴结清扫术，必要时行放疗、化疗、免疫治疗等辅助治疗[9]。目前的NCCN 指南推荐大多数宫颈腺癌患者采用根治性手术和淋巴结清扫术。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "然而，根治性手术和淋巴结清扫术的并发症显著，包括排尿困难、尿路感染、出血、戳孔血肿、疼痛、发热和神经损伤等早期并发症。晚期并发症包括淋巴水肿、淋巴囊肿、尿失禁和静脉血栓形成等；除此之外，年轻患者往往失去生育能力[10] [11]。2015 年 Roma 等对来自 12 个机构的 352 例宫颈腺癌病例分析显示 Silva 各型的比例分布：Silva A 型占比 $2 0 .7 \\%$ ，Silva B 型约占 $2 5 .",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "6 \\%$ ，Silva C 型占 $5 3 .7 \\%$ [7]。一项针对中国宫颈腺癌患者 Silva 分型的研究回顾性分析了3 个医疗中心 191 例宫颈腺癌病例的临床病理资料，其中 Silva A 型占 $2 4 .1 \\%$ ，Silva B 型占 $2 1 .5 \\%$ ，Silva C 型占 $5 4 .5 \\%$ [12]。Silva 分型在普通型宫颈腺癌中的占比大致相同。如果上述推荐分层治疗策略能够被广泛应用，会有将近半数的宫颈腺癌患者避免过度治疗，约 1/5 的宫颈腺癌女性甚至可以保留生育功能，从而减轻部分患者的术后并发症，提高生活质量。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "# 1.3.3.Silva 分型的局限性 虽然 Silva 分型展示了良好的应用前景，并对WHO 分类、FIGO 分期和NCCN 指南进行了补充和提示，但其自身还存在很多问题，并有待于进一步验证、拓展和修订。目前 Silva 分型的样本组织类型仅针对宫颈腺癌普通型，尚未将其他特殊组织学亚型的浸润性子宫颈腺癌纳入研究范围，这在一定程度上限制了 Silva 分型的应用。另外，Silva 分型主要基于肿瘤生长的病理学特征进行分类，而没有考虑其他重要因素，如基因突变、免疫组化指标、HPV 感染亚型、患者年龄等，这可能导致分型结果无法全面反映患者的病情和预后，对于个体化治疗的指导有一定限制。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "同时，Silva 分型在显微镜下的病理学诊断在不同的实验室和医生之间可能存在主观性和操作者依赖性的差异，这可能导致分型结果的不一致性，对于 临床的一致性和可靠性提出了一定的挑战。综上所述，Silva 分型在宫颈癌的诊断和治疗中具有一定的应用价值，但其尚处于新生阶段，目前还需要更多的研究和验证来进一步评估其准确性和可靠性，需经过严密的临床观察和检验，反复推敲打磨、补充完善才能在临床实践中大规模推广。# 2.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "免疫组化标志物 免疫组化全称为免疫组织化学，主要应用免疫学抗原和抗体特异性结合的基本原理，再通过化学反应使标记抗体的显色剂显色，从而对组织细胞内的抗原(主要为蛋白质)进行定性、定位及相对定量研究，有助于了解疾病的发病机理和鉴别诊断。宫颈肿瘤的发生、发展及预后，与许多抑癌基因有关，免疫组化最常见的标志物有以下一些类型。# 2.1.抑癌基因 # 2.1.1.p16 p16 参与细胞周期从G1 期到S 期的调控，是细胞周期蛋白依赖性激酶CDK4、CDK6 活性的抑制剂，可以阻断 CDK4 和 CDK6 介导的视网膜母细胞基因 Rb 磷酸化，通常 p16 其在细胞中的浓度极低[13]。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "在大多数宫颈癌中，HPV E7 癌基因对视网膜母细胞基因 Rb 的功能失活导致 p16 的过度表达和 p16 蛋白在细胞内的积累。因此p16 是HPV E7 病毒癌基因介导的视网膜母细胞基因Rb 分解代谢的替代标志物[14]。p16 不仅是诊断宫颈鳞状细胞肿瘤和鳞状细胞癌的敏感而特异的标记物[15]，而且可用于鉴别宫颈腺上皮肿瘤的几种组织学类型[16]。免疫组化分析表明，p16 蛋白在宫颈鳞状上皮和腺上皮的癌前病变和恶性病变中广泛表达[17]。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "# 2.1.2.p53 p53 在调节细胞增殖、DNA 修复、细胞凋亡、基因组稳定性、衰老和代谢稳态等方面发挥重要作用[18]。p53 蛋白在 DNA 损伤、缺氧、癌基因表达、核糖核苷酸耗竭等多种信号激活下，主要作为转录因子发挥作用。p53 功能缺失使细胞异常增殖，继之导致肿瘤的发生，在许多恶性肿瘤中都观察到 p53 的功能异常[19] [20]。在许多肿瘤细胞遗传不稳定的条件下，p53 基因发生突变，p53 蛋白的表达增加，这是肿瘤发生发展过程的标志。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "p53 的失活与宫颈癌的发生有关，Notch1 是一种肿瘤抑制基因[21]，通过E6 和 E7 癌基因减少宫颈癌细胞系中的细胞增殖[22]。Yugawa 等人研究证明[23]，E6 通过失活 p53 抑制Notch1 的表达。此外，正常情况下编码跨膜受体蛋白的原癌基因 ErbB2 的表达被 p53 抑制，E6 通过灭活p53 使 ErbB2 积累，促进 HPV 感染的上皮形成细胞增殖[24]。# 2.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "1.3.p63 p63 是一个编码转录因子的基因，它属于 p53 家族，位于3q27\\~29 号染色体上[25]，p63 基因编码的蛋白质也被称为 p63，具有类似于p53 的结构域，但在功能上有所不同。p63 通常在表皮的基底细胞中强烈表达[26] [27] [28]，在复层鳞状上皮的发展和分化中起着至关重要的作用，具有肿瘤抑制和致癌性。p63的免疫组化染色可以帮助鉴别鳞状细胞癌和腺癌。Vosmik 等人分析了 70 名宫颈鳞状细胞癌患者，发现$9 4 .",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "2 9 \\%$ (66/70)的p63表达呈阳性[29]但是p63对宫颈鳞癌的诊断特异度和灵敏度并不十分理想，Kaufmann等人研究发现，p63 也可以在少量腺癌、基底细胞癌和移行上皮癌中表达[30]。# 2.1.4.p40 $\\mathsf { p } 4 0$ 是 p63 蛋白的一种亚型，表达于鳞状上皮细胞、尿路上皮细胞、乳腺的肌上皮细胞、汗腺和唾液腺以及前列腺的基底细胞，其在标记鳞状上皮时具有较高的特异性[31]，被认为是特异性和敏感性最高的鳞癌标志物。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "近年来国内外大量文献报道 $\\mathsf { p } 4 0$ 在肺鳞状细胞癌病理诊断中具有指导意义[32] [33] [34]。Bishop 等人研究表明[35]，在 81 例肺鳞状细胞癌和 237 例肺腺癌中， $\\mathsf { p } 6 3$ 在肺鳞状细胞癌诊断中的敏感性和特异性分别为 $100 \\%$ 和 $60 \\%$ ， $\\mathsf { p } 4 0$ 的敏感性和特异性分别为 $100 \\%$ 和 $9 8 \\%$ 。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "因此， $\\mathsf { p } 4 0$ 被认为是一种高度特异性和敏感性的鳞状上皮来源的肿瘤标志物。# 2.2.细胞角蛋白(CK) 细胞角蛋白(CK)主要分布于上皮细胞，是细胞骨架的中间丝蛋白家族中最大、最复杂的亚类，其主要功能是维持上皮组织的完整性及连续性，是上皮分化的标志物，已经有20 多种亚型的 CK 在不同类型的人类上皮细胞中被鉴定出来。CK5/6 是一种高分子量的基底细胞角蛋白，正常时主要表达于鳞状上皮细胞、导管上皮基底细胞、肌上皮细胞和间皮细胞中，而在腺上皮细胞中表达极少[36]。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "一些研究结果表明 CK5/6 在鳞状细胞癌的诊断中具有很高的敏感性和特异性[36] [37]。Ma 等人研究发现在76 名肺鳞状细胞癌中，CK5/6 的敏感性和特异性分别为 $7 8 .9 \\%$ 和 $9 7 .7 \\%$ 。CK7 是鳞柱交界细胞标记物，主要分布于宫颈癌好发区域，即鳞柱交界处的基底与基底上层储备细胞胞浆内，在癌前病变及宫颈癌中均呈阳性表达。有学者指出，CK7 的表达与 HPV 感染有关[38]。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "宫颈细胞感染 HPV 后，通常引起宫颈炎症，炎症作用下，残留胚胎鳞柱交界细胞迁移至相邻鳞状细胞中，此时 CK7 阳性细胞异常增生，随着病变级别增加，向下增殖扩张，最终诱发宫颈癌。CK8/18 存在于所有单层上皮，尤其是各种腺上皮，正常的角化/非角化的鳞状上皮不表达，是与上皮细胞增殖、分化密切相关的肿瘤标志物，在胃癌、乳腺癌中阳性表达明显增高[39] [40]。# 2.3.细胞增殖指数(Ki-67) Ki-67 是一种核抗原，与细胞增殖相关，是获得临床普遍认可的核增殖标志，Ki-67 存在于除 G0 期以外的所有细胞周期活跃阶段，包括G1、S、G2 和M 期，因此，Ki-67 用于确定细胞群的生长分数[41]。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "在正常宫颈组织中，Ki-67 仅表达于复层鳞状上皮基底细胞层，而在子宫颈上皮内瘤变中Ki-67 表达于整个上皮层，表明细胞增殖[42]。多项研究表明，p16 和Ki-67 的共同表达提高了宫颈癌筛查的诊断准确性，并且 Ki-67 的表达与肿瘤分级呈线性增加[43] [44] [45]。# 3.展望 宫颈癌是全球性的健康问题，需要跨国界的合作来推动研究进展。未来的研究可以通过建立多中心合作网络和共享大规模数据集，这将有助于增加样本量、提高研究效力，并促进全球范围内的合作和知识交流。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "组织病理学可以聚焦于宫颈癌不同亚型的分子特征和细胞特征，通过使用基因测序、单细胞测序和多组学分析等先进的研究方法，更全面地揭示宫颈癌的异质性和发展机制。另外，进一步探索新的免疫组化标志物，提高宫颈癌诊断的准确性和预测患者的生存率，目前已有一些免疫组化标志物被应用于临床实践，如 p16、Ki-67 等，但仍需要进一步验证和优化。希望通过这些研究，我们可以提高宫颈癌的早期诊断率和治疗效果，从而减少患者的发病率和死亡风险，并改善患者的生活质量。",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "# 参考文献 [1] Small Jr., W., Bacon, M.A., Bajaj, A., et al.(2017) Cervical Cancer: A Global Health Crisis.Cancer, 123, 2404-2412.https://doi.org/10.1002/cncr.30667 [2] Giroux, V.and Rustgi, A.K.(2017) Metaplasia: Tissue Injury Adaptation and a Precursor to the Dysplasia-Cancer Sequence.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "Nature Reviews Cancer, 17, 594-604.https://doi.org/10.1038/nrc.2017.68 [3] 方三高, 魏建国, 陈真伟.WHO (2020)女性生殖系统肿瘤分类[J].诊断病理学杂志, 2021, 28(2): 142-148.[4] Cohen, P.A., Jhingran, A., Oaknin, A., et al.(2019) Cervical Cancer.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "The Lancet (London, England), 393, 169-182.https://doi.org/10.1016/S0140-6736(18)32470-X [5] Xie, X., Song, K., Cui, B., et al.(2018) A Comparison of the Prognosis between Adenocarcinoma and Squamous Cell Carcinoma in Stage IB-IIA Cervical Cancer.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "International Journal of Clinical Oncology, 23, 522-531.https://doi.org/10.1007/s10147-017-1225-8 [6] Stolnicu, S., Barsan, I., Hoang, L., et al.(2018) International Endocervical Adenocarcinoma Criteria and Classification (IECC): A New Pathogenetic Classification for Invasive Adenocarcinomas of the Endocervix.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "The American Journal of Surgical Pathology, 42, 214-226.https://doi.org/10.1097/PAS.0000000000000986 [7] Roma, A.A., Diaz De Vivar, A., Park, K.J., et al.(2015) Invasive Endocervical Adenocarcinoma: A New Pattern-Based Classification System with Important Clinical Significance.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "The American Journal of Surgical Pathology, 39, 667-672.https://doi.org/10.1097/PAS.0000000000000986 [8] Rutgers, J.K.L., Roma, A.A., Park, K.J., et al.(2016) Pattern Classification of Endocervical Adenocarcinoma: Reproducibility and Review of Criteria.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "Modern Pathology, 29, 1083-1094.https://doi.org/10.1038/modpathol.2016.94 [9] Roma, A.A., Mistretta, T.A., Vivar, A.D.D., et al.(2016) New Pattern-Based Personalized Risk Stratification for Endocervical Adenocarcinoma with Important Clinical Implications and Surgical Outcome.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "Gynecologic Oncology, 141, 36-42.https://doi.org/10.1016/j.ygyno.2016.02.028 [10] Zikan, M., Fischerova, D., Pinkavova, I., et al.(2015) A Prospective Study Examining the Incidence of Asymptomatic and Symptomatic Lymphoceles Following Lymphadenectomy in Patients with Gynecological Cancer.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "Gynecologic Oncology, 137, 291-298.https://doi.org/10.1016/j.ygyno.2015.02.016 [11] Mehra, G., Weekes, A., Vantrappen, P., et al.(2010) Laparoscopic Assisted Radical Vaginal Hysterectomy for Cervical Carcinoma: Morbidity and Long-Term Follow-Up.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "European Journal of Surgical Oncology, 36, 304-308.https://doi.org/10.1016/j.ejso.2009.08.009 [12] Wang, W., Song, G., Lin, J., et al.(2019) Study of the Revisited, Revised, and Expanded Silva Pattern System for Chinese Endocervical Adenocarcinoma Patients.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "Human Pathology, 84, 35-43.https://doi.org/10.1016/j.humpath.2018.08.029 [13] Zhang, H.S., Postigo, A.A.and Dean, D.C.(1999) Active Transcriptional Repression by the Rb-E2F Complex Mediates G1 Arrest Triggered by $\\mathrm { P l } 6 ^ { \\mathrm { I N K 4 a } }$ , TGFβ, and Contact Inhibition.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "Cell, 97, 53-61.https://doi.org/10.1016/S0092-8674(00)80714-X [14] Klaes, R., Friedrich, T., Spitkovsky, D., et al.(2001) Overexpression of $\\mathrm { P l } 6 ^ { \\mathrm { I N K 4 a } }$ as a Specific Marker for Dysplastic and Neoplastic Epithelial Cells of the Cervix Uteri.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "International Journal of Cancer, 92, 276-284.https://doi.org/10.1002/ijc.1174 [15] Sarwath, H., Bansal, D., Husain, N.E., et al.(2017) Introduction of $\\mathrm { P l } 6 ^ { \\mathrm { I N K 4 a } }$ as a Surrogate Biomarker for HPV in Women with Invasive Cervical Cancer in Sudan.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "Infectious Agents and Cancer, 12, Article No.50.https://doi.org/10.1186/s13027-017-0159-0 [16] Lee, S., Sahasrabuddhe, V.V., Mendoza-Cervantes, D., et al.(2017) Tissue-Based Immunohistochemical Biomarker Expression in Malignant Glandular Lesions of the Uterine Cervix: A Systematic Review.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "International Journal of Gynecological Pathology: Official Journal of the International Society of Gynecological Pathologists, 36, 310-322.https://doi.org/10.1097/PGP.0000000000000345 [17] Tringler, B.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": ", Gup, C.J., Singh, M., et al.(2004) Evaluation of $\\mathrm { P l } 6 ^ { \\mathrm { I N K 4 a } }$ and pRb Expression in Cervical Squamous and Glandular Neoplasia.Human Pathology, 6, 689-696.https://doi.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "org/10.1016/j.humpath.2004.02.012 [18] Li, Y., Zhang, M.C., Xu, X.K., et al.(2019) Functional Diversity of p53 in Human and Wild Animals.Frontiers in Endocrinology, 10, Article No.152.https://doi.org/10.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "3389/fendo.2019.00152 [19] Olivier, M., Hollstein, M.and Hainaut, P.(2010) TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use.Cold Spring Harbor Perspectives in Biology, 2, A001008.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "https://doi.org/10.1101/cshperspect.a001008 [20] Petitjean, A., Mathe, E., Kato, S., et al.(2007) Impact of Mutant p53 Functional Properties on TP53 Mutation Patterns and Tumor Phenotype: Lessons from Recent Developments in the IARC TP53 Database.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "Human Mutation, 28, 622-629.https://doi.org/10.1002/humu.20495 [21] Nicolas, M., Wolfer, A., Raj, K., et al.(2003) Notch1 Functions as a Tumor Suppressor in Mouse Skin.Nature Genetics, 33, 416-421.https://doi.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "org/10.1038/ng1099 [22] Talora, C., Sgroi, D.C., Crum, C.P., et al.(2002) Specific Down-Modulation of Notch1 Signaling in Cervical Cancer Cells Is Required for Sustained HPV-E6/E7 Expression and Late Steps of Malignant Transformation.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "Genes & Development, 16, 2252-2263.https://doi.org/10.1101/gad.988902 [23] Yugawa, T., Handa, K., Narisawa-Saito, M., et al.(2007) Regulation of Notch1 Gene Expression by p53 in Epithelial Cells.Molecular and Cellular Biology, 27, 3732-3742.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "https://doi.org/10.1128/MCB.02119-06 [24] Narisawa-Saito, M., Handa, K., Yugawa, T., et al.(2007) HPV16 E6-Mediated Stabilization of ErbB2 in Neoplastic Transformation of Human Cervical Keratinocytes.Oncogene, 26, 2988-2996.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "https://doi.org/10.1038/sj.onc.1210118 [25] Yang, A., Kaghad, M., Wang, Y., et al.(1998) P63, a p53 Homolog at 3q27-29, Encodes Multiple Products with Transactivating, Death-Inducing, and Dominant-Negative Activities.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "Molecular Cell, 2, 305-316.https://doi.org/10.1016/S1097-2765(00)80275-0 [26] Pozzi, S., Zambelli, F., Merico, D., et al.(2009) Transcriptional Network of p63 in Human Keratinocytes.PLOS ONE, 4, e5008.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "https://doi.org/10.1371/journal.pone.0005008 [27] Senoo, M., Pinto, F., Crum, C.P., et al.(2007) P63 Is Essential for the Proliferative Potential of Stem Cells in Stratified Epithelia.Cell, 129, 523-536.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "https://doi.org/10.1016/j.cell.2007.02.045 [28] Barbieri, C.E.and Pietenpol, J.A.(2006) P63 and Epithelial Biology.Experimental Cell Research, 312, 695-706.https://doi.org/10.1016/j.yexcr.2005.11.028 [29] Vosmik, M.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": ", Laco, J., Sirak, I., et al.(2014) Prognostic Significance of Human Papillomavirus (HPV) Status and Expression of Selected Markers (HER2/Neu, EGFR, VEGF, CD34, p63, p53 and Ki67/MIB-1) on Outcome after (Chemo-) Radiotherapy in Patients with Squamous Cell Carcinoma of Uterine Cervix.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "Pathology & Oncology Research, 20, 131-137.https://doi.org/10.1007/s12253-013-9674-5 [30] Kaufmann, O., Fietze, E., Mengs, J., et al.(2001) Value of p63 and Cytokeratin 5/6 as Immunohistochemical Markers for the Differential Diagnosis of Poorly Differentiated and Undifferentiated Carcinomas.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "American Journal of Clinical Pathology, 116, 823-830.https://doi.org/10.1309/21TW-2NDG-JRK4-PFJX [31] 金雪梅, 韩龙哲.免疫组织化学方法检测P16 P13 P40 在颈部淋巴结转移性鳞状细胞癌鉴别诊断中的应用[J].实 用医技杂志, 2016, 23(8): 888-889.[32] 杜倩, 赵焕芬, 康林, 等.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "肺鳞状细胞癌组织中 p63、CK5/6 和 p40 的表达及其病理诊断价值[J].现代肿瘤医学, 2019, 27(11): 1907-1910.[33] Kriegsmann, K., Cremer, M., Zgorzelski, C., et al.(2019) Agreement of CK5/6, p40, and p63 Immunoreactivity in Non-Small Cell Lung Cancer.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "Pathology, 51, 240-245.https://doi.org/10.1016/j.pathol.2018.11.009 [34] Pelosi, G., Rossi, G., Cavazza, A., et al.(2013) ΔNp63 (P40) Distribution inside Lung Cancer: A Driver Biomarker Approach to Tumor Characterization.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "International Journal of Surgical Pathology, 21, 229-239.https://doi.org/10.1177/1066896913476750 [35] Bishop, J.A., Teruya-Feldstein, J., Westra, W.H., et al.(2012) P40 (ΔNp63) Is Superior to p63 for the Diagnosis of Pulmonary Squamous Cell Carcinoma.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "Modern Pathology, 25, 405-415.https://doi.org/10.1038/modpathol.2011.173 [36] Ma, Y., Fan, M., Dai, L., et al.(2015) Expression of p63 and CK5/6 in Early-Stage Lung Squamous Cell Carcinoma Is Not Only an Early Diagnostic Indicator but Also Correlates with a Good Prognosis.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "Thoracic Cancer, 6, 288-295.https://doi.org/10.1111/1759-7714.12181 [37] Downey, P., Cummins, R., Moran, M., et al.(2008) If It’s Not CK5/6 Positive, TTF-1 Negative It’s Not a Squamous Cell Carcinoma of Lung.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "APMIS: Acta Pathologica, Microbiologica, et Immunologica Scandinavica, 116, 526-529.https://doi.org/10.1111/j.1600-0463.2008.00932.x [38] Lee, H., Lee, H.and Cho, Y.K.(2017) Cytokeratin7 and Cytokeratin19 Expression in High Grade Cervical Intraepithelial Neoplasm and Squamous Cell Carcinoma and Their Possible Association in Cervical Carcinogenesis.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "Diagnostic Pathology, 12, Article No.18.https://doi.org/10.1186/s13000-017-0609-4 [39] 李亦明, 王贵明, 龙中华, 等.IHC 联合FISH 检测胃癌中HER2 与CK8/18、P53、CEA 的表达及其相关性研究[J].诊 断病理学杂志, 2019, 26(12): 812-816.[40] Raap, M., Gierendt, L.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": ", Werlein, C., et al.(2021) Co-Expression of Transcription Factor AP-2beta (TFAP2B) and GATA3 in Human Mammary Epithelial Cells with Intense, Apicobasal Immunoreactivity for CK8/18.Journal of Molecular Histology, 52, 1257-1264.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "https://doi.org/10.1007/s10735-021-09980-2 [41] Gerdes, J., Schwab, U., Lemke, H., et al.(1983) Production of a Mouse Monoclonal Antibody Reactive with a Human Nuclear Antigen Associated with Cell Proliferation.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "International Journal of Cancer, 31, 13-20.https://doi.org/10.1002/ijc.2910310104 [42] Konishi, I., Fujii, S., Nonogaki, H., et al.(1991) Immunohistochemical Analysis of Estrogen Receptors, Progesterone Receptors, Ki-67 Antigen, and Human Papillomavirus DNA in Normal and Neoplastic Epithelium of the Uterine Cervix.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "Cancer, 68, 1340-1350.https://doi.org/10.1002/1097-0142(19910915)68:6<1340::AID-CNCR2820680626>3.0.CO;2-Q [43] Tjalma, W.A.A.(2017) Diagnostic Performance of Dual-Staining Cytology for Cervical Cancer Screening: A Systematic Literature Review.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "European Journal of Obstetrics & Gynecology and Reproductive Biology, 210, 275-280.https://doi.org/10.1016/j.ejogrb.2017.01.009 [44] Silva, D.C., Gonçalves, A.K., Cobucci, R.N., et al.(2017) Immunohistochemical Expression of p16, Ki-67 and p53 in Cervical Lesions—A Systematic Review.Pathology, Research and Practice, 213, 723-729.",
    "source": "宫颈癌的临床病理研究进展",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/宫颈癌的临床病理研究进展/宫颈癌的临床病理研究进展.md"
  },
  {
    "text": "# ·论著·宫颈癌专题研究· # 放射治疗在宫颈癌治疗中的应用及更新 林雨璇，孔为民 ，王元景，李凤霜 【摘要】 放射治疗作为宫颈癌三大治疗方法之一，在宫颈癌治疗中占有重要地位。近年来，三维体外照射及三维腔内照射等新技术开始广泛应用于宫颈癌治疗，这些新技术在提高肿瘤照射剂量的同时还减少了周围正常组织的受量。此外，对于以影像学指标指导个体化放射治疗、质子治疗的探索等研究也在不断进行中。本文对宫颈癌放射治疗的基本知识、放射治疗在宫颈癌治疗中的应用进展进行阐述，总结新技术的适用情况，并提出新技术使用中需注意的问题，以期指导临床应用。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "【关键词】 宫颈肿瘤；放射疗法；放射疗法，影像引导；分次剂量，放射疗法 【中图分类号】 R 737.33 【文献标识码】 DOI：10.12114/j.issn.1007-9572.2022.0058林雨璇，孔为民，王元景，等 .放射治疗在宫颈癌治疗中的应用及更新［J］.中国全科医学，2022，25（18）：2239-2243.［www.chinagp.net］LIN Y X，KONG W M，WANG Y J，et al.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "Application and update of radiotherapy in the treatment of cervical cancer［J］.Chinese General Practice，2022，25（18）：2239-2243.Application and Update of Radiotherapy in the Treatment of Cervical Cancer LIN Yuxuan，KONG Weimin\\*，WANG Yuanjing，LI Fengshuang Department of Gynecologic Oncology，Beijing Obstetrics and Gynecology Hospital，Capital Medical University，Beijing 10006， China \\*Corresponding author：KONG Weimin，Chief physician；E-mail：kwm1967@ccmu.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "edu.cn 【Abstract】 As one of the three major treatments for cervical cancer，radiotherapy plays an important role in treating cervical cancer.In recent years，new technologies such as three-dimensional external beam radiotherapy and image-based brachytherapy have been widely used in the treatment of cervical cancer，which can increase the dose of tumor radiation while reducing the dose radiating surrounding normal tissues.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "In addition，the researches on the use of individualized radiotherapy guided by imaging indicators and proton therapy are also in progress.This paper presents the basic knowledge of radiotherapy for cervical cancer and the application of radiotherapy in the treatment of cervical cancer，summarizes the application of new technologies，and proposes issues that need to be emphasized in the use of new technologies，in order to guide clinical application.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "【Key words】 Uterine cervical neoplasms；Radiotherapy；Radiotherapy，image-guided；Dose fractionation， radiation 放射治疗（以下简称放疗）作为宫颈癌的主要治疗方法之一，与 $70 \\% { \\sim } 8 0 \\%$ 的宫颈癌治疗相关［1］。近年来，以三维体外照射及三维腔内照射为主的放疗新技术广泛应用于宫颈癌治疗，并取得良好的效果。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "本文对宫颈癌放疗的基本知识，放疗（特别是放疗新技术）在宫颈癌治疗中的应用进行阐述，以提高广大妇科医师和全科医师对该方面知识的认识。# 1 各种放疗在宫颈癌治疗中的应用标准 1.1 单纯放疗 单纯放疗适用于以下情况：（1）Ⅱ B期及以上的宫颈癌：Ⅱ A 期以下首选手术治疗，Ⅱ B期以上则首选放疗，迄今为止，这个治疗格局尚无大的改变。（2）Ⅰ B3 期和Ⅱ A2 期宫颈癌：即狭义的局部晚期宫颈癌（locally advanced cervical cancer，LACC）；根 据 美 国 国 立 综 合 癌 症 网 络（National ComprehensiveCancer Network，NCCN）指南（2021 版）［2］，Ⅰ B3 期和Ⅱ A2 期首选根治性同步放化疗，即盆腔外照射 $^ +$ 含铂同期化疗 $^ +$ 阴道近距离放疗（证据等级1 级）。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "（3）Ⅱ a 期以前，有严重内科合并症，无法耐受手术的宫颈癌患者可推荐放疗或同步放化疗，预后与手术相当［3］。1.2 手术联合放疗 手术联合放疗包括术前放疗、术中放疗和术后放疗。术前放疗适用于：（1）狭义上的 LACC，如Ⅰ B3期和Ⅱ A2 期；（2）Ⅱ A 期，阴道侵犯较多；（3）不良病理类型，如透明细胞癌等。术前放疗作为手术的辅助方法，可缩小肿块、改善局部情况、降低手术难度、提高肿瘤切除率。目前，由于手术水平的提高及治疗方法的选择趋于单一，如上述（1）、（2）情况下临床倾向于直接选择放疗或同步放化疗，因此，术前放疗已经很少应用于宫颈癌的治疗［3］。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "术中放疗适用于宫颈癌局部复发或局部晚期患者。术中放疗是指在开腹手术过程中，对于肿瘤残留风险部位或无法切除的孤立瘤灶给予单次大剂量放疗。术中放疗需要手术时具备放疗的条件及较好的放射防护措施，因此其应用受到了限制，目前国内仅少数单位可进行术中放疗。术后放疗适用于术后发现病理存在高危或中危因素，其中，高危因素包括淋巴结阳性、宫旁浸润、切缘阳性。具备任何一项高危因素时，均推荐术后补充盆腔放疗 $^ +$ 顺铂同期化疗（证据等级 1 级）± 阴道近距离放疗；阴道切缘阳性者，阴道近距离放疗可以增加疗效。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "中危因素包括淋巴脉管间隙受侵（lymph-vascular space invasion，LVSI）、宫颈间质浸润深度（deepstromal invasion，DSI）、肿瘤大小（tumor size，TS）。术后出现中危因素时，若病理组织学类型为鳞癌时，采用 Sedlis 标准［4］（表 1）选择进行补充盆腔外照射 ±含铂同期化疗（证据等级 1 级），如若出现 LVSI，且${ \\mathrm { D S I } } { > } 2 / 3$ ，则无论肿瘤有多大，均需进行补充盆腔外照射 $\\pm$ 含铂同期化疗；若为腺癌或腺鳞癌，则参照“四因素模型”（腺癌或腺鳞癌合并下面三项之一：肿瘤最大直径 $\\geqslant 3 \\ \\mathrm { c m }$ 、LVSI、外 1/3 宫颈间质浸润），补充放疗可获益［4］。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "表 1 Sedlis 标准［4］Table 1 Sedlis eligibility criteria <html><body><table><tr><td>LVSI</td><td>DSI</td><td>TS</td></tr><tr><td>+</td><td>>2/3</td><td>任意大小</td></tr><tr><td>+</td><td>1/3~2/3</td><td>≥ 2 cm</td></tr><tr><td>+</td><td><1/3</td><td>≥ 5 cm</td></tr><tr><td></td><td>>1/3</td><td>≥ 4 cm</td></tr></table></body></html> 注：LVSI= 淋巴脉管间隙受侵， $\\mathrm { D S I } =$ 宫颈间质浸润深度， $\\mathrm { T S } =$ 肿瘤大小 1.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "3 化疗联合放疗 化疗联合放疗的具体方式包括序贯放化疗及同步放化疗。序贯放化疗包括先化疗后放疗、先放疗后化疗及化疗 $^ +$ 放疗 $^ +$ 化疗。由于序贯放化疗在宫颈癌治疗中尚缺乏充分的循证医学证据，因此目前在临床上尚未得到广泛应用。同步放化疗是指在放疗的同时穿插化疗（主要指在体外照射的同时，给予顺铂周疗或以顺铂为基础的双药化疗），多应用于Ⅱ B 期以后 LACC 或复发患者的治疗，并已成为目前中晚期宫颈癌的标准治疗方案。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "研究表明［5］同步放化疗相比单纯放疗，尽管增加了Ⅲ / Ⅳ级急性毒性反应，但是其对于 LACC 患者治疗效果有着显著优势（一般认为相校于单纯放疗，LACC 同步放化疗5 年生存率可提高 $6 \\% { \\sim } 1 0 \\%$ ）。# 2 传统放疗技术 传统放疗技术是三维体外照射及三维腔内照射技术的基础。目前，国内仍有少数医疗机构采用传统的二维体外照射及二维腔内照射技术。因此，本文对传统放疗技术进行简单地阐述。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "2.1 二维体外照射 二维体外照射主要包括全盆腔照射、盆腔四野照射、腹主动脉旁延伸野照射、腹股沟区照射、全腹照射等，其原理是基于二维平面设计剂量分布图，确定照射范围后输出射线，在穿透表面皮肤及其他组织后，最终到达肿瘤病灶进行治疗。然而，二维体外照射不能较好地防护病灶周围的正常组织。因此，放射性膀胱炎、放射性直肠炎等毒副作用的发生率较高，严重影响了患者放疗后的生活质量［6］。此外，传统体外照射受周围正常组织耐受剂量的限制，病灶区有时无法达到根治性放疗的剂量，从而影响治疗效果。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "2.2 近距离放疗 近距离放疗包括腔内放疗、管道内放疗及组织间放疗。宫颈癌放疗中最为常用的为腔内放疗，其原理为利用人体自然管道，将放射源放入阴道、子宫宫腔中进行放疗。百余年来，腔内放疗技术不断进步。为保护医疗工作人员免受射线照射，后装放疗技术开始用于腔内放疗。后装放疗是指先把不带放射源的治疗容器置于治疗部位，然后将患者送入治疗室，利用电机将放射源送入治疗容器进行治疗。在剂量率方面，高剂量率后装治疗逐渐得到青睐，缩短了患者治疗时间，也增加了每台机器的可治疗人数，经济而又高效。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "传统近距离放疗在治疗过程中虽然不断改进技术，但是由于其基于二维图像，因而不能很好地保护周围正常的器官。# 3 放疗新技术在宫颈癌治疗中的应用 近年来，随着计算机和影像技术的进步，诸多放疗新技术应运而生，主要包括三维适形放疗（3-dimensional conformal radiotherapy，3D-CRT）、 调强 放 疗（intensity-modulated radiotherapy，IMRT） 及 图像引导放疗等。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "3.1 体外照射新技术 目前，3D-CRT 和 IMRT 是体外放疗的主流技术。相比传统体外照射，三维放疗提高了放疗的精准性，在增加肿瘤靶区剂量的同时，可以更好地保护正常组织，进一步提高疗效。3.1.1 3D-CRT 一般意义上的 3D-CRT 是指射线束在射野方向和靶区形状一致的技术，其原理为利用计算机层析成像的集成，使得放疗剂量辐射以匹配或符合靶标的轮廓进行输出，这种辐射场的形成称为适形放疗。宋慧胜等［7］研究发现，与传统放疗相比，3D-CRT 能够明显降低直肠反应的发生率及严重性，改善患者的生存质量。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "郭智等［8］研究发现，3D-CRT 用于治疗复发宫颈癌时，其危及器官（organs at risk，OAR）的受照射体积明显小于常规放疗，从而减少 OAR 放疗毒副作用的发生率。因此，3D-CRT 与传统放疗技术相比，具有诸多优点：（1）具有定位准确、治疗剂量精确的优点，可减少对正常组织的损害，并提高疗效；（2）为宫颈癌术后或放疗后复发再治疗提供更有效、更能保护患者生活质量的治疗方法。3.1.2 IMRT IMRT 是新型 3D-CRT，采用了 3D-CRT的所有技术，而靶区的剂量分布与适形度较常规3D-CRT 明显改善，真正在三维空间上实现了剂量分布与肿瘤形状一致。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "适形 IMRT 在宫颈癌治疗中的应用最广泛，利用多叶光栅（multileaf collimators，MLC）技术实现对于辐射束强度和形状的调节，做到更精确地塑形。IMRT 的剂量分布对计划靶区（planning target volume，PTV）更加适形。与传统放疗相比，IMRT 在剂量学上更有优势，在宫颈癌术后和根治性放疗中可使膀胱、直肠、结肠和骨髓的受照射体积减小［9-10］，RTOG 1203（TIME-C）［11］报告显示，相比传统放疗，IMRT 可使患者胃肠道和泌尿系统放射性炎性反应发病率显著降低，生活质量显著提高。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "此外，与 3D-CRT 相比，IMRT也有明显优势：在盆腔/主动脉旁淋巴结行放疗时，使用 IMRT 可降低急性和慢性放射性炎性反应［12-13］，同时对淋巴结同步加量尤其是对于接受同步化疗的患者［14-15］；两项前瞻性随机对照试验和一项荟萃分析共同表明，IMRT 比 3D-CRT 更能降低患者急性和晚期胃肠道和泌尿系统放射性炎性反应发病率［10，13-14，16］；MARJANOVIC 等［17］研究发现，IMRT 组中 OAR 的保护效果比 3D-CRT 组更好，并在靶区覆盖方面表现出优势。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "然而，尚无数据表明 IMRT 比二维 / 三维适形技术能提高疾病特异性生存率或总生存率。IMRT 可 分 为 旋 转 调 强（volumetric modulated arctherapy，VMAT）、动态/ 静态调强、螺旋断层放疗（tomotherapy，TOMO）。VMAT 是指在旋转加速器机架的同时，也在调整加速器的剂量率和 MLC 射野形状，从而达到调强目的。VMAT 可调节的参数包括剂量率、MLC 位置、机架转速等。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "VMAT 最大的优势为在各个角度输出射线，在保证总剂量不变的情况下使正常组织平均受量减少，受到的放射损伤也相应减少。GUO 等［18］研究发现，与固定场IMRT（f-IMRT）相比，VMAT 显示出更好的靶区肿瘤剂量覆盖、更好的直肠和膀胱保护，并显著减少了治疗时间。WALI 等［19］研究发现，与高剂量率近距离放疗相比，VMAT 实现了直肠、膀胱和乙状结肠剂量的显著减少，以及更均匀地靶区覆盖。动态调强是指多叶准直器运动和照射同时进行的调强方法。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "静态调强是指多叶准直器运动和照射不同时进行的调强方法。TOMO 是一种基于螺旋断层放疗系统设备，在 CT的引导下，对瘤灶进行 $3 6 0 ^ { \\circ }$ 聚焦断层照射的放疗技术。TOMO 集调强适形放疗、影像引导放疗（image-guided radioherapy，IGRT）、剂量引导放疗（dose-guidedradiotherapy，DGRT）为一体。郭明芳等［20］研究认为TOMO 技术较IMRT 能获得更好的靶区适形度和均匀性，对于盆腔各正常器官（如卵巢）的保护更好，因此可以作为早期年轻宫颈癌患者保留卵巢根治术后放疗的一种选择。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "3.1.3 质子与调强质子治疗 由于质子治疗拥有独特的Bragg 型剂量分布，即质子在行进过程中转移给组织的能量与质子运动速度的平方呈反比，在质子接近其射程终点时能量损失最大，这一特性在肿瘤学放疗中备受瞩目。利用这一性质，将质子峰值能量对准瘤灶，而周围正常组织（包括瘤灶前与瘤灶后）所受到的剂量将极大减少，对于保护OAR 有重要的临床意义。有研究表明，质子治疗应用于宫颈癌放疗可显著降低 OAR 所受放射剂量以及小肠放射性炎［21］。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "这种治疗方式可成为宫颈癌放疗的一种选择。目前国内已有单位拥有质子放疗的设备。3.2 腔内照射新技术 腔内照射新技术主要为三维近距离照射技术（image-based brachytherapy，IBBT）的应用，其基于三维影像学，对照射野的剂量分布进行三维空间上的立体塑形，增加了腔内照射剂量分布的精准性。MAYADEV 等［22］回顾性分析了近年来相关研究，发现与传统 A 点剂量方案相比，IBBT 组报告了显著改善的盆腔控制率和无瘤生存期，同时泌尿生殖系统晚期毒性反应也得到改善。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "IBBT 可在CT、磁共振成像（magneticresonance imaging，MRI）的引导下进行，但 MRI 是目前 IBBT 的首选成像方式，因为 MRI 比 CT 具有更好的软组织对比度。在一项研究中，CT 对 TS 的估计明显偏大［23］，导致与 MRI 相比，肿瘤的 D90（照射 $9 0 \\%$ 肿瘤体积的剂量）和D100（照射 $100 \\%$ 肿瘤体积的剂量）显著降低。在另一项研究中，与 CT 相比，采用 MRI 引导腔内治疗，对原发肿瘤的覆盖范围得到了改善，而对于正常组织的剂量减少了，即提高了对靶区调控的精准性。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "MRI 的这些优势在肿瘤病灶较大或有宫旁侵犯的宫颈癌患者中最为显著［23］。3.3 影像学技术的应用 随着影像学技术发展，将CT、MRI、PET-CT、PET-MRI 等 技 术 引 入 宫 颈 癌 放疗中，使宫颈癌放疗告别了二维时代，迎来了三维时代。FIELDS 等［23］认为影像学的引导可以提高近距离放疗的精准性，可以显著改善针头定位的准确性。GYN GEC-ESTRO 工作组［24］强调了 MRI 有着卓越的软组织分辨率，可在近距离放疗中发挥关键作用。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "但无论是MRI 还是 CT 引导，两者在放射剂量学上无明显差异，但是 CT 目前仍是主要引导方式［25］。PET-CT 除了应用于宫颈癌初次分期、定位、检测淋巴结和远处转移、治疗效果评估等，目前还具有预测宫颈癌预后的重要价值［26］，其原理为通过成像结果、最大标准化摄取值、代谢肿瘤体积和总病变糖酵解等定量参数，进行预后及临床结果的预测。此外，使用其他放射性示踪剂检测和量化缺氧组织的 PET 成像可能也有助于识别侵袭性肿瘤并预测治疗结果，即使其目前还没有广泛用于临床。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "PET 通过预测宫颈癌预后，可以帮助医师及时调整放疗策略，使得放疗更趋于个体化，如对预后预测不佳的患者可以适当增加照射剂量、增大照射野等，以进一步改善患者预后［27］。# 4 放疗过程中如何提高靶区准确性 放疗过程中，由于治疗摆位误差、靶区移位或变形、靶区器官运动等因素的影响，治疗靶区的准确性受到极大挑战，更积极的应对策略是采用某些技术方式探测摆位误差和靶区运动，并采取相应措施。常用的图像引导放疗技术包括电子射线影像装置（electronic portalimaging device，EPID）、 锥 形 束 CT（cone beam-CT，CBCT）、呼吸门控技术和四维放疗技术。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "在每次治疗过程中，患者摆位完成后利用 EPID 技术采集患者位置图像，通过与模拟进行图像匹配，计算摆位误差，予以实时校正，然后实施放疗，可提高靶区准确性。CBCT即在直线加速器对侧导轨上安装一台 CT 机，在治疗开始前行 CT 扫描，根据 CT 断层图像和 3D 重建图像确定摆位误差。CBCT 技术图像具有以下优势：（1）提供 6个维度的摆位误差数据；（2）可追踪器官形态变化，采用变形匹配技术，提供更为精准的治疗误差数据；（3）可以将治疗计划整合到校位 3D 图像中，重新计算剂量分布，获得患者治疗时的实际受照射剂量分布，以便对后续分次治疗进行适当调整。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "目前三维新技术广泛应用于宫颈癌放疗，但是存在靶位准确性被忽视的问题，这可能导致放疗期间的脱靶，并影响最终的治疗效果。因此，减少靶器官形变及位移措施将成为宫颈癌放疗的一个关注重点。为减少靶区形变的影响，治疗过程中增加图像验证次数；对于靶区肿瘤缩小明显，可考虑再次定位，做二次计划再治疗，注意治疗过程不应被中断。宫颈癌放疗过程中靶区位移明显，以宫颈及子宫最著。受膀胱直肠充盈、肿瘤退缩等多个因素影响。针对靶区位移，有多种解决方法，其中以靶区外扩、图像引导及个体化治疗研究最多。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "靶区有均匀外扩及不均匀外扩两种方法，外扩边界大小尚存在争议。图像引导使靶区外扩边界缩小，放疗精确度提高。体外照射是放射物理学上的进步。三维体外照射技术的应用增加了肿瘤接受体外照射时的精准性，但是问题也随之而来，这种精准放疗（包括IMRT、3D-CRT）能否取代腔内照射呢？答案是否定的。一方面是由于腔内照射本身具有独特的物理学优势，即反平方定律，可以更好地保护周围正常器官；另一方面近年来放疗新技术包括IMRT、3D-CRT 等技术快速发展，在这个过程中，作为传统放疗方式之一的腔内照射的使用率有所降低。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "但有研究表明，腔内照射使用率降低可导致患者死亡率增加，对患者生存期产生负面影响［28］。因此，妇科肿瘤学会（Society of Gynecologic Oncology，SGO）、NCCN均认为外照射新技术不能完全取代腔内照射［28］。综上所述，放疗在宫颈癌治疗中占有重要地位。放疗技术的发展日新月异，对妇科肿瘤医生来说，掌握放疗，尤其是掌握放疗新技术进展较为重要。宫颈癌放疗技术主要包括体外照射和腔内治疗，但是两者联合才能保证单纯放疗的效果。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "三维技术（包括三维体外照射及三维腔内治疗等）的广泛应用，一方面可以提高肿瘤照射部位的剂量，另一方面可以减少周围正常组织的受量，进而提高肿瘤放疗的疗效。三维体外照射及三维腔内治疗应用于宫颈癌放疗已有近 20 年的时间，目前已积累了丰富的经验，大量临床数据表明可以广泛应用这些放疗新技术来治疗宫颈癌，但仍需强调以下几个方面的问题：（1）放疗新技术在基层医院应用时，仍需严格掌握应用的原则；（2）重视放疗经验的积累；（3）由于放疗新技术带来了治疗费用的大幅度上涨，部分患者因为经济承受能力差而影响了治疗，应引起社会及广大妇科肿瘤工作者的重视。",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "作者贡献：林雨璇负责论文主要部分的撰写，完成相关文献资料的收集和分析及论文初稿的写作；孔为民负责论文的构思布局，指导论文写作、审查及编辑，进行最终版本的修订，并对论文负责；王元景、李凤霜负责文献资料的分析、整理。本文无利益冲突。# 参考文献 ［1］孙建衡，盛修贵，白萍.妇科肿瘤学［M］.2 版.北京：北京大学医学出版社，2019：236.［2］National Comprehensive Cancer Network.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "NCCN clinical practiceguidelines in oncology.Cervical cancer ［EB/OL］.［2021-02-19］.https://www.nccn.org/professionals/ physician_gls/pdf/cervical cancer.pdf.［3］LANDONI F，MANEO A，COLOMBO A，et al.Randomised studyof radical surgery versus radiotherapy for stage Ⅰ b- Ⅱ a cervicalcancer［J］.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "Lancet，1997，350（9077）：535-540.DOI：10.1016/S0140-6736（97）02250-2.［4］SEDLIS A，BUNDY B N，ROTMAN M Z，et al.A randomizedtrial of pelvic radiation therapy versus no further therapy in selectedpatients with stage Ⅰ B carcinoma of the cervix after radicalhysterectomy and pelvic lymphadenectomy：a Gynecologic OncologyGroup Study［J］.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "Gynecol Oncol，1999，73（2）：177-183.DOI：10.1006/gyno.1999.5387.［5］D A T T A N R ， S T U T Z E ， L I U M ， e t a l .C o n c u r r e n tchemoradiotherapy vs.radiotherapy alone in locally advancedcervix cancer：a systematic review and meta-analysis［J］Gynecol Oncol，2017，145（2）：374-385.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "DOI：10.1016/j.ygyno.2017.01.033.［6］CHINO J，ANNUNZIATA C M，BERIWAL S，et al.Radiationtherapy for cervical cancer：executive summary of an ASTROclinical practice guideline［J］.Pract Radiat Oncol，2020，10（4）：220-234.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "DOI：10.1016/j.prro.2020.04.002.［7］宋慧胜，陈龙华，冯正富，等 .宫颈癌三维适形放射治疗与常规放射治疗临床观察［J］.西部医学，2011，23（5）：838-841.DOI：10.3969/j.issn.1672-3511.2011.05.014.［8］郭智，臧志芳，麻富卯，等 .三维适形放疗治疗复发子宫颈癌的剂量学研究［J］.肿瘤研究与临床，2008，20（6）：387-389.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "DOI：10.3760/cma.j.issn.1006-9801.2008.06.010.［9］LUO H C，LIN G S，LIAO S G，et al.Cervical cancer treated withreduced-volume intensity-modulated radiation therapy base on Sedliscriteria（NCCN VS RTOG）［J］.Br J Radiol，2018，91（1081）：20170398.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "DOI：10.1259/bjr.20170398.［10］NAIK A，GURJAR O P，GUPTA K L，et al.Comparison ofdosimetric parameters and acute toxicity of intensity-modulated andthree-dimensional radiotherapy in patients with cervix carcinoma：a randomized prospective study［J］.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "Cancer Radiother，2016，20（5）：370-376.DOI：10.1016/j.canrad.2016.05.011.［11］KLOPP A H，YEUNG A R，DESHMUKH S，et al.Patient-reported toxicity during pelvic intensity-modulated radiationtherapy：NRG oncology-RTOG 1203［J］.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "J Clin Oncol，2018，36（24）：2538-2544.DOI：10.1200/JCO.2017.77.4273.［12］CHANG Y，YANG Z Y，LI G L，et al.Correlations betweenradiation dose in bone marrow and hematological toxicity in patientswith cervical cancer：a comparison of 3DCRT，IMRT，andRapidARC［J］.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "Int J Gynecol Cancer，2016，26（4）：770-776.DOI：10.1097/IGC.0000000000000660.［13］LIN A J，KIDD E，DEHDASHTI F，et al.Intensity modulatedradiation therapy and image-guided adapted brachytherapy forcervix cancer［J］.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys，2019，103（5）：1088-1097.DOI：10.1016/j.ijrobp.2018.11.012.［14］OSBORNE E M，KLOPP A H，JHINGRAN A，et al.Impactof treatment year on survival and adverse effects in patients withcervical cancer and paraortic lymph node metastases treatedwith definitive extended-field radiation therapy［J］.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "PractRadiat Oncol，2017，7（3）：e165-173.DOI：10.1016/j.prro.2016.09.003.［15］WAKATSUKI M，KATO S，OHNO T，et al.Multi-institutionalobservational study of prophylactic extended-field concurrentchemoradiation therapy using weekly cisplatin for patients withpelvic node-positive cervical cancer in east and SoutheastAsia［J］.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "Int J Radiat Oncol Biol Phys，2019，105（1）：183-189.DOI：10.1016/j.ijrobp.2019.04.039.［16］YU C，ZHU W，JI Y，et al.A comparative study of intensity-modulated radiotherapy and standard radiation field with concurrentchemotherapy for local advanced cervical cancer［J］.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "Eur JGynaecol Oncol，2015，36（3）：278-282.［17］MARJANOVIC D，PLESINAC KARAPANDZIC V，STOJANOVICRUNDIC S，et al.Implementation of intensity-modulatedradiotherapy and comparison with three-dimensional conformalradiotherapy in the postoperative treatment of cervical cancer［J］.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "J BUON，2019，24（5）：2028-2034.［18］GUO M F，HUANG E L，LIU X F，et al.Volumetric modulatedarc therapy versus fixed-field intensity-modulated radiotherapy inradical irradiation for cervical cancer without lymphadenectasis：dosimetric and clinical results［J］.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "Oncol Res Treat，2018，41（3）：105-109.DOI：10.1159/000484608.［19］WALI L，HELAL A，DARWESH R，et al.A dosimetriccomparison of Volumetric Modulated Arc Therapy （VMAT）and High Dose Rate （HDR） brachytherapy in localized cervicalcancer radiotherapy［J］.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "J Xray Sci Technol，2019，27（3）：473-483.DOI：10.3233/XST-180468.［20］郭明芳，柳先锋，刘俐，等 .螺旋断层放疗在早期年轻宫颈癌患者保卵巢根治术后放疗中的剂量学研究［J］.重庆医科 大 学 学 报，2019，44（1）：39-42.DOI：10.13406/j.cnki.cyxb.001873.［21］DE BOER P，VAN DE SCHOOT A J A J，WESTERVELD H，et al.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "Target tailoring and proton beam therapy to reduce smallbowel dose in cervical cancer radiotherapy：a comparison ofbenefits［J］.Al，2018，194（3）：255-263.DOI：10.1007/s00066-017-1224-8.［22］MAYADEV J，VISWANATHAN A，LIU Y，et al.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "AmericanBrachytherapy Task Group Report：a pooled analysis ofclinical outcomes for high-dose-rate brachytherapy for cervicalcancer［J］.Brachytherapy，2017，16（1）：22-43.DOI：10.1016/j.brachy.2016.03.008.［23］FIELDS E C，HAZELL S，MORCOS M，et al.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "Image-guidedgynecologic brachytherapy for cervical cancer［J］.SeminRadiat Oncol，2020，30（1）：16-28.DOI：10.1016/j.semradonc.2019.08.010.［24］DIMOPOULOS J C A，PETROW P，TANDERUP K，et al.Recommendations from Gynaecological （GYN） GEC-ESTROWorking Group （IV）：basic principles and parameters for MRimaging within the frame of image based adaptive cervix cancerbrachytherapy［J］.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "Radiother Oncol，2012，103（1）：113-122.DOI：10.1016/j.radonc.2011.12.024.［25］BATUMALAI V，BURKE S，ROACH D，et al.Impact ofdosimetric differences between CT and MRI derived target volumesfor external beam cervical cancer radiotherapy［J］.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "Br J Radiol，2020，93（1114）：20190564.DOI：10.1259/bjr.20190564.［26］CARESIA-ARÓZTEGUI A P，DELGADO-BOLTON R C，ALVAREZ-RUIZ S，et al.18F-FDG PET/CT in locally advancedcervical cancer：a review［J］.Rev Esp Med Nucl ImagenMol （Engl Ed），2019，38（1）：59-68.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "DOI：10.1016/j.remn.2018.08.004.［27］KHIEWVAN B，TORIGIAN D A，EMAMZADEHFARD S，et al.Update of the role of PET/CT and PET/MRI in the management ofpatients with cervical cancer［J］.Hell J Nucl Med，2016，19（3）：254-268.",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "DOI：10.1967/s002449910409.［28］HOLSCHNEIDER C H，PETEREIT D G，CHU C，et al.Brachytherapy：a critical component of primary radiation therapyfor cervical cancer：from the Society of Gynecologic Oncology（SGO） and the American Brachytherapy Society （ABS）［J］.Brachytherapy，2019，18（2）：123-132.DOI：10.1016/j.brachy.2018.11.009.（收稿日期：2021-12-12；修回日期：2022-03-30）（本文编辑：毛亚敏）",
    "source": "放射治疗在宫颈癌治疗中的应用及更新",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/放射治疗在宫颈癌治疗中的应用及更新/放射治疗在宫颈癌治疗中的应用及更新.md"
  },
  {
    "text": "登录 <html><body><table><tr><td>用户名</td><td rowspan=\"3\"></td></tr><tr><td>密码</td></tr><tr><td></td></tr><tr><td>图形验证码</td><td>V </td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td>提交</td><td></td></tr><tr><td></td><td></td></tr></table></body></html> # 注册账号 | 忘记密码 社交账号登录 !",
    "source": "科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科.md"
  },
  {
    "text": "[](images/61a7860f73a8e815a2445f03fd63dff181570ab2ff79060863efc76cc6432a99.jpg) 首页 关于我们o 医院简介o 医院荣誉 新闻动态。医院动态行业资讯媒体报道 专家团队科室专家先进设备 治疗案例专家案例科研进展联系我们 请输入关键词首页 > 新闻动态 > 行业资讯 # 科普 | 宫颈癌的治疗与放疗选择 作者：小编 更新时间：2022-12-27 点击数：2693 近20年，我国宫颈癌的发病率呈持续上升趋势，且发病年轻化，大量的晚期患者，我们仍面临着较大的治疗压力。",
    "source": "科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科.md"
  },
  {
    "text": "由国家卫健委发布的《宫颈癌诊疗指南》(2022年版)指出，放射治疗适用于各期宫颈癌，包括体外照射和近距离放疗及二者的联合应用。放疗完成的期限是获得最佳疗效的必备因素。放疗时间超过 9 周比少于 7 周的患者有更高的盆腔控制失败率，推荐 56 天内完成所有的外照射和近距离放疗。宫颈癌的治疗选择依分期而定，宫颈癌分为四期，每期又分A、B两期。各期的治疗方案如下： 1）IA期以手术为首选，不能手术者可放疗。",
    "source": "科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科.md"
  },
  {
    "text": "2）IB、IIA期根治性手术或根治性放疗。3）IIB-IVA期首选放疗，增敏化疗可提高疗效 4）IVB期姑息治疗。![](images/fdf51e4cccad1abbf763e6959e86266c5ca930161d647e0b6c480aaaab9285ed.jpg) ▲图1/ 不同分期的宫颈癌治疗选择 其中，Ⅰ期和Ⅱ期的患者放射治愈率在 $7 0 \\sim 9 0 \\%$ ，Ⅲ期的患者放射治愈率在 $4 0 \\sim 6 0 \\%$ ，Ⅳ期患者放射治疗后5年生存率约 $20 \\%$ 。",
    "source": "科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科.md"
  },
  {
    "text": "因此，那种“放疗只是辅助，是不能手术者的无奈之举”的观点，对于宫颈癌的放射治疗是错误的。对于肿瘤直径大于4cm的早期宫颈癌，临床研究结果亦证明，放疗联合化疗效果优于手术联合放化疗。现代放射治疗技术下，宫颈癌放疗效果进一步提升、副反应继续下降。在精准治愈肿瘤的同时，完美保护了膀胱、直肠、阴道的正常功能，使患者获得了更高生活质量的生命延续。![](images/cdf06db4e9ed8727d8e9e66ea25b8d7d4af3b4ff0c514e0957e2a372b5fd44e8.",
    "source": "科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科.md"
  },
  {
    "text": "jpg) $\\blacktriangle$ 图2/ 宫颈癌的放射治疗选择 对于宫颈癌的放射治疗选择，程淑霞教授表示： 1）放射治疗是可以治愈宫颈癌的，特别对于中晚期宫颈癌，疗效优于手术； 2）正确规范的放疗才能保障好的治疗效果； 3）单纯化疗无法治愈宫颈癌，避免单用化疗，延误病情。与此同时，随着临床数据的积累，免疫药物（ICIs）在宫颈癌治疗中的推荐日渐增强。现有研究提示，免疫治疗宫颈癌的主要获益人群为 PD-L1 阳性患者。",
    "source": "科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科.md"
  },
  {
    "text": "Papadopoulos KP, et al 的研究显示，Cemiplimab 联合低分割放疗治疗晚期肿瘤，有助在免疫疗效基础上，进一步缩短反应时间，帮助较快降低肿瘤负荷。Yin Z, et al 的研究显示，初诊伴内脏转移的宫颈癌患者接受系统化疗时，同步行放疗，较单纯化疗 $\\pm$ 姑息性盆腔放疗，可带来生存裨益（OS：17.3 vs 10 月）。上述研究提示，在晚期转移性宫颈癌的治疗中，放疗 ± 免疫治疗有望提升反应率、降低初期进展风险，并带来生存获益。",
    "source": "科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科.md"
  },
  {
    "text": "<html><body><table><tr><td colspan=\"4\">宫颈癌系统治疗</td></tr><tr><td colspan=\"4\">鳞癌、腺癌、腺鳞癌</td></tr><tr><td rowspan=\"2\">放化疗</td><td colspan=\"3\">复发/转移性疾病</td></tr><tr><td>一线联合治疗</td><td>一线单药治疗</td><td>二纟</td></tr><tr><td>推荐方案：顺铂、 卡铂（顺铂不耐 受)</td><td>推荐方案: Pembrolizumab十顺铂/紫 杉醇±BEV（PD-L1+) （1类）、Pembrolizumab 十卡铂/紫杉醇土BEV （PD-L1+）（1类）、 顺铂/紫杉醇/BEV （1类）、 卡铂/紫杉醇/BEV</td><td>推荐方案：顺铂 其他推荐方案：卡 铂、紫杉醇</td><td>推荐方案：「 L1十或MSI-F Nivolumab ( 其他推荐方 杉醇，多西1 吉西他滨，!",
    "source": "科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科.md"
  },
  {
    "text": "替康，丝裂 拓扑替康，· 特定情况下j Pembrolizum Larotrectinib 融合阳性)</td></tr></table></body></html> 免疫治疗最初推荐二线/后线用于 MSI-H/dMMR，或 PD-L1 阳性宫颈癌患者，而在 2022.V1 NCCN 宫颈癌指南，PD-L1 表达阳性、复发/转移性宫颈癌患者，一线推荐 pembrolizumab 联合化疗治疗。加入收藏 上一篇：前列腺癌放射性粒子治疗 下一篇：什么是质子治疗、对哪些癌症疗效最好？",
    "source": "科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科.md"
  },
  {
    "text": "透视质子疗法 3 大优质 返回列表 # 随便看看 哪种肺癌需要通过放射治疗 老师傅突冒1.4公分肝癌 「精准放射治疗」消灭癌肿瘤 一文带你了解食管癌放疗，食管癌什么情况选择放疗？肺癌肿瘤分几期 结节大于几厘米需重视？肝癌肿瘤治疗新利器 成大引进新型微波消融治疗 乳腺癌放疗后，出现皮肤痒红肿，疲累想睡觉，怎么办？TOMO放疗：告别‘杀敌一千，自损八百’，精准治疗新篇章！放疗x化疗 有何优缺点？华式医学研究院隆重成立了（肿瘤患者的福音） 膀胱癌介绍：症状与放射、化疗、免疫治疗方式说明 # 产品推荐 # 【专家简介】 !",
    "source": "科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科.md"
  },
  {
    "text": "[](images/da7005d77a0413b9528248e6e4dad185f8c2fd9fe7f6334a5e93d79640534233.jpg) 武汉济和医院主任医师。从事肿瘤临床工作30多年，长期担任三甲医院科主任，对各种肿瘤的规范化诊疗，均有很深的研究。对内科常见病、多发病的诊断治疗有较丰富的经验。# 【专业擅长】 对临床肿瘤内科的实用技术熟练掌握，开展各种肿瘤的术前、术后的辅助放化疗及各种肿瘤的根治性放化疗、靶向、免疫及细胞免疫等治疗，放疗技术从普通外照射、适型、调强、放射治疗外科。",
    "source": "科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科.md"
  },
  {
    "text": "# 【坐诊时间：周一至周五】 # 肿瘤科专家 主任医师 马玉芳 ![](images/54202577a707b93cdd48b4c42ac17afe136eb4fe82e30f694b53c3c5b7a7872d.jpg) # 【专家简介】 湖北省肿瘤医院主任医师。从事肿瘤的基础和临床研究工作近20年，主要的研究方向包括肺癌脑转移转移生物标志物及信号传导、肿瘤放化疗、肿瘤抗血管生成治疗、正常组织的放射耐受及不良反应等。",
    "source": "科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科.md"
  },
  {
    "text": "# 【专业擅长】 擅长肺癌、食管癌、鼻咽癌、脑胶质瘤、头颈鳞癌和乳腺癌等各种常见恶性肿瘤的放化疗等综合治疗及靶向、免疫治疗。![](images/55ea3b12d17d46e874ad046f61b60a691b33ebbb25bd590166099c954d463c58.jpg) # 【专家简介】 湖北省人民医院副主任物理师。从事肿瘤放射物理技术工作20余年，在肿瘤医学放射物理技术领域有较深造谐，特别是现代的静态/动态/容积调强适形放疗、全身肿瘤放疗、立体定向放疗。",
    "source": "科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科.md"
  },
  {
    "text": "# 【专业擅长】 主要擅长临床数据采集、临床数据建模、辐射测量学、临床剂量学以及各种特殊放疗技术的剂量测量、各种放疗设备质控、各种肿瘤放射治疗计划的设计、各种放疗设备的验收评审。# 【坐诊时间：周四上午】 # 肿瘤科专家 副主任物理师 阮长利 ![](images/88503eedd0dcc0d9f7604f1211ee1e1b8af09bb9658cd3ee638bd4b147838b5f.jpg) # 【专家简介】 湖北省人民医院肿瘤中心主任医师，从事临床工作35年，兼任湖北省肺癌专业委员会委员，湖北省生物医学工程学会肿瘤靶向专业委员会常委，湖北省抗癌协会鼻咽癌专业委员会常委。",
    "source": "科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科.md"
  },
  {
    "text": "# 【专业擅长】 各种恶性肿瘤的早期诊断及综合治疗，擅长常见头颈部肿瘤、肺癌、乳腺癌、胃肠道肿瘤等恶性肿瘤放疗、化疗、生物靶向免疫综合治疗，尤其乳腺癌、鼻咽癌、肺癌、妇科肿瘤等恶性肿瘤的综合治疗。坐诊时间：周二下午） # 【专家简介】 ![](images/9acd87eaafa61c1c2913aecb02c5a239ffffda8e8e1216c8b4b5f8a109760b9d.jpg) 湖北省肿瘤医院主任医师。",
    "source": "科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科.md"
  },
  {
    "text": "从事肿瘤放化疗工作30余年，能熟练、正确地诊治放疗科常见复杂、疑难病症及危、急、重症病例，是胃肠道肿瘤MDT、肝癌MDT、泌尿系肿瘤MDT的核心成员。# 【专业擅长】 对胃肠道恶性肿瘤、泌尿系统肿瘤、肺癌、食管癌、肝胆胰恶性肿瘤、乳腺癌、淋巴瘤等恶性肿瘤有着丰富的临床经验，能熟练地进行上手肿瘤的精确放疗、化疗、靶向、免疫等综合治疗。# 【坐诊时间：周二上午】 # 肿瘤科专家 主任医师 陈卫东 # 关于我们 o 医院简介 o 医院荣誉 新闻动态 o 医院动态C 行业资讯o 媒体报道 专家团队 科室专家o 先进设备 治疗案例专家案例 武汉市蔡甸区蔡甸大街216号 18511195050 zhongliu@whjh120.com 关注我们 友情链接",
    "source": "科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科",
    "markdown_source": "/home/clouduser/home/wangxiaojing/HuatuoGPT-II/adaption/data_unification/markdown_files/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科/科普 _ 宫颈癌的治疗与放疗选择_武汉济和医院肿瘤科.md"
  }
]